

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/000815

International filing date: 11 January 2005 (11.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/536,010  
Filing date: 12 January 2004 (12.01.2004)

Date of receipt at the International Bureau: 18 February 2005 (18.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

128287

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*February 08, 2005*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 60/536,010**

**FILING DATE: *January 12, 2004***

**RELATED PCT APPLICATION NUMBER: *PCT/US05/00815***



Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

# PROVISIONAL APPLICATION COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION Under 37 CFR 1.53 (b)(2).

Attorney Docket No.	587.P	Type a plus sign (+) inside this box ----->	+
---------------------	-------	--	---

INVENTOR(s)/APPLICANT(s)			
LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)
Jin	Haolun		293 Billingsgate Lane, Foster City, California 94404
Kim	Choung	U.	1750 Elizabeth St., San Carlos, California 94070
TITLE OF THE INVENTION (280 characters max)			
PYRIMIDYL PHOSPHONATE ANTIVIRAL COMPOUNDS AND METHODS OF USE			
CORRESPONDENCE ADDRESS			
Alex Andrus Gilead Sciences, Inc. 333 Lakeside Drive Foster City			
STATE	California	ZIP CODE	94404 COUNTRY U.S.A.
ENCLOSED APPLICATION PARTS (check all that apply)			
<input checked="" type="checkbox"/> Specification	Number of pages	153	<input type="checkbox"/> Small Entity Statement
<input type="checkbox"/> Drawing(s)	Number of sheets		<input type="checkbox"/> Other (specify)
METHOD OF PAYMENT (check one)			
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees (as well as any additional fees which may be required by this paper) and credit Deposit Account Number <u>07-1250</u> .			Provisional Filing Fee Amount (\$) <b>\$160.00</b>

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.  
☐ Yes, the name of the U.S. Government Agency and the Government contract number are:

Respectfully submitted, Alex Andrus DATE January 9, 2004

SIGNATURE TYPED or PRINTED NAME Alex Andrus REGISTRATION NO. (if appropriate) 44,509

☐ Additional inventors are being named on separately numbered sheets attached hereto



13049 U.S. PTO  
011204

**PATENT**

Attorney Docket No. 587.P

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Haolun Jin and Choung U. Kim

For: PYRIMIDYL PHOSPHONATE ANTIVIRAL COMPOUNDS AND  
METHODS OF USE

**Mail Stop Provisional Patent Application**

**Commissioner for Patents**

**P.O. Box 1450**

**Alexandria, VA 22313-1450**

**PROVISIONAL APPLICATION COVER SHEET**  
(37 C.F.R. § 1.51 (2) (i))

---

**CERTIFICATION UNDER 37 CFR 1.10**

I hereby certify that this "Provisional Application Cover Sheet" and the documents referred to as attached therein are being deposited with the United States Postal Service on this date January 12, 2004 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL939648467US addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Susan Thal-Shafer

(Type or print name of person mailing paper)

Susan Thal-Shafer

(Signature of person mailing paper)

A<sup>3</sup> has the structure:



where:

Y<sup>1</sup> is independently O, S, NR<sup>x</sup>, N(O)(R<sup>x</sup>), N(OR<sup>x</sup>), N(O)(OR<sup>x</sup>), or N(N(R<sup>x</sup>)<sub>2</sub>);

Y<sup>2</sup> is independently a bond, O, NR<sup>x</sup>, N(O)(R<sup>x</sup>), N(OR<sup>x</sup>), N(O)(OR<sup>x</sup>), N(N(R<sup>x</sup>)<sub>2</sub>), -S(O)- (sulfoxide), -S(O)<sub>2</sub>- (sulfone), -S- (sulfide), or -S-S- (disulfide);


M2 is 0, 1 or 2;

M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12;

M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12;

R<sup>y</sup> is independently H, C<sub>1</sub>-C<sub>18</sub> alkyl, C<sub>1</sub>-C<sub>18</sub> substituted alkyl, C<sub>6</sub>-C<sub>20</sub> aryl, C<sub>6</sub>-C<sub>20</sub> substituted aryl, or a protecting group, or where taken together at a carbon atom, two vicinal R<sup>y</sup> groups form a carbocycle or a heterocycle; and


R<sup>x</sup> is independently H, C<sub>1</sub>-C<sub>18</sub> alkyl, C<sub>1</sub>-C<sub>18</sub> substituted alkyl, C<sub>6</sub>-C<sub>20</sub> aryl, C<sub>6</sub>-C<sub>20</sub> substituted aryl, or a protecting group, or the formula:



where M1a, M1c, and M1d are independently 0 or 1, and M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; and


wherein at least one of R, R<sup>1</sup>, R<sup>2a</sup>, R<sup>2b</sup>, R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> comprises a phosphonate group.

2. A compound according to claim 1 having the structure:



or a pharmaceutically acceptable salt thereof, and including enol and tautomeric resonance isomers.


3. A compound according to claim 1 having the structure:



5


or a pharmaceutically acceptable salt thereof, and including enol and tautomeric resonance isomers.

4. A compound according to claim 1 having the structure:




or a pharmaceutically acceptable salt thereof, and including enol and tautomeric resonance isomers.

5. A compound according to claim 1 having the structure:




- 5 or a pharmaceutically acceptable salt thereof, and including enol and tautomeric resonance isomers.

6. A compound according to claim 1 having the structure:




- 10 or a pharmaceutically acceptable salt thereof, and including all enol, tautomeric, and resonance isomers, enantiomers, diastereomers, and racemic mixtures thereof.

7. A compound according to claim 1 having the structure:



or a pharmaceutically acceptable salt thereof, and including enol and tautomeric resonance isomers.


8. A compound according to claim 1 having the structure:



5

or a pharmaceutically acceptable salt thereof, and including enol and tautomeric resonance isomers.


9. A compound according to claim 1 having the structure:






or a pharmaceutically acceptable salt thereof, and including enol and tautomeric resonance isomers.

10. The compound of claim 1 wherein substituted alkyl, substituted alkenyl, substituted alkynyl, substituted aryl, and substituted heterocycle are independently substituted with one or more substituents selected from F, Cl, Br, I, OH, amino ( $-\text{NH}_2$ ), ammonium ( $-\text{NH}_3^+$ ), alkylamino ( $-\text{NHR}$ ), dialkylamino ( $-\text{NR}_2$ ), trialkylammonium ( $-\text{NR}_3^+$ ),  $\text{C}_1$ – $\text{C}_8$  alkyl,  $\text{C}_1$ – $\text{C}_8$  alkylhalide, carboxylate, thiol ( $-\text{SH}$ ), sulfate ( $-\text{OSO}_3\text{R}$ ), sulfamate, sulfonate ( $-\text{SO}_3\text{R}$ ), 5-7 membered ring sultam,  $\text{C}_1$ – $\text{C}_8$  alkylsulfonate,  $\text{C}_1$ – $\text{C}_8$  alkylamino, 4-dialkylaminopyridinium,  $\text{C}_1$ – $\text{C}_8$  alkylhydroxyl,  $\text{C}_1$ – $\text{C}_8$  alkylthiol, alkylsulfone ( $-\text{SO}_2\text{R}$ ), arylsulfone ( $-\text{SO}_2\text{Ar}$ ), arylsulfoxide ( $-\text{SOAr}$ ), arylthio ( $-\text{SAr}$ ), sulfonamide ( $-\text{SO}_2\text{NR}_2$ ), alkylsulfoxide ( $-\text{SOR}$ ), ester ( $-\text{C}(=\text{O})\text{OR}$ ), amido ( $-\text{C}(=\text{O})\text{NR}_2$ ), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile ( $-\text{CN}$ ), azido ( $-\text{N}_3$ ), nitro ( $-\text{NO}_2$ ),  $\text{C}_1$ – $\text{C}_8$  alkoxy ( $-\text{OR}$ ),  $\text{C}_1$ – $\text{C}_8$  alkyl,  $\text{C}_1$ – $\text{C}_8$  substituted alkyl,  $\text{C}_6$ – $\text{C}_{20}$  aryl,  $\text{C}_6$ – $\text{C}_{20}$  substituted aryl,  $\text{C}_2$ – $\text{C}_{20}$  heterocycle, and  $\text{C}_2$ – $\text{C}_{20}$  substituted heterocycle, phosphonate, phosphate, polyethyleneoxy, and a prodrug moiety.
11. A compound of claim 1 wherein  $\text{R}^{2a}$  and  $\text{R}^{2b}$  are selected from H,  $\text{C}(=\text{O})\text{OR}$ ,  $\text{C}(=\text{O})\text{NR}_2$ ,  $\text{C}(=\text{O})\text{R}$ ,  $\text{SO}_2\text{NR}_2$  (sulfamate), and a prodrug moiety.
12. The compound of claim 1 where  $\text{R}^3$  or  $\text{R}^4$  is 4-fluorobenzyl.
13. The compound of claim 1 wherein at least one of  $\text{R}^1$ ,  $\text{R}^{2a}$ ,  $\text{R}^{2b}$ ,  $\text{R}^3$ ,  $\text{R}^4$ , and  $\text{R}^5$  comprise a prodrug moiety selected from the structures:




wherein  $\text{R}^8$  is comprised of an ester, an amide, or a carbamate.

14. The compound of claim 1 wherein phosphonate group has the structure:




15. The compound of claim 14 wherein phosphonate group has the structure:




where  $Y^{2b}$  is O or  $N(R^x)$ .

- 5 16. The compound of claim 14 wherein phosphonate group has the structure:




where  $W^5$  is a carbocycle, and  $Y^{2c}$  is O,  $N(R^y)$  or S.


17. The compound of claim 16 wherein  $W^5$  is selected from the structures:



18. The compound of claim 14 wherein phosphonate group has the structure:




19. The compound of claim 18 wherein phosphonate group has the structure:




5

wherein  $Y^{2b}$  is O or  $N(R^x)$ ; M12d is 1, 2, 3, 4, 5, 6, 7 or 8;  $R^1$  is H or  $C_1-C_6$  alkyl; and the phenyl carbocycle is substituted with 0 to 3  $R^2$  groups where  $R^2$  is  $C_1-C_6$  alkyl or substituted alkyl.


20. The compound of claim 19 wherein phosphonate group has the structure:




21. The compound of claim 14 wherein R<sup>x</sup> is selected from the structures:



5 22. The compound of claim 21 wherein R<sup>1</sup> is selected from the structures:




23. The compound of claim 21 wherein R<sup>1</sup> is selected from the structures:




24. A compound of claim 1 wherein R<sup>1</sup> comprises a phosphonate prodrug moiety.

25. The compound of claim 1 wherein R<sup>3</sup> or R<sup>4</sup> is selected from the structures:



5 26. A compound of claim 1 having the structure:



27. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

28. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a therapeutically effective amount of an AIDS treatment agent selected from:

- 5 (1) an AIDS antiviral agent,  
(2) an anti-infective agent, and  
(3) an immunomodulator.

29. The composition of claim 33 wherein the antiviral agent is an HIV protease inhibitor.



10 30. A process for making a pharmaceutical composition comprising combining a compound of claim 1 and a pharmaceutically acceptable carrier.

31. A method of inhibiting HIV integrase, comprising the administration to a mammal in need of such treatment of a therapeutically effective amount of a compound of claim 1.

15 32. A method of treating infection by HIV, or of treating AIDS or ARC, comprising administration to a mammal in need of such treatment of a therapeutically effective amount of a compound of claim 1.

# ABSTRACT

Pyrimidine I and pyrimidinone II phosphonate compounds and methods for viral inhibition are disclosed. The compounds include at least one phosphonate group covalently attached at any site.



This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label No. EL939648467US

Date of Deposit January 12, 2004

5 I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan Thal-Shafer

10 (Typed or Printed Name of Person Mailing Paper or Fee)

Susan Thal-Shafer  
(Signature of Person Mailing Paper or Fee)

15  
**PYRIMIDYL PHOSPHONATE ANTIVIRAL COMPOUNDS AND  
METHODS OF USE**

20  
**FIELD OF THE INVENTION**

The invention relates generally to compounds with antiviral activity and more specifically with HIV-integrase inhibitory properties.

**BACKGROUND OF THE INVENTION**

25 Human immunodeficiency virus (HIV) infection and related diseases are a major public health problem worldwide. A virally encoded integrase protein mediates specific incorporation and integration of viral DNA into the host genome. Integration is essential for viral replication. Accordingly, inhibition of HIV integrase is an important therapeutic pursuit for treatment of HIV infection of the related diseases.

30 Human immunodeficiency virus type 1 (HIV-1) encodes three enzymes which are required for viral replication: reverse transcriptase, protease, and integrase. Although drugs targeting reverse transcriptase and protease are in wide use and have shown effectiveness, particularly when employed in combination, toxicity and development of resistant strains have limited their usefulness (Palella, et al *N. Engl. J. Med.* (1998) 338:853-860; Richman, D. D. *Nature* (2001) 410:995-1001). There is a need for new agents directed against alternate  
35 sites in the viral life cycle. Integrase has emerged as an attractive target, because it is necessary for stable infection and homologous enzymes are lacking in the human host

(LaFemina, et al *J. Virol.* (1992) 66:7414-7419). The function of integrase is to catalyze integration of proviral DNA, resulting from the reverse transcription of viral RNA, into the host genome, by a stepwise fashion of endonucleolytic processing of proviral DNA within a cytoplasmic preintegration complex (termed 3'-processing or "3'-P") with specific DNA sequences at the end of the HIV-1 long terminal repeat (LTR) regions, followed by translocation of the complex into the nuclear compartment where integration of 3'-processed proviral DNA into host DNA occurs in a "strand transfer" (ST) reaction (Hazuda, et al *Science* (2000) 287:646-650; Katzman, et al *Adv. Virus Res.* (1999) 52:371-395; Asante-Aplah, et al *Adv. Virus Res.* (1999) 52:351-369). Although numerous agents potentially inhibit 3'-P and ST in extracellular assays that employ recombinant integrase and viral long-terminal-repeat oligonucleotide sequences, often such inhibitors lack inhibitory potency when assayed using fully assembled preintegration complexes or fail to show antiviral effects against HIV-infected cells (Pommier, et al *Adv. Virus Res.* (1999) 52:427-458; Farnet, et al *Proc. Natl. Acad. Sci. U.S.A.* (1996) 93:9742-9747; Pommier, et al *Antiviral Res.* (2000) 47:139-148).

Certain HIV integrase inhibitors have been disclosed which block integration in extracellular assays and exhibit good antiviral effects against HIV-infected cells (Anthony, et al WO 02/30426; Anthony, et al WO 02/30930; Anthony, et al WO 02/30931; WO 02/055079; Zhuang, et al WO 02/36734; US 6395743; US 6245806; US 6271402; Fujishita, et al WO 00/039086; Uenaka et al WO 00/075122; Selnick, et al WO 99/62513; Young, et al WO 99/62520; Payne, et al WO 01/00578; Jing, et al *Biochemistry* (2002) 41:5397-5403; Pais, et al *Jour. Med. Chem.* (2002) 45:3184-94; Goldgur, et al *Proc. Natl. Acad. Sci. U.S.A.* (1999) 96:13040-13043; Espeseth, et al *Proc. Natl. Acad. Sci. U.S.A.* (2000) 97:11244-11249).

HIV integrase inhibitory compounds with improved antiviral and pharmacokinetic properties are desirable, including enhanced activity against development of HIV resistance, improved oral bioavailability, greater potency and extended effective half-life *in vivo* (Nair, V. "HIV integrase as a target for antiviral chemotherapy" *Reviews in Medical Virology* (2002) 12(3):179-193; Young (2001) *Current Opinion in Drug Discovery & Development*, Vol. 4, No. 4, 402-410; Neamati (2002) *Expert. Opin. Ther. Patents* Vol. 12, No. 5, 709-724). Three-dimensional quantitative structure-activity relationship studies and docking simulations (Buolamwini, et al *Jour. Med. Chem.* (2002) 45:841-852) of conformationally-restrained cinnamoyl-type integrase inhibitors (Artico, et al *Jour. Med. Chem.* (1998) 41:3948-3960)

have shown a large contribution of hydrogen-bonding interactions to the inhibitory activity differences among the compounds. Conformationally-constrained hydrogen-bonding functionality such as hydroxyl was correlated with inhibitory activity. Compounds with binding functionality in a pre-organized configuration may possess optimized inhibitory properties against HIV integrase. The prior art does not show or suggest compounds with integrase binding functionality in a pre-organized conformation or molecular structure. In addition to therapeutic uses, the value of compounds in diagnostic assays for HIV, for use in the preparation of polymers and for use as surfactants, and in other industrial utilities will be readily apparent to those skilled in the art.

Dihydroxypyrimidine carboxamide (WO 03/035076A1) and N-substituted hydroxypyrimidinone carboxamide (WO 03/035077A1) compounds have been reported to have HIV integrase inhibitory properties.


Improving the delivery of drugs and other agents to target cells and tissues has been the focus of considerable research for many years. Though many attempts have been made to develop effective methods for importing biologically active molecules into cells, both *in vivo* and *in vitro*, none has proved to be entirely satisfactory. Optimizing the association of the inhibitory drug with its intracellular target, while minimizing intercellular redistribution of the drug, e.g. to neighboring cells, is often difficult or inefficient.

Most agents currently administered to a patient parenterally are not targeted, resulting in systemic delivery of the agent to cells and tissues of the body where it is unnecessary, and often undesirable. This may result in adverse drug side effects, and often limits the dose of a drug (e.g., cytotoxic agents and other anti-cancer or anti-viral drugs) that can be administered. By comparison, although oral administration of drugs is generally recognized as a convenient and economical method of administration, oral administration can result in either (a) uptake of the drug through the cellular and tissue barriers, e.g. blood/brain, epithelial, cell membrane, resulting in undesirable systemic distribution, or (b) temporary residence of the drug within the gastrointestinal tract. Accordingly, a major goal has been to develop methods for specifically targeting agents to cells and tissues. Benefits of such treatment includes avoiding the general physiological effects of inappropriate delivery of such agents to other cells and tissues, such as uninfected cells. Intracellular targeting may be achieved by methods and compositions which allow accumulation or retention of biologically active agents inside cells.


## SUMMARY OF THE INVENTION

The present invention provides compositions and methods for inhibition of viruses, including HIV. Compositions and methods of the present invention inhibit HIV-integrase.

In one aspect, the invention includes 4,5-dihydroxypyrimidine, 6-carboxamide  
5 phosphonate compounds having Formula I:



In another aspect, the invention includes 3-N-substituted, 5-hydroxypyrimidinone, 6-carboxamide phosphonate compounds having Formula II:



The invention includes pharmaceutically acceptable salts of Formulas I and II, and enol and tautomeric resonance isomers thereof.

Formula I and II compounds are substituted with one or more covalently attached phosphonate groups. The compounds of the invention include at least one phosphonate group  
15 covalently attached at any site, i.e. R<sup>1</sup>, R<sup>2a</sup>, R<sup>2b</sup>, R<sup>3</sup>, R<sup>4</sup> or R<sup>5</sup>.

The invention also includes a pharmaceutical composition comprising an effective amount of a compound selected from Formula I or Formula II, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable diluent or carrier.

This invention also includes a method of increasing cellular accumulation and  
20 retention of drug compounds, thus improving their therapeutic and diagnostic value.

The invention also includes a method of inhibiting HIV, comprising administering to a mammal infected with HIV (HIV positive) an amount of a compound of Formula I or Formula II, effective to inhibit the growth of said HIV infected cells.

5 The invention also includes a compound selected from Formula I or Formula II for use in medical therapy (preferably for use in treating cancer, e.g. solid tumors), as well as the use of a compound of Formula I or Formula II for the manufacture of a medicament useful for the treatment of cancer, e.g. solid tumors.

The invention also includes processes and novel intermediates disclosed herein which are useful for preparing compounds of the invention. Some of the compounds of Formula I or  
10 Formula II are useful to prepare other compounds of Formula I or Formula II.

In another aspect of the invention, the activity of HIV integrase is inhibited by a method comprising the step of treating a sample suspected of containing HIV virus with a compound or composition of the invention.

Another aspect of the invention provides a method for inhibiting the activity of HIV  
15 integrase comprising the step of contacting a sample suspected of containing HIV virus with the composition embodiments of the invention.

In other aspects, novel methods for the synthesis, analysis, separation, isolation, crystallization, purification, characterization, and testing of the compounds of this invention are provided.

## 20 DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS

Reference will now be made in detail to certain embodiments of the invention, examples of which are illustrated in the accompanying descriptions, structure and formulas. While the invention will be described in conjunction with the enumerated embodiments, it will be understood that they are not intended to limit the invention to those embodiments. On the  
25 contrary, the invention is intended to cover all alternatives, modifications, and equivalents, which may be included within the scope of the present invention as defined by the claims.

### DEFINITIONS

Unless stated otherwise, the following terms and phrases as used herein are intended to have the following meanings:

The terms "phosphonate" and "phosphonate group" mean a functional group or moiety within a molecule that comprises at least one phosphorus-carbon bond, and at least one phosphorus-oxygen double bond. The phosphorus atom is further substituted with oxygen, sulfur, and nitrogen substituents. These substituents may be part of a prodrug moiety. As defined herein, "phosphonate" and "phosphonate group" include phosphonic acid, phosphonic monoester, phosphonic diester, diphosphophosphonate, phosphonamidate, phosphondiamidate, and phosphonthioate functional groups; and the group A<sup>3</sup>.

The term "prodrug" as used herein refers to any compound that when administered to a biological system generates the drug substance, i.e. active ingredient, as a result of spontaneous chemical reaction(s), enzyme catalyzed chemical reaction(s), photolysis, and/or metabolic chemical reaction(s). A prodrug is thus a covalently modified analog or latent form of a therapeutically-active compound.

"Pharmaceutically acceptable prodrug" refers to a compound that is metabolized in the host, for example hydrolyzed or oxidized, by either enzymatic action or by general acid or base solvolysis, to form an active ingredient. Typical examples of prodrugs of the compounds of the invention have biologically labile protecting groups on a functional moiety of the compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, esterified, deesterified, alkylated, dealkylated, acylated, deacylated, phosphorylated, dephosphorylated, photolyzed, hydrolyzed, or other functional group change or conversion involving forming or breaking chemical bonds on the prodrug.

"Prodrug moiety" means a labile functional group which separates from the active inhibitory compound during metabolism, systemically, inside a cell, by hydrolysis, enzymatic cleavage, or by some other process (Bundgaard, Hans, "Design and Application of Prodrugs" in Textbook of Drug Design and Development (1991), P. Krogsgaard-Larsen and H. Bundgaard, Eds. Harwood Academic Publishers, pp. 113-191). Enzymes which are capable of an enzymatic activation mechanism with the phosphonate prodrug compounds of the invention include, but are not limited to, amidases, esterases, microbial enzymes, phospholipases, cholinesterases, and phosphatases. Prodrug moieties can serve to enhance solubility, absorption and lipophilicity to optimize drug delivery, bioavailability and efficacy. A "prodrug" is thus a covalently modified analog of a therapeutically-active compound. A prodrug moiety may include an active metabolite or drug itself.

Exemplary prodrug moieties include the hydrolytically sensitive or labile acyloxymethyl esters  $-\text{CH}_2\text{OC}(=\text{O})\text{R}^9$  and acyloxymethyl carbonates  $-\text{CH}_2\text{OC}(=\text{O})\text{OR}^9$  where  $\text{R}^9$  is  $\text{C}_1$ – $\text{C}_6$  alkyl,  $\text{C}_1$ – $\text{C}_6$  substituted alkyl,  $\text{C}_6$ – $\text{C}_{20}$  aryl or  $\text{C}_6$ – $\text{C}_{20}$  substituted aryl. The acyloxyalkyl ester was first used as a prodrug strategy for carboxylic acids and then applied to phosphates and phosphonates by Farquhar et al (1983) *J. Pharm. Sci.* 72: 324; also US Patent Nos. 4816570, 4968788, 5663159 and 5792756. In certain compounds of the invention, a prodrug moiety is part of a phosphonate group. Subsequently, the acyloxyalkyl ester was used to deliver phosphonic acids across cell membranes and to enhance oral bioavailability. A close variant of the acyloxyalkyl ester, the alkoxycarbonyloxyalkyl ester (carbonate), may also enhance oral bioavailability as a prodrug moiety in the compounds of the combinations of the invention. An exemplary acyloxymethyl ester is pivaloyloxymethoxy, (POM)  $-\text{CH}_2\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$ . Exemplary acyloxymethyl carbonate prodrug moieties are pivaloyloxymethylcarbonate (POC)  $-\text{CH}_2\text{OC}(=\text{O})\text{OC}(\text{CH}_3)_3$  and  $-\text{CH}_2\text{OC}(=\text{O})\text{OCH}(\text{CH}_3)_2$ .

The phosphonate group may be a phosphonate prodrug moiety. The prodrug moiety may be sensitive to hydrolysis, such as, but not limited to a pivaloyloxymethyl carbonate (POC) or POM group. Alternatively, the prodrug moiety may be sensitive to enzymatic potentiated cleavage, such as a lactate ester or a phosphoramidate-ester group.

Aryl esters of phosphorus groups, especially phenyl esters, are reported to enhance oral bioavailability (DeLambert et al (1994) *J. Med. Chem.* 37: 498). Phenyl esters containing a carboxylic ester ortho to the phosphate have also been described (Khamnei and Torrence, (1996) *J. Med. Chem.* 39:4109–4115). Benzyl esters are reported to generate the parent phosphonic acid. In some cases, substituents at the *ortho*-or *para*-position may accelerate the hydrolysis. Benzyl analogs with an acylated phenol or an alkylated phenol may generate the phenolic compound through the action of enzymes, e.g. esterases, oxidases, etc., which in turn undergoes cleavage at the benzylic C–O bond to generate the phosphoric acid and the quinone methide intermediate. Examples of this class of prodrugs are described by Mitchell et al (1992) *J. Chem. Soc. Perkin Trans. I* 2345; Brook et al WO 91/19721. Still other benzylic prodrugs have been described containing a carboxylic ester-containing group attached to the benzylic methylene (Glazier et al WO 91/19721). Thio-containing prodrugs are reported to be useful for the intracellular delivery of phosphonate drugs. These proesters contain an ethylthio group in which the thiol group is either esterified with an acyl group or combined

with another thiol group to form a disulfide. Deesterification or reduction of the disulfide generates the free thio intermediate which subsequently breaks down to the phosphoric acid and episulfide (Puech et al (1993) *Antiviral Res.*, 22: 155-174; Benzaria et al (1996) *J. Med. Chem.* 39: 4958). Cyclic phosphonate esters have also been described as prodrugs of  
5 phosphorus-containing compounds (Erion et al, US Patent No. 6312662).

“Protecting group” refers to a moiety of a compound that masks or alters the properties of a functional group or the properties of the compound as a whole. The chemical substructure of a protecting group varies widely. One function of a protecting group is to serve as intermediates in the synthesis of the parental drug substance. Chemical protecting  
10 groups and strategies for protection/deprotection are well known in the art. See: Protective Groups in Organic Chemistry, Theodora W. Greene (John Wiley & Sons, Inc., New York, 1991). Protecting groups are often utilized to mask the reactivity of certain functional groups, to assist in the efficiency of desired chemical reactions, e.g. making and breaking chemical bonds in an ordered and planned fashion. Protection of functional groups of a compound  
15 alters other physical properties besides the reactivity of the protected functional group, such as the polarity, lipophilicity (hydrophobicity), and other properties which can be measured by common analytical tools. Chemically protected intermediates may themselves be biologically active or inactive.

Protected compounds may also exhibit altered, and in some cases, optimized  
20 properties *in vitro* and *in vivo*, such as passage through cellular membranes and resistance to enzymatic degradation or sequestration. In this role, protected compounds with intended therapeutic effects may be referred to as prodrugs. Another function of a protecting group is to convert the parental drug into a prodrug, whereby the parental drug is released upon conversion of the prodrug *in vivo*. Because active prodrugs may be absorbed more effectively  
25 than the parental drug, prodrugs may possess greater potency *in vivo* than the parental drug. Protecting groups are removed either *in vitro*, in the instance of chemical intermediates, or *in vivo*, in the case of prodrugs. With chemical intermediates, it is not particularly important that the resulting products after deprotection, e.g. alcohols, be physiologically acceptable, although in general it is more desirable if the products are pharmacologically innocuous.

30 Any reference to any of the compounds of the invention also includes a reference to a physiologically acceptable salt thereof. Examples of physiologically acceptable salts of the



compounds of the invention include salts derived from an appropriate base, such as an alkali metal (for example, sodium), an alkaline earth (for example, magnesium), ammonium and  $\text{NX}_4^+$  (wherein X is  $\text{C}_1\text{--C}_4$  alkyl). Physiologically acceptable salts of an hydrogen atom or an amino group include salts of organic carboxylic acids such as acetic, benzoic, lactic, fumaric, tartaric, maleic, malonic, malic, isethionic, lactobionic and succinic acids; organic sulfonic acids, such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids; and inorganic acids, such as hydrochloric, sulfuric, phosphoric and sulfamic acids. Physiologically acceptable salts of a compound of an hydroxy group include the anion of said compound in combination with a suitable cation such as  $\text{Na}^+$  and  $\text{NX}_4^+$  (wherein X is independently selected from H or a  $\text{C}_1\text{--C}_4$  alkyl group).

For therapeutic use, salts of active ingredients of the compounds of the invention will be physiologically acceptable, i.e. they will be salts derived from a physiologically acceptable acid or base. However, salts of acids or bases which are not physiologically acceptable may also find use, for example, in the preparation or purification of a physiologically acceptable compound. All salts, whether or not derived from a physiologically acceptable acid or base, are within the scope of the present invention.

"Alkyl" is  $\text{C}_1\text{--C}_{18}$  hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms. Examples are methyl (Me,  $-\text{CH}_3$ ), ethyl (Et,  $-\text{CH}_2\text{CH}_3$ ), 1-propyl (n-Pr, n-propyl,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ), 2-propyl (i-Pr, i-propyl,  $-\text{CH}(\text{CH}_3)_2$ ), 1-butyl (n-Bu, n-butyl,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ), 2-methyl-1-propyl (i-Bu, i-butyl,  $-\text{CH}_2\text{CH}(\text{CH}_3)_2$ ), 2-butyl (s-Bu, s-butyl,  $-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$ ), 2-methyl-2-propyl (t-Bu, t-butyl,  $-\text{C}(\text{CH}_3)_3$ ), 1-pentyl (n-pentyl,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ), 2-pentyl ( $-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{CH}_3$ ), 3-pentyl ( $-\text{CH}(\text{CH}_2\text{CH}_3)_2$ ), 2-methyl-2-butyl ( $-\text{C}(\text{CH}_3)_2\text{CH}_2\text{CH}_3$ ), 3-methyl-2-butyl ( $-\text{CH}(\text{CH}_3)\text{CH}(\text{CH}_3)_2$ ), 3-methyl-1-butyl ( $-\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$ ), 2-methyl-1-butyl ( $-\text{CH}_2\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$ ), 1-hexyl ( $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ), 2-hexyl ( $-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ), 3-hexyl ( $-\text{CH}(\text{CH}_2\text{CH}_3)(\text{CH}_2\text{CH}_2\text{CH}_3)$ ), 2-methyl-2-pentyl ( $-\text{C}(\text{CH}_3)_2\text{CH}_2\text{CH}_2\text{CH}_3$ ), 3-methyl-2-pentyl ( $-\text{CH}(\text{CH}_3)\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$ ), 4-methyl-2-pentyl ( $-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}(\text{CH}_3)_2$ ), 3-methyl-3-pentyl ( $-\text{C}(\text{CH}_3)(\text{CH}_2\text{CH}_3)_2$ ), 2-methyl-3-pentyl ( $-\text{CH}(\text{CH}_2\text{CH}_3)\text{CH}(\text{CH}_3)_2$ ), 2,3-dimethyl-2-butyl ( $-\text{C}(\text{CH}_3)_2\text{CH}(\text{CH}_3)_2$ ), 3,3-dimethyl-2-butyl ( $-\text{CH}(\text{CH}_3)\text{C}(\text{CH}_3)_3$ ).

"Alkenyl" is C<sub>2</sub>-C<sub>18</sub> hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon,  $sp^2$  double bond. Examples include, but are not limited to: ethylene or vinyl (-CH=CH<sub>2</sub>), allyl (-CH<sub>2</sub>CH=CH<sub>2</sub>), cyclopentenyl (-C<sub>5</sub>H<sub>7</sub>), and 5-hexenyl (-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH=CH<sub>2</sub>)

5 "Alkynyl" is C<sub>2</sub>-C<sub>18</sub> hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon,  $sp$  triple bond. Examples include, but are not limited to: acetylenic (-C≡CH) and propargyl (-CH<sub>2</sub>C≡CH),

The terms "alkylene" and "alkyldiyl" each refer to a saturated, branched or straight chain or cyclic hydrocarbon radical of 1-18 carbon atoms, and having two monovalent radical centers  
10 derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane. Typical alkylene radicals include, but are not limited to: methylene (-CH<sub>2</sub>-), 1,2-ethyl (-CH<sub>2</sub>CH<sub>2</sub>-), 1,3-propyl (-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-), 1,4-butyl (-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-), and the like.

"Alkenylene" refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical of 2-18 carbon atoms, and having two monovalent radical centers derived by the removal  
15 of two hydrogen atoms from the same or two different carbon atoms of a parent alkene, i.e. double carbon-carbon bond moiety. Typical alkenylene radicals include, but are not limited to: 1,2-ethylene (-CH=CH-).

"Alkynylene" refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical of 2-18 carbon atoms, and having two monovalent radical centers derived by the removal  
20 of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne, i.e. triple carbon-carbon bond moiety. Typical alkynylene radicals include, but are not limited to: acetylene (-C≡C-), propargyl (-CH<sub>2</sub>C≡C-), and 4-pentynyl (-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>C≡CH-).

"Aryl" means a monovalent aromatic hydrocarbon radical of 6-20 carbon atoms derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring  
25 system. Typical aryl groups include, but are not limited to, radicals derived from benzene, substituted benzene, naphthalene, anthracene, biphenyl, and the like.

"Arylene" means a divalent aromatic hydrocarbon radical, i.e. aryldiyl, of 6-20 carbon atoms derived by the removal of two hydrogen atoms from carbon or non-carbon atoms of a parent aromatic ring system. Typical arylene groups include, but are not limited to, radicals  
30 derived from benzene, such as 1,2 phenyldiyl, 1,3 phenyldiyl, and 1,4 phenyldiyl.

"Heterocycle" means a monovalent aromatic radical of one or more carbon atoms and

one or more atoms selected from N, O, S, or P, derived by the removal of one hydrogen atom from a single atom of a parent aromatic ring system. Heterocyclic groups may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S) or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S). Heterocyclic bicycles have 7 to 10 ring atoms (6 to 9 carbon atoms and 1 to 2 heteroatoms selected from N, O, and S) arranged as a bicyclo [4,5], [5,5], [5,6], or [6,6] system; or 9 to 10 ring atoms (8 to 9 carbon atoms and 1 to 2 heteroatoms selected from N and S) arranged as a bicyclo [5,6] or [6,6] system. The heterocyclic group may be bonded to the drug scaffold through a carbon, nitrogen, sulfur, phosphorus or other atom by a stable covalent bond.

Heterocycle groups include, for example: pyridyl, dihydropyridyl isomers, pyridazinyl, pyrimidinyl, pyrazinyl, s-triazinyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, furanyl, thiofuranyl, thienyl, and pyrrolyl.


"Arylalkyl" refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or  $sp^3$  carbon atom, is replaced with an aryl radical. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethen-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl and the like. The arylalkyl group comprises 6 to 20 carbon atoms, e.g. the alkyl moiety, including alkanyl, alkenyl or alkynyl groups, of the arylalkyl group is 1 to 6 carbon atoms and the aryl moiety is 5 to 14 carbon atoms.

Substituted substituents such as "substituted alkyl", "substituted aryl", "substituted heterocycle" and "substituted arylalkyl" mean alkyl, aryl, and arylalkyl respectively, in which one or more hydrogen atoms are each independently replaced with a substituent. Typical substituents include, but are not limited to, -X, -R, -O<sup>-</sup>, -OR, -SR, -S<sup>-</sup>, -NR<sub>2</sub>, -NR<sub>3</sub>, =NR, -CX<sub>3</sub>, -CN, -OCN, -SCN, -N=C=O, -NCS, -NO, -NO<sub>2</sub>, =N<sub>2</sub>, -N<sub>3</sub>, NC(=O)R, -C(=O)R, -C(=O)NRR, -S(=O)<sub>2</sub>O<sup>-</sup>, -S(=O)<sub>2</sub>OH, -S(=O)<sub>2</sub>R, -OS(=O)<sub>2</sub>OR, -S(=O)<sub>2</sub>NR, -S(=O)R, -OP(=O)O<sub>2</sub>RR, -P(=O)O<sub>2</sub>RR, -P(=O)(O<sup>-</sup>)<sub>2</sub>, -P(=O)(OH)<sub>2</sub>, -C(=O)R, -C(=O)X, -C(S)R, -C(O)OR, -C(O)O<sup>-</sup>, -C(S)OR, -C(O)SR, -C(S)SR, -C(O)NRR, -C(S)NRR, -C(NR)NRR, where each X is independently a halogen: F, Cl, Br, or I; and each R is independently -H, alkyl, aryl, heterocycle, protecting group or prodrug moiety. Alkylene, alkenylene, and alkynylene groups may also be similarly substituted.

"Heterocycle" means a saturated, unsaturated or aromatic ring system including at least one N, O, S, or P. Heterocycle thus include heteroaryl groups. Heterocycle as used herein includes by way of example and not limitation these heterocycles described in Paquette, Leo A. "Principles of Modern Heterocyclic Chemistry" (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; "The Chemistry of Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; Katritzky, Alan R., Rees, C.W. and Scriven, E. "Comprehensive Heterocyclic Chemistry" (Pergamon Press, 1996); and *J. Am. Chem. Soc.* (1960) 82:5566.

- 10 Examples of heterocycles include by way of example and not limitation pyridyl, dihydropyridyl, tetrahydropyridyl (piperidyl), thiazolyl, tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinoliny, isoquinoliny, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl,
- 15 tetrahydrofuranyl, bis-tetrahydrofuranyl, tetrahydropyranyl, bis-tetrahydropyranyl, tetrahydroquinoliny, tetrahydroisoquinoliny, decahydroquinoliny, octahydroisoquinoliny, azociny, triazinyl, 6H-1,2,5-thiadiazinyl, 2H,6H-1,5,2-dithiazinyl, thienyl, thianthrenyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathinyl, 2H-pyrrolyl, isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indoliziny, isoindolyl, 3H-indolyl, 1H-indazolyl, purinyl,
- 20 4H-quinoliziny, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnoliny, pteridinyl, 4aH-carbazolyl, carbazolyl,  $\beta$ -carboliny, phenanthridinyl, acridinyl, pyrimidinyl, phenanthroliny, phenazinyl, phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl, imidazoliny, pyrazolidinyl, pyrazoliny, piperazinyl, indoliny, isoindoliny, quinuclidiny, morpholiny, oxazolidinyl, benzotriazolyl, benzisoxazolyl,
- 25 oxindolyl, benzoxazoliny, and isatinoyl.

One embodiment of the bis-tetrahydrofuranyl group is:



By way of example and not limitation, carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6

of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline. Still more typically, carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl.

By way of example and not limitation, nitrogen bonded heterocycles are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or  $\beta$ -carboline. Still more typically, nitrogen bonded heterocycles include 1-aziridyl, 1-azetetyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.

"Carbocycle" means a saturated, unsaturated or aromatic ring system having 3 to 7 carbon atoms as a monocycle or 7 to 12 carbon atoms as a bicycle. Monocyclic carbocycles have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms. Bicyclic carbocycles have 7 to 12 ring atoms, e.g. arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system. Examples of monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, phenyl, spiryl and naphthyl. Carbocycle thus includes some aryl groups.

"Linker" or "link" means a chemical moiety comprising a covalent bond or a chain of atoms that covalently attaches a phosphonate group to a drug, or between the Formula I scaffold and substituents. Linkers include L interposed between Ar and the nitrogen of Formula I compounds. Linkers may also be interposed between a phosphorus containing A<sup>3</sup> group and the R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> or R<sup>7</sup> positions of Formula I. Linkers include, but are not limited to moieties such as O, S, NR, N-OR, C<sub>1</sub>-C<sub>12</sub> alkylene, C<sub>1</sub>-C<sub>12</sub> substituted alkylene, C<sub>2</sub>-C<sub>12</sub> alkenylene, C<sub>2</sub>-C<sub>12</sub> substituted alkenylene, C<sub>2</sub>-C<sub>12</sub> alkynylene, C<sub>2</sub>-C<sub>12</sub> substituted

alkynylene,  $C(=O)NH$ ,  $C(=O)$ ,  $S(=O)_2$ ,  $C(=O)NH(CH_2)_n$ , and  $(CH_2CH_2O)_n$ , where n may be 1, 2, 3, 4, 5, or 6. Linkers also include repeating units of alkyloxy (e.g. polyethylenoxy, PEG, polymethyleneoxy) and alkylamino (e.g. polyethyleneamino, Jeffamine™); and diacid ester and amides including succinate, succinamide, diglycolate, malonate, and caproamide.

5       The term "chiral" refers to molecules which have the property of non-superimposability of the mirror image partner, while the term "achiral" refers to molecules which are superimposable on their mirror image partner.

      The term "stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.

10       "Diastereomer" refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.



15       "Enantiomers" refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.

      Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and l or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or l meaning  
25       that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there  
30       has been no stereoselection or stereospecificity in a chemical reaction or process. The terms

"racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.

#### PYRIMIDINE AND PYRIMIDINONE PHOSPHONATE COMPOUNDS

- 5 Novel phosphonate compounds with inhibitory activity against HIV integrase are described, as embodied in Formula I pyrimidines and Formula II pyrimidinones, including any pharmaceutically acceptable salts thereof. Formula I pyrimidine and Formula II pyrimidinone compounds each have at least one phosphonate group.



- 10 Formula I and II compounds include all pharmaceutically acceptable salts thereof. Formula I and II compounds also include all enol, tautomeric, and resonance isomers, enantiomers, diastereomers, and racemic mixtures thereof. Formula I and II compounds are related as regioisomers, constrained to their particular isomeric forms by their covalent substituents;  $R^1$ ,  $R^{2a}$ ,  $R^{2b}$ ,  $R^3$ ,  $R^4$ , and  $R^5$ .
- 15  $R^1$  is selected from H, F, Cl, Br, I, OH, OR, amino ( $-NH_2$ ), ammonium ( $-NH_3^+$ ), alkylamino ( $-NHR$ ), dialkylamino ( $-NR_2$ ), trialkylammonium ( $-NR_3^+$ ), carboxyl ( $-CO_2H$ ), sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, 4-dialkylaminopyridinium, alkylsulfone ( $-SO_2R$ ), arylsulfone ( $-SO_2Ar$ ), arylsulfoxide ( $-SOAr$ ), arylthio ( $-SAr$ ), sulfonamide

( $-\text{SO}_2\text{NR}_2$ ), alkylsulfoxide ( $-\text{SOR}$ ), formyl ( $-\text{CHO}$ ), ester ( $-\text{CO}_2\text{R}$ ), amido ( $-\text{C}(=\text{O})\text{NR}_2$ ), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile ( $-\text{CN}$ ), azido ( $-\text{N}_3$ ), nitro ( $-\text{NO}_2$ ),  $\text{C}_1-\text{C}_{18}$  alkyl,  $\text{C}_1-\text{C}_{18}$  substituted alkyl,  $\text{C}_2-\text{C}_{18}$  alkenyl,  $\text{C}_2-\text{C}_{18}$  substituted alkenyl,  $\text{C}_2-\text{C}_{18}$  alkynyl,  $\text{C}_2-\text{C}_{18}$  substituted alkynyl,  $\text{C}_6-\text{C}_{20}$  aryl,  $\text{C}_6-\text{C}_{20}$  substituted aryl,  $\text{C}_2-\text{C}_{20}$  heterocycle, and  $\text{C}_2-\text{C}_{20}$  substituted heterocycle, phosphonate, phosphate, polyethyleneoxy, a protecting group,  $\text{L}-\text{A}^3$ , and a prodrug moiety.

$\text{R}^{2a}$  and  $\text{R}^5$  are each independently selected from H, carboxyl ( $-\text{CO}_2\text{H}$ ), sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, 4-dialkylaminopyridinium, alkylsulfone ( $-\text{SO}_2\text{R}$ ), arylsulfone ( $-\text{SO}_2\text{Ar}$ ), arylsulfoxide ( $-\text{SOAr}$ ), arylthio ( $-\text{SAr}$ ), sulfonamide ( $-\text{SO}_2\text{NR}_2$ ), alkylsulfoxide ( $-\text{SOR}$ ), formyl ( $-\text{CHO}$ ), ester ( $-\text{CO}_2\text{R}$ ), amido ( $-\text{C}(=\text{O})\text{NR}_2$ ), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile ( $-\text{CN}$ ), azido ( $-\text{N}_3$ ), nitro ( $-\text{NO}_2$ ),  $\text{C}_1-\text{C}_{18}$  alkyl,  $\text{C}_1-\text{C}_{18}$  substituted alkyl,  $\text{C}_2-\text{C}_{18}$  alkenyl,  $\text{C}_2-\text{C}_{18}$  substituted alkenyl,  $\text{C}_2-\text{C}_{18}$  alkynyl,  $\text{C}_2-\text{C}_{18}$  substituted alkynyl,  $\text{C}_6-\text{C}_{20}$  aryl,  $\text{C}_6-\text{C}_{20}$  substituted aryl,  $\text{C}_2-\text{C}_{20}$  heterocycle, and  $\text{C}_2-\text{C}_{20}$  substituted heterocycle, phosphonate, phosphate, polyethyleneoxy, a protecting group,  $\text{L}-\text{A}^3$ , and a prodrug moiety.

$\text{R}^{2b}$ ,  $\text{R}^3$ , and  $\text{R}^4$  are each independently selected from H, OH, OR, amino ( $-\text{NH}_2$ ), ammonium ( $-\text{NH}_3^+$ ), alkylamino ( $-\text{NHR}$ ), dialkylamino ( $-\text{NR}_2$ ), trialkylammonium ( $-\text{NR}_3^+$ ), carboxyl ( $-\text{CO}_2\text{H}$ ), sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, 4-dialkylaminopyridinium, alkylsulfone ( $-\text{SO}_2\text{R}$ ), arylsulfone ( $-\text{SO}_2\text{Ar}$ ), arylsulfoxide ( $-\text{SOAr}$ ), arylthio ( $-\text{SAr}$ ), sulfonamide ( $-\text{SO}_2\text{NR}_2$ ), alkylsulfoxide ( $-\text{SOR}$ ), formyl ( $-\text{CHO}$ ), ester ( $-\text{CO}_2\text{R}$ ), amido ( $-\text{C}(=\text{O})\text{NR}_2$ ), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile ( $-\text{CN}$ ), azido ( $-\text{N}_3$ ), nitro ( $-\text{NO}_2$ ),  $\text{C}_1-\text{C}_{18}$  alkyl,  $\text{C}_1-\text{C}_{18}$  substituted alkyl,  $\text{C}_2-\text{C}_{18}$  alkenyl,  $\text{C}_2-\text{C}_{18}$  substituted alkenyl,  $\text{C}_2-\text{C}_{18}$  alkynyl,  $\text{C}_2-\text{C}_{18}$  substituted alkynyl,  $\text{C}_6-\text{C}_{20}$  aryl,  $\text{C}_6-\text{C}_{20}$  substituted aryl,  $\text{C}_2-\text{C}_{20}$  heterocycle, and  $\text{C}_2-\text{C}_{20}$  substituted heterocycle, phosphonate, phosphate, polyethyleneoxy, a protecting group,  $\text{L}-\text{A}^3$ , and a prodrug moiety.


$\text{R}$  is independently selected from H,  $\text{C}_1-\text{C}_{18}$  alkyl,  $\text{C}_1-\text{C}_{18}$  substituted alkyl,  $\text{C}_2-\text{C}_{18}$  alkenyl,  $\text{C}_2-\text{C}_{18}$  substituted alkenyl,  $\text{C}_2-\text{C}_{18}$  alkynyl,  $\text{C}_2-\text{C}_{18}$  substituted alkynyl,  $\text{C}_6-\text{C}_{20}$  aryl,  $\text{C}_6-\text{C}_{20}$  substituted aryl,  $\text{C}_2-\text{C}_{20}$  heterocycle,  $\text{C}_2-\text{C}_{20}$  substituted heterocycle, phosphonate, phosphate, polyethyleneoxy, a protecting group, and a prodrug moiety.



Substituted alkyl, substituted alkenyl, substituted alkynyl, substituted aryl, and substituted heterocycle are independently substituted with one or more substituents selected from F, Cl, Br, I, OH, amino ( $-\text{NH}_2$ ), ammonium ( $-\text{NH}_3^+$ ), alkylamino ( $-\text{NHR}$ ), dialkylamino ( $-\text{NR}_2$ ), trialkylammonium ( $-\text{NR}_3^+$ ),  $\text{C}_1\text{--C}_8$  alkyl,  $\text{C}_1\text{--C}_8$  alkylhalide, carboxylate, thiol ( $-\text{SH}$ ), sulfate ( $-\text{OSO}_3\text{R}$ ), sulfamate, sulfonate ( $-\text{SO}_3\text{R}$ ), 5-7 membered ring sultam,  $\text{C}_1\text{--C}_8$  alkylsulfonate,  $\text{C}_1\text{--C}_8$  alkylamino, 4-dialkylaminopyridinium,  $\text{C}_1\text{--C}_8$  alkylhydroxyl,  $\text{C}_1\text{--C}_8$  alkylthiol, alkylsulfone ( $-\text{SO}_2\text{R}$ ), arylsulfone ( $-\text{SO}_2\text{Ar}$ ), arylsulfoxide ( $-\text{SOAr}$ ), arylthio ( $-\text{SAr}$ ), sulfonamide ( $-\text{SO}_2\text{NR}_2$ ), alkylsulfoxide ( $-\text{SOR}$ ), ester ( $-\text{C}(=\text{O})\text{OR}$ ), amido ( $-\text{C}(=\text{O})\text{NR}_2$ ), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile ( $-\text{CN}$ ), azido ( $-\text{N}_3$ ), nitro ( $-\text{NO}_2$ ),  $\text{C}_1\text{--C}_8$  alkoxy ( $-\text{OR}$ ),  $\text{C}_1\text{--C}_8$  alkyl,  $\text{C}_1\text{--C}_8$  substituted alkyl,  $\text{C}_6\text{--C}_{20}$  aryl,  $\text{C}_6\text{--C}_{20}$  substituted aryl,  $\text{C}_2\text{--C}_{20}$  heterocycle, and  $\text{C}_2\text{--C}_{20}$  substituted heterocycle, phosphonate, phosphate, polyethyleneoxy, and a prodrug moiety.

Embodiments of  $\text{R}^1$ ,  $\text{R}^{2a}$ ,  $\text{R}^{2b}$ ,  $\text{R}^3$ ,  $\text{R}^4$ , and  $\text{R}^5$  include  $-\text{C}(=\text{S})\text{NR}_2$ ,  $-\text{C}(=\text{O})\text{OR}$ ,  $-\text{C}(=\text{O})\text{NR}_2$ ,  $-\text{C}(=\text{O})\text{NRNR}_2$ ,  $-\text{C}(=\text{O})\text{R}$ ,  $-\text{SO}_2\text{NR}_2$ ,  $-\text{NRSO}_2\text{R}$ ,  $-\text{NRC}(=\text{S})\text{NR}_2$ ,  $-\text{SR}$ ,  $-\text{S}(\text{O})\text{R}$ ,  $-\text{SO}_2\text{R}$ ,  $-\text{SO}_2\text{R}$ ,  $-\text{P}(=\text{O})(\text{OR})_2$ ,  $-\text{P}(=\text{O})(\text{OR})(\text{NR}_2)$ ,  $-\text{P}(=\text{O})(\text{NR}_2)_2$ ,  $-\text{P}(=\text{S})(\text{OR})_2$ ,  $-\text{P}(=\text{S})(\text{OR})(\text{NR}_2)$ ,  $-\text{P}(=\text{S})(\text{NR}_2)_2$ , and including prodrug substituted forms thereof.

Embodiments of  $\text{R}^1$ ,  $\text{R}^{2a}$ ,  $\text{R}^{2b}$ ,  $\text{R}^3$ ,  $\text{R}^4$ , and  $\text{R}^5$  may also individually or in combination form a ring, e.g. 4-7 membered ring lactam, carbonate, or sultam, or piperazinyl sulfamate:




Embodiments of  $\text{R}^1$  also include  $-\text{OC}(=\text{S})\text{NR}_2$ ,  $-\text{OC}(=\text{O})\text{OR}$ ,  $-\text{OC}(=\text{O})\text{NR}_2$ ,  $-\text{OC}(=\text{O})\text{NRNR}_2$ ,  $-\text{OC}(=\text{O})\text{R}$ ,  $-\text{OP}(=\text{O})(\text{OR})_2$ ,  $-\text{OP}(=\text{O})(\text{OR})(\text{NR}_2)$ ,  $-\text{OP}(=\text{O})(\text{NR}_2)_2$ ,  $-\text{OP}(=\text{S})(\text{OR})_2$ ,  $-\text{OP}(=\text{S})(\text{OR})(\text{NR}_2)$ ,  $-\text{OP}(=\text{S})(\text{NR}_2)_2$ , and including prodrug substituted forms thereof.

A linker may be interposed between positions  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ , or  $\text{R}^5$  and substituent  $\text{A}^3$ , as exemplified in some structures herein as “ $\text{L-A}^3$ ”. The linker L may be O, S, NR, N-OR,  $\text{C}_1\text{--C}_{12}$  alkylene,  $\text{C}_1\text{--C}_{12}$  substituted alkylene,  $\text{C}_2\text{--C}_{12}$  alkenylene,  $\text{C}_2\text{--C}_{12}$  substituted

alkenylene, C<sub>2</sub>-C<sub>12</sub> alkynylene, C<sub>2</sub>-C<sub>12</sub> substituted alkynylene, C(=O)NH, C(=O), S(=O)<sub>2</sub>, C(=O)NH(CH<sub>2</sub>)<sub>n</sub>, and (CH<sub>2</sub>CH<sub>2</sub>O)<sub>n</sub>, where n may be 1, 2, 3, 4, 5, or 6. Linkers may also be repeating units of alkyloxy (e.g. polyethylenoxy, PEG, polymethyleneoxy) and alkylamino (e.g. polyethyleneamino, Jeffamine™); and diacid ester and amides including succinate, succinamide, diglycolate, malonate, and caproamide. For example, the linker may comprise propargyl, urea, or alkoxy groups.

A<sup>3</sup> has the structure:



where:

Y<sup>1</sup> is independently O, S, NR<sup>x</sup>, N(O)(R<sup>x</sup>), N(OR<sup>x</sup>), N(O)(OR<sup>x</sup>), or N(N(R<sup>x</sup>)<sub>2</sub>);

Y<sup>2</sup> is independently a bond, O, NR<sup>x</sup>, N(O)(R<sup>x</sup>), N(OR<sup>x</sup>), N(O)(OR<sup>x</sup>), N(N(R<sup>x</sup>)<sub>2</sub>), -S(O)- (sulfoxide), -S(O)<sub>2</sub>- (sulfone), -S- (sulfide), or -S-S- (disulfide);

M2 is 0, 1 or 2;

M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; and

M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12.

R<sup>y</sup> is independently H, C<sub>1</sub>-C<sub>18</sub> alkyl, C<sub>1</sub>-C<sub>18</sub> substituted alkyl, C<sub>6</sub>-C<sub>20</sub> aryl, C<sub>6</sub>-C<sub>20</sub> substituted aryl, or a protecting group, or where taken together at a carbon atom, two vicinal R<sup>y</sup> groups form a carbocycle or a heterocycle. Alternatively, taken together at a carbon atom, two vicinal R<sup>y</sup> groups form a ring, i.e. a spiro carbon. The ring may be all carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, or alternatively, the ring may contain one or more heteroatoms, for example, piperazinyl, piperidiny, pyran, or tetrahydrofuryl.

R<sup>x</sup> is independently H, C<sub>1</sub>-C<sub>18</sub> alkyl, C<sub>1</sub>-C<sub>18</sub> substituted alkyl, C<sub>6</sub>-C<sub>20</sub> aryl, C<sub>6</sub>-C<sub>20</sub> substituted aryl, or a protecting group, or the formula:




8, 9, 10, 11 or 12.

At least one of R, R<sup>1</sup>, R<sup>2a</sup>, R<sup>2b</sup>, R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> in each Formula I and Formula II


**5** compound comprises a phosphonate group.

Exemplary embodiments of C<sub>6</sub>–C<sub>20</sub> substituted aryl groups include halo-substituted phenyl such as 4-fluorophenyl, 4-chlorophenyl, 3,5-dichlorophenyl, and 3,5-difluorophenyl.

**Ar groups include:**




10



where a wavy line , in any orientation, indicates the covalent attachment site of the other


structural moieties of the compound.

Examples of substituted phenyl groups include:





- 5 A compound of the invention includes one or more phosphonate group or phosphonate prodrug moiety. At least one of  $R^1$ ,  $R^{2a}$ ,  $R^{2b}$ ,  $R^3$ ,  $R^4$ , and  $R^5$  comprises a phosphonate group. The phosphonate group may be a prodrug moiety. The phosphonate group may be directly attached to a carbon, nitrogen or oxygen atom of Formula I or Formula II. Alternatively, and by example,  $R^1$ ,  $R^{2a}$ ,  $R^{2b}$ ,  $R^3$ ,  $R^4$ , and  $R^5$  may comprise the structure  $A^3$ .

- 10 Embodiments of  $A^3$  include where M2 is 0, such as:




and where M12b is 1,  $Y^1$  is oxygen, and  $Y^{2b}$  is independently oxygen (O) or nitrogen ( $N(R^x)$ ) such as:






An embodiment of A<sup>3</sup> includes:




- 5 where W<sup>5</sup> is a carbocycle such as phenyl or substituted phenyl, and Y<sup>2c</sup> is independently O, N(R<sup>y</sup>) or S. For example, R<sup>1</sup> may be H and n may be 1.


W<sup>5</sup> also includes, but is not limited to, aryl and heterocycle groups such as:



Another embodiment of A<sup>3</sup> includes:




Such embodiments include:




where  $Y^{2b}$  is O or  $N(R^x)$ ; M12d is 1, 2, 3, 4, 5, 6, 7 or 8;  $R^a$  is H or  $C_1-C_6$  alkyl; and the

5 phenyl carbocycle is substituted with 0 to 3  $R^b$  groups where  $R^b$  is  $C_1-C_6$  alkyl or substituted alkyl. Such embodiments of  $A^3$  include phenyl phosphonamidate amino acid, e.g. alanate esters and phenyl phosphonate-lactate esters:




Embodiments of  $R^x$  include esters, carbamates, carbonates, thioesters, amides,





10 thioamides, and urea groups:



Exemplary structures within Formula I include **Ia**, **Ib**, **Ic**, **Id**:



5 Exemplary structures within Formula II include **IIa**, **IIb**, **IIc**, **IId**:



The compounds of the invention include one or more prodrug moieties located as a covalently-attached substituent at any location of Formula I or Formula II, e.g.  $R^1$ ,  $R^{2a}$ ,  $R^{2b}$ ,  $R^3$ ,  $R^4$ , or  $R^5$ . One substituent which may be modified as a prodrug moiety is a phosphonate, phosphate, phosphinate or other phosphorus functionality (Oliyai et al *Pharmaceutical Res.* (1999) 16:1687-1693; Krise, J. and Stella, V. *Adv. Drug Del. Reviews* (1996) 19:287-310; Bischofberger et al, U.S. Patent No. 5,798,340). Prodrug moieties of phosphorus functionality serve to mask anionic charges and decrease polarity. The phosphonate prodrug moiety may be an ester (Oliyai, et al *Intl. Jour. Pharmaceutics* (1999) 179:257-265), e.g. POC and POM (pivaloyloxymethyl, Yuan, et al *Pharmaceutical Res.* (2000) 17:1098-1103), or amidate which separates from the integrase inhibitor compound *in vivo* or by exposure *in vitro* to biological conditions, e.g. cells, tissue isolates. The separation may be mediated by general hydrolytic conditions, oxidation, enzymatic action or a combination of steps.

Compounds of the invention bearing one or more prodrug moieties may increase or optimize the bioavailability of the compounds as therapeutic agents. For example,




bioavailability after oral administration may be preferred and depend on resistance to metabolic degradation in the gastrointestinal tract or circulatory system, and eventual uptake inside cells. Prodrug moieties are considered to confer said resistance by slowing certain hydrolytic or enzymatic metabolic processes. Lipophilic prodrug moieties may also increase active or passive transport of the compounds of the invention across cellular membranes (Darby, G. *Antiviral Chem. & Chemotherapy* (1995) Supp. 1, 6:54-63).

In one aspect, the compounds of the invention include an active form for inhibition of nuclear integration of reverse-transcribed HIV DNA.

Exemplary embodiments of the invention includes phosphonamidate and phosphoramidate (collectively "amidate") prodrug compounds. General formulas for phosphonamidate and phosphoramidate prodrug moieties include:




The phosphorus atom of the phosphonamidate group is bonded to a carbon atom. The nitrogen substituent  $\text{R}^8$  may include an ester, an amide, or a carbamate functional group. For example,  $\text{R}^8$  may be  $\text{---CR}_2\text{C(=O)OR}'$  where  $\text{R}'$  is H,  $\text{C}_1\text{--C}_6$  alkyl,  $\text{C}_1\text{--C}_6$  substituted alkyl,  $\text{C}_6\text{--C}_{20}$  aryl,  $\text{C}_6\text{--C}_{20}$  substituted aryl,  $\text{C}_2\text{--C}_{20}$  heterocycle, or  $\text{C}_2\text{--C}_{20}$  substituted heterocycle. The nitrogen atom may comprise an amino acid residue within the prodrug moiety, such as a glycine, alanine, or valine ester (e.g. valacyclovir, see: Beauchamp, etal *Antiviral Chem. Chemotherapy* (1992) 3:157-164), such as the general structure:



where  $\text{R}'$  is the amino acid side-chain, e.g. H,  $\text{CH}_3$ ,  $\text{CH}(\text{CH}_3)_2$ , etc.

An exemplary embodiment of a phosphoramidate prodrug moiety is:



Those of skill in the art will also recognize that the compounds of the invention may exist in many different protonation states, depending on, among other things, the pH of their environment. While the structural formulae provided herein depict the compounds in only one of several possible protonation states, it will be understood that these structures are illustrative only, and that the invention is not limited to any particular protonation state--any and all protonated forms of the compounds are intended to fall within the scope of the invention.

The compounds of this invention optionally comprise salts of the compounds herein, especially pharmaceutically acceptable non-toxic salts containing, for example,  $\text{Na}^+$ ,  $\text{Li}^+$ ,  $\text{K}^+$ ,  $\text{Ca}^{+2}$  and  $\text{Mg}^{+2}$ . Such salts may include those derived by combination of appropriate cations such as alkali and alkaline earth metal ions or ammonium and quaternary amino ions with an acid anion moiety, typically a carboxylic acid. The compounds of the invention may bear multiple positive or negative charges. The net charge of the compounds of the invention may be either positive or negative. Any associated counter ions are typically dictated by the synthesis and/or isolation methods by which the compounds are obtained. Typical counter ions include, but are not limited to ammonium, sodium, potassium, lithium, halides, acetate, trifluoroacetate, etc., and mixtures thereof. It will be understood that the identity of any associated counter ion is not a critical feature of the invention, and that the invention encompasses the compounds in association with any type of counter ion. Moreover, as the compounds can exist in a variety of different forms, the invention is intended to encompass not only forms of the compounds that are in association with counter ions (e.g., dry salts), but also forms that are not in association with counter ions (e.g., aqueous or organic solutions).

Metal salts typically are prepared by reacting the metal hydroxide with a compound of this invention. Examples of metal salts which are prepared in this way are salts containing  $\text{Li}^+$ ,  $\text{Na}^+$ , and  $\text{K}^+$ . A less soluble metal salt can be precipitated from the solution of a more

soluble salt by addition of the suitable metal compound. In addition, salts may be formed from acid addition of certain organic and inorganic acids, e.g., HCl, HBr, H<sub>2</sub>SO<sub>4</sub>, H<sub>3</sub>PO<sub>4</sub> or organic sulfonic acids, to basic centers, typically amines, or to acidic groups. Finally, it is to be understood that the compositions herein comprise compounds of the invention in their unionized, as well as zwitterionic form, and combinations with stoichiometric amounts of water as in hydrates.

Also included within the scope of this invention are the salts of the parental compounds with one or more amino acids, especially the naturally-occurring amino acids found as protein components. The amino acid typically is one bearing a side chain with a basic or acidic group, e.g., lysine, arginine or glutamic acid, or a neutral group such as glycine, serine, threonine, alanine, isoleucine, or leucine.

The compounds of the invention can also exist as tautomeric, resonance isomers in certain cases. Typically, the structures shown herein exemplify only one tautomeric or resonance form of the compounds. For example, hydrazine, oxime, hydrazone groups may be shown in either the syn or anti configurations. The corresponding alternative configuration is contemplated as well. All possible tautomeric and resonance forms are within the scope of the invention.

One enantiomer of a compound of the invention can be separated substantially free of its opposing enantiomer by a method such as formation of diastereomers using optically active resolving agents (Stereochemistry of Carbon Compounds, (1962) by E. L. Eliel, McGraw Hill; Lochmuller, C. H., (1975) *J. Chromatogr.*, 113:(3) 283-302). Separation of diastereomers formed from the racemic mixture can be accomplished by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure enantiomers. Alternatively, enantiomers can be separated directly under chiral conditions, method (3).

Under method (1), diastereomeric salts can be formed by reaction of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine,  $\alpha$ -methyl- $\beta$ -phenylethylamine (amphetamine), and the like with asymmetric compounds bearing acidic functionality, such as carboxylic acid and sulfonic acid. The diastereomeric salts may be

induced to separate by fractional crystallization or ionic chromatography. For separation of the optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids, such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts.

5           Alternatively, by method (2), the substrate to be resolved may be reacted with one enantiomer of a chiral compound to form a diastereomeric pair (Eliel, E. and Wilen, S. (1994) Stereochemistry of Organic Compounds, John Wiley & Sons, Inc., p. 322). Diastereomeric compounds can be formed by reacting asymmetric compounds with enantiomerically pure chiral derivatizing reagents, such as menthyl derivatives, followed by separation of the  
10   diastereomers and hydrolysis to yield the free, enantiomerically enriched xanthene. A method of determining optical purity involves making chiral esters, such as a menthyl ester or Mosher ester,  $\alpha$ -methoxy- $\alpha$ -(trifluoromethyl)phenyl acetate (Jacob III. (1982) *J. Org. Chem.* 47:4165), of the racemic mixture, and analyzing the NMR spectrum for the presence of the two atropisomeric diastereomers. Stable diastereomers can be separated and isolated by  
15   normal- and reverse-phase chromatography following methods for separation of atropisomeric naphthyl-isoquinolines (Hoye, T., WO 96/15111).

By method (3), a racemic mixture of two asymmetric enantiomers can be separated by chromatography using a chiral stationary phase (Chiral Liquid Chromatography (1989) W. J. Lough, Ed. Chapman and Hall, New York; Okamoto, (1990) "Optical resolution of  
20   dihydropyridine enantiomers by High-performance liquid chromatography using phenylcarbamates of polysaccharides as a chiral stationary phase", *J. of Chromatogr.* 513:375-378).

Enantiomers can be distinguished by methods used to distinguish other chiral molecules with asymmetric carbon atoms, such as optical rotation and circular dichroism.

## 25   SYNTHESIS OF PYRIMIDINE AND PYRIMIDINONE PHOSPHONATE COMPOUNDS

The compounds of the invention may be prepared by a variety of synthetic routes and methods known to those skilled in the art. The invention also relates to methods of making the compounds of the invention. The compounds are prepared by any of the applicable techniques of organic synthesis. Many such techniques are well known in the art. However,  
30   many of the known techniques are elaborated in: Compendium of Organic Synthetic Methods,

John Wiley & Sons, New York, Vol. 1 Ian T. Harrison and Shuyen Harrison, 1971; Vol. 2, Ian T. Harrison and Shuyen Harrison, 1974; Vol. 3, Louis S. Hegedus and Leroy Wade, 1977; Vol. 4, Leroy G. Wade, jr., 1980; Vol. 5, Leroy G. Wade, Jr., 1984; and Vol. 6, Michael B. Smith; as well as March, J., Advanced Organic Chemistry, Third Edition, John Wiley & Sons, New York, 1985; Comprehensive Organic Synthesis. Selectivity, Strategy & Efficiency in Modern Organic Chemistry (9 Volume set) Barry M. Trost, Editor-in-Chief, Pergamon Press, New York, 1993.

A number of exemplary methods for the preparation of the compounds of the invention are provided herein. These methods are intended to illustrate the nature of such preparations are not intended to limit the scope of applicable methods.

Deliberate use may be made of protecting groups to mask reactive functionality and direct reactions regioselectively (Greene, etal (1991) Protective Groups in Organic Synthesis, 2nd Ed., John Wiley & Sons). For example, useful protecting groups for the 8-hydroxyl group and other hydroxyl substituents include methyl, MOM (methoxymethyl), trialkylsilyl, benzyl, benzoyl, trityl, and tetrahydropyranyl. Certain aryl positions may be blocked from substitution, such as the 2-position as fluorine.

Dihydroxypyrimidine carboxamide (WO 03/035076A1) and N-substituted hydroxypyrimidinone carboxamide (WO 03/035077A1) compounds have been prepared.


#### **Preparation of Formula Ia-d and Formula IIa-d phosphonate esters.**

Structures of exemplary pyrimidine Formula I phosphonate esters **Ia-d** are shown in Chart 1. Structures of exemplary pyrimidine Formula II phosphonate esters **IIa-d** are shown in Chart 2. Ring substituents  $R^1$ ,  $R^{2a}$ ,  $R^{2b}$ ,  $R^3$ ,  $R^4$ , and  $R^5$  are as previously defined. Phosphonate ester substituent  $R^x$  is as previously defined. Compounds of Formula **Ia-d** and Formula **IIa-d** may each be an active pharmaceutical ingredient, or an intermediate for preparing other compounds of the invention by subsequent chemical modifications.

Compounds of Formula **Ia-d** and Formula **IIa-d** incorporate a phosphonate group  $(R^1O)_2P(O)$  connected to the pyrimidine and pyrimidinone scaffold, respectively, by means of a divalent and variable linking group, designated as "L" in the attached structures. Charts 3 and 4 illustrates examples of the phosphonate linking groups  $(L-A^3)$  present in the structures **Ia-d** and **IIa-d**.

- The methods described for the introduction of phosphonate substituents are, with modifications made by one skilled in the art, transferable within the phosphonate esters **Ia-d** and **IIa-d**. For example, reaction sequences which produce the phosphonates **Ia** are, with appropriate modifications, applicable to the preparation of the phosphonates **Ib-d** and **IIa-d**.
- 5 Methods described below for the attachment of phosphonate groups by means of reactive substituents such as OH, Br, NH<sub>2</sub>, CH<sub>3</sub>, CH<sub>2</sub>Br, COOH, CHO etc are applicable to each of the scaffolds **Ia-d** and **IIa-d**.

**Chart 1. Structures of the pyrimidine phosphonates Ia-d**



**Chart 2. Structures of pyrimidinone phosphonates IIa-d**



























Chart 3. Examples of phosphonate linkages L-A<sup>3</sup>





**Chart 4. Examples of phosphonate linkages L-A<sup>3</sup>**



Schemes 1-31 illustrate the syntheses of the phosphonate compounds of this invention, Formulas I and II, and of the intermediate compounds necessary for their synthesis.

- 5        Scheme 32 illustrates methods for the interconversion of phosphonate diesters, monoesters and acids, and Scheme 33 illustrates methods for the preparation of carbamates. Schemes 34-37 illustrate the conversion of phosphonate esters and phosphonic acids into carboalkoxy-substituted phosphondiamidates, phosphonamidates, phosphonate monoesters, phosphonate diesters. Scheme 38 illustrates further synthesis of gem-dialkyl amino
- 10       phosphonate reagents for preparation of Formulas I and II compounds.

**Protection of reactive substituents.**

Depending on the reaction conditions employed, it may be necessary to protect certain reactive substituents from unwanted reactions by protection before the sequence described, and to deprotect the substituents afterwards, according to the knowledge of one skilled in the art. Protection and deprotection of functional groups are described, for example, in Protective Groups in Organic Synthesis, by T.W. Greene and P.G.M. Wuts, Wiley, Second Edition 1990. Reactive substituents which may be protected are shown in the accompanying schemes as, for example, [OH], [SH], [NH] etc. Protecting groups are also exemplified as "PG". The selection of a suitable stage in the synthetic sequence for the introduction of the phosphonate group is made by one skilled in the art, depending on the reactivity and stability of the substrates in a given reaction sequence.


#### Protection of phosphonate esters

Scheme 3a depicts the preparation of phosphonate esters **Id** and **IId** in which the phosphonate group is directly attached to the group Ar. In this procedure, a bromo-substituted amine **3.1**, in which Ar is an aromatic or heteroaromatic group, is reacted, in the presence of a palladium catalyst, with a dialkyl phosphite **3.2** to yield the aryl phosphonate **3.3**. The preparation of arylphosphonates by means of a coupling reaction between aryl bromides and dialkyl phosphites is described in *J. Med. Chem.*, 35, 1371, 1992. This reaction is performed in an inert solvent such as toluene, in the presence of a base such as triethylamine and a palladium (0) catalyst such as tetrakis(triphenylphosphine)palladium(0). Optionally, the amine group is protected prior to the coupling reaction, and deprotected afterwards.

Amine reagent **3.3** is reacted with the ester **3.4** to afford the amide **3.5**, and with the ester **3.6** to afford the amide **3.7**. The conversion of esters into amides is described in Comprehensive Organic Transformations, by R. C. Larock, VCH, 1989, p. 987. The reactants are combined in a solvent such as toluene or xylene, in the presence of a base such as sodium methoxide under azeotropic conditions, or of a dialkyl aluminum or trialkyl tin derivative of the amine. The use of trimethylaluminum in the conversion of esters to amides is described in *J. Med. Chem. Chim. Ther.*, 34, 1999, 1995, and *Syn. Comm.*, 25, 1401, 1995. The reaction is conducted in an inert solvent such as dichloromethane or toluene. The conversion of esters such as **3.4** and **3.6**, or the corresponding carboxylic acids, into amides is described in WO 03035077 A1, Optionally, the 5-hydroxyl group of the ester **3.4** and **3.6** is protected, for example as a p-toluenesulfonyl derivative, prior to reaction with the amine component **3.3**.

### Scheme 3a. Phosphonates Id and IId.

#### Method




For example, 3-bromo-4-fluorobenzylamine **3.8** (Lancaster) is reacted in toluene solution at ca. 100 °C, with one molar equivalent of a dialkyl phosphite **3.9**, triethylamine and 3 mol % of tetrakis(triphenylphosphine)palladium(0), to give the phosphonate product **3.10** in

5 Scheme 3b. Compound **3.10** is then reacted, in toluene solution at reflux temperature with **3.11** to yield the pyrimidine amide **3.12**. Alternatively, **3.10** is reacted, in toluene solution at reflux temperature with **3.13** to yield the pyrimidinone amide **3.14**

Using the above procedures, but employing, in place of the amine **3.8**, different amines **3.1**, and/or different esters **3.4**, the corresponding amides **3.5** are obtained.

**Scheme 3b.**

**Example**



Scheme 4 depicts the preparation of phosphonate esters **1** in which the phosphonate group is attached by means of a saturated or unsaturated alkylene chain. In this procedure, a bromo-substituted amine **4.1**, in which Ar is an aryl or heterocycle group, is subjected to a Heck coupling reaction, in the presence of a palladium catalyst, with a dialkyl alkenyl phosphonate **4.2**, in which  $\text{R}^{5a}$  is a direct bond, a divalent group such as alkylene, alkenylene, alkynylene or cycloalkylene group, optionally incorporating a heteroatom O, S or N, ethyleneoxy, polyethyleneoxy, or a functional group such as an amide, ester, oxime, sulfoxide or sulfone etc, or an optionally substituted aryl, heterocycle or aralkyl group, to give the amine **4.3**. The coupling of aryl halides with olefins by means of the Heck reaction is described, for example, in Advanced Organic Chemistry, by F. A. Carey and R. J. Sundberg,


Plenum, 2001, p. 503ff and in *Acc. Chem. Res.*, 12, 146, 1979. The aryl bromide and the olefin are coupled in a polar solvent such as dimethylformamide or dioxane, in the presence of a palladium(0) catalyst such as tetrakis(triphenylphosphine)palladium(0) or a palladium(II) catalyst such as palladium(II) acetate, and optionally in the presence of a base such as triethylamine or potassium carbonate. Optionally, the amine substituent is protected prior to the coupling reaction, and deprotected afterwards. The phosphonate amine 4.3 is then coupled, as described above, with the ester 4.4, or the corresponding carboxylic acid, to produce the amide 4.5. Optionally, the double bond is reduced to give the saturated analog 4.6. The reduction of olefinic bonds is described in Comprehensive Organic Transformations, by R. C. Larock, VCH, 1989, p. 6ff. The transformation is effected by means of catalytic hydrogenation, for example using a palladium on carbon catalyst and hydrogen or a hydrogen donor, or by the use of diimide or diborane.

For example, 3-bromo-4-methoxybenzylamine 4.7 (Lancaster) is reacted in dioxane solution with one molar equivalent of a dialkyl vinyl phosphonate 4.8 (Aldrich) and potassium carbonate, to yield the olefinic phosphonate 4.9. The product is then reacted, as described above, with 6-methyl ester 4.10, prepared as described in Scheme 1A, to give the amide 4.11. The latter compound is reacted with diimide, prepared by basic hydrolysis of diethyl azodicarboxylate, as described in *Angew. Chem. Int. Ed.*, 4, 271, (1965), to yield the saturated product 4.12.


Using the above procedures, but employing, in place of the amine 4.7, different amines 4.1, and/or different phosphonates 4.2, and/or different bicyclic esters 4.4, the corresponding amides 4.5 and 4.6 are obtained.

#### Scheme 4. Phosphonates 1.

##### Method



##### Example



Scheme 5 depicts the preparation of phosphonate esters **Id** in which the phosphonate group is attached by means of an amide linkage. In this procedure, the amine group of a carboxy-substituted amine **5.1** is protected to afford the derivative **5.2**. The protection of amino groups is described in Protective Groups in Organic Synthesis, by T.W. Greene and P.G.M. Wuts, Wiley, Second Edition 1990, p. 309ff. Amino groups are protected, for example by alkylation, such as by mono or dibenylation, or by acylation. The conversion of amines into mono or dibenzylamines, for example by treatment with benzyl bromide in a polar solvent such as acetonitrile or aqueous ethanol, in the presence of a base such as triethylamine or sodium carbonate, is described in Protective Groups in Organic Synthesis, by T.W. Greene

and P.G.M. Wuts, Wiley, Second Edition 1990, p. 364. The N-protected carboxylic acid 5.2 is then coupled with an amino-substituted dialkyl phosphonate 5.3, in which the group R<sup>5a</sup> is as defined in Scheme 4, to yield the amide 5.4. The preparation of amides from carboxylic acids and derivatives is described, for example, in Organic Functional Group Preparations, by S.R.

- 5 Sandler and W. Karo, Academic Press, 1968, p. 274, and in Comprehensive Organic Transformations, by R. C. Larock, VCH, 1989, p. 972ff. The carboxylic acid is reacted with the amine in the presence of an activating agent, such as, for example, dicyclohexylcarbodiimide or diisopropylcarbodiimide, optionally in the presence of, for example, hydroxybenzotriazole, N-hydroxysuccinimide or N-hydroxypyridone, in a non-protic solvent such as, for example, pyridine, DMF or dichloromethane, to afford the amide.

Alternatively, the carboxylic acid is first converted into an activated derivative such as the acid chloride, anhydride, mixed anhydride, imidazolide and the like, and then reacted with the amine, in the presence of an organic base such as, for example, pyridine, to afford the amide.

- 15 The conversion of a carboxylic acid into the corresponding acid chloride is effected by treatment of the carboxylic acid with a reagent such as, for example, thionyl chloride or oxalyl chloride in an inert organic solvent such as dichloromethane, optionally in the presence of a catalytic amount of dimethylformamide.

- The amino-protecting group is then removed from the product 5.4 to give the free amine 5.5. Deprotection of amines is described in Protective Groups in Organic Synthesis, by T.W. Greene and P.G.M. Wuts, Wiley, Second Edition 1990, p. 309ff. The amine is then coupled with the carboxylic acid 5.6, as described above, to produce the amide 5.7.


- For example, 4-carboxycyclohexylmethylamine 5.8 (Aldrich) is converted into the phthalimido derivative 5.9 (pht = phthalimide). The conversion of amines into phthalimido derivatives is described in Protective Groups in Organic Synthesis, by T.W. Greene and P.G.M. Wuts, Wiley, Second Edition 1990, p. 358. The conversion is effected by reaction of the amine with an equimolar amount of 2-carbomethoxybenzoyl chloride, N-carboethoxyphthalimide, or preferably, phthalic anhydride. The reaction is performed in an inert solvent such as toluene, dichloromethane or acetonitrile, to prepare the phthalimido derivative 5.9. This material is then reacted with one molar equivalent of a dialkyl aminoethyl phosphonate 5.10, (*J. Org. Chem.*, (2000), 65, 676) and dicyclohexylcarbodiimide in

dimethylformamide, to give the amide **5.11**. The phthalimido protecting group is then removed, for example by reaction with ethanolic hydrazine at ambient temperature, as described in *J. Org. Chem.*, 43, 2320, (1978), to afford the amine **5.12**. This compound is coupled in dimethylformamide solution with 6-carboxylic acid **5.13**, to afford the amide **5.14**.


- 5 Using the above procedures, but employing, in place of the amine **5.8**, different amines **5.1**, and/or different phosphonates **5.3**, and/or different carboxylic acids **5.6**, the corresponding products **5.7** are obtained.

#### Scheme 5. Phosphonates 1.


##### Method



##### Example







Scheme 6 depicts the preparation of phosphonates **II**d in which the phosphonate is attached by means of an ether linkage. In this procedure, the amino group of a hydroxy-substituted amine **6.1** may be protected (PG = protecting group), as described above, to give the derivative **6.2**. The carbinol is then reacted, with base catalysis, with a dialkyl bromomethyl phosphonate **6.3**, in which the group R<sup>5</sup> is as defined in Scheme 4. The reaction is conducted in a polar aprotic solvent such as tetrahydrofuran, dimethylformamide or dimethylsulfoxide, in the presence of a base such as potassium carbonate, for cases in which Ar is an aromatic group, or a strong base such as sodium hydride, for cases in which Ar is an aliphatic group. The amino group of the resulting ether **6.4** is then deprotected, as previously described, to give the amine **6.5**. The amine is then reacted with the ester **6.6**, as described in Scheme 3, to give the amide **6.7**.

For example, N-methyl 3-hydroxyphenethylamine **6.8** is reacted with one molar equivalent of acetyl chloride in dichloromethane containing pyridine, to give the N-acetyl product **6.9**. The product is then reacted at ca. 60 °C in dimethylformamide (DMF) solution with one molar equivalent of a dialkyl 3-bromopropenyl phosphonate **6.10** (Aurora) and cesium carbonate, to produce the ether **6.11**. The N-acetyl group is then removed, for example by treatment with hog kidney acylase, as described in *Tetrahedron*, 44, 5375, (1988), to give

the amine 6.12. The product is then reacted in toluene solution at reflux, 6.13, to yield the amide 6.14.

Using the above procedures, but employing, in place of the amine 6.8, different amines 6.1, and/or different phosphonates 6.3, and/or different bicyclic esters 6.6, the corresponding products 6.7 are obtained.



Scheme 7 depicts the preparation of phosphonates IIId in which the phosphonate is attached by means of an ether or thioether linkage. In this procedure, a N-protected hydroxyamine 6.2, in which Ar is an aromatic moiety, is subjected to a Mitsunobu reaction with a hydroxy or mercapto-substituted dialkyl phosphonate 7.1, in which R<sup>5a</sup> is as defined in Scheme 4, to prepare the ether or thioether product 7.2. The preparation of aromatic ethers and thioethers by means of the Mitsunobu reaction is described, for example, in Comprehensive Organic Transformations, by R. C. Larock, VCH, 1989, p. 448, and in Advanced Organic Chemistry, Part B, by F.A. Carey and R. J. Sundberg, Plenum, 2001, p. 153-4 and in *Org. React.*, 1992, 42, 335. The phenol and the alcohol or thiol component are reacted together in an aprotic solvent such as, for example, tetrahydrofuran or dioxane, in the presence of a dialkyl azodicarboxylate and a triarylphosphine, to afford the ether or thioether products. The N-protecting group is then removed and the resultant amine is converted, as described in Scheme 6, into the amide 7.3.

For example, N-acetyl 3,5-dichloro-4-hydroxybenzylamine 7.4 is reacted in a tetrahydrofuran solution with one molar equivalent of a dialkyl mercaptoethyl phosphonate 7.5, (*Zh. Obshchei. Khim.*, 1973, 43, 2364) diethyl azodicarboxylate and tri-*o*-tolylphosphine, to afford the thioether product 7.6. The N-acetyl group is removed, as described in Scheme 6, and the amine 7.7 is then reacted with methyl ester 7.8 (TBDMS = *tert*-butyldimethylsilyl), to afford the amide 7.9.


Using the above procedures, but employing, in place of the amine 7.4, different amines 6.2, and/or different phosphonates 7.2, the corresponding products 7.3 are obtained.


**Scheme 6.**

**Method**




**Example**






### Scheme 7.

#### Method



#### Example






Scheme 8 depicts the preparation of phosphonates **Id** in which the phosphonate is attached by means of an alkylene chain incorporating an amide linkage. In this procedure, an amine **8.1** is reacted with a bromoalkyl ester **8.2**, in which  $R^{5a}$  is as defined in Scheme 4, to yield the alkylated amine **8.3**. The preparation of substituted amines by the reaction of amines with alkyl halides is described, for example, in Comprehensive Organic Transformations, by R. C. Larock, VCH, 1989, p. 397. Equimolar amounts of the reactants are combined in a polar solvent such as an alkanol or dimethylformamide and the like, in the presence of a base such as cesium carbonate, diazabicyclononene or dimethylaminopyridine, to yield the substituted amine. The ester group is then hydrolyzed to give the carboxylic acid **8.4**, and this compound is then coupled, as described in Scheme 5, with a dialkyl aminoalkyl phosphonate **8.5**, to produce the aminoamide **8.6**. Optionally, the amino group of the amine **8.4** is protected prior to the coupling reaction, and deprotected afterwards. The product is then reacted with the bicyclic hydroxyester **8.7** to afford the amide **8.8**.

For example, 4-trifluoromethylbenzylamine **8.9** is reacted in dimethylformamide with one molar equivalent of methyl bromoacetate **8.10** and potassium carbonate to give the ester **8.11**. Hydrolysis, employing one molar equivalent of lithium hydroxide in aqueous dimethoxyethane, affords the carboxylic acid **8.12**, and this compound is coupled in tetrahydrofuran solution with a dialkyl aminomethyl phosphonate **8.13** (Aurora), in the presence of dicyclohexylcarbodiimide, to give the aminoamide **8.14**. The product is then reacted with 4-sulfonamide, 6-methyl ester **8.15**, prepared by the methods described above, to yield the amide **8.16**.




Using the above procedures, but employing, in place of the amine **8.9**, different amines **8.1**, and/or different bromoesters **8.2**, and/or different phosphonates **8.5**, and/or different hydroxyesters **8.7**, the corresponding products **8.8** are obtained.

**Scheme 8.**

**Method**



**Example**



Scheme 9 depicts the preparation of phosphonates **IIId** in which the phosphonate is attached by means of a variable carbon chain. In this procedure, a primary amine **9.1** is

subjected to a reductive amination reaction with a dialkyl formyl-substituted phosphonate **9.2**, in which R<sup>5</sup> is as defined in Scheme 4, to afford the alkylated amine **9.3**. The preparation of amines by means of reductive amination procedures is described, for example, in



Comprehensive Organic Transformations, by R. C. Larock, VCH, p. 421, and in Advanced

- 5 Organic Chemistry, Part B, by F.A. Carey and R. J. Sundberg, Plenum, 2001, p. 269. In this procedure, the amine component and the aldehyde or ketone component are reacted together in a polar solvent in the presence of a reducing agent such as, for example, borane, sodium cyanoborohydride, sodium triacetoxyborohydride or diisobutylaluminum hydride, optionally in the presence of a Lewis acid, such as titanium tetrakisopropoxide, as described in *J. Org.*  
10 *Chem.*, 55, 2552, 1990. The product **9.3** is then reacted, as described previously, with the bicyclic ester **9.4** to give the amide **9.5**.



For example, 3,4-dichlorobenzylamine is reacted in methanol solution with one molar equivalent of a dialkyl 3-formylphenyl phosphonate **9.7**, (Epsilon) and sodium cyanoborohydride, to yield the alkylated product **9.8**. This compound is then reacted with 2-  
15 dimethylcarbamoyl-5,6-dihydroxy-pyrimidine-4-carboxylic acid methyl ester **9.9**, prepared using the methods described above, from the corresponding bromo compound and N-methyl methanesulfonamide, to give the amide **9.10**.

Using the above procedures, but employing, in place of the amine **9.6**, different amines **9.1**, and/or different phosphonates **9.2**, and/or different bicyclic esters **9.4**, the  
20 corresponding products **9.5** are obtained.

**Scheme 9.**  
**Method**



**Example**



Scheme 10 depicts an alternative method for the preparation of phosphonates **IId** in which the phosphonate is attached by means of a variable carbon chain. In this procedure, the phenolic group of a bicyclic amide **10.1**, prepared as described above, and in WO 02 30930




A2, is protected to give the product 10.2. The protection of phenolic hydroxyl groups is described in Protective Groups in Organic Synthesis, by T.W. Greene and P.G.M. Wuts, Wiley, Second Edition 1990, p. 10ff. For example, hydroxyl substituents are protected as trialkylsilyloxy ethers. Trialkylsilyl groups are introduced by the reaction of the phenol with a chlorotrialkylsilane and a base such as imidazole, for example as described in Protective Groups in Organic Synthesis, by T.W. Greene and P.G.M. Wuts, Wiley, Second Edition 1990, p. 10, p. 68-86. Alternatively, phenolic hydroxyl groups are protected as benzyl or substituted benzyl ethers, or as acetal ethers such as methoxymethyl or tetrahydropyranyl. The O-protected amide 10.2 is then reacted with the phosphonate-substituted trifluoromethanesulfonate 10.3, in which R<sup>5a</sup> is as defined in Scheme 4, to produce the alkylated amide 10.4. The alkylation reaction is conducted between equimolar amounts of the reactants in an aprotic organic solvent such as dimethylformamide or dioxane, in the presence of a strong base such as lithium hexamethyl disilylazide or sodium hydride, at from ambient temperature to about 90 °C. The hydroxyl group is then deprotected to give the phenol 10.5. Deprotection of phenolic hydroxyl groups is described in Protective Groups in Organic Synthesis, by T.W. Greene and P.G.M. Wuts, Wiley, Second Edition 1990, p.10ff. For example, silyl protecting groups are removed by reaction with tetrabutylammonium fluoride, benzyl groups are removed by catalytic hydrogenation and acetal ethers are removed by treatment with acids.


Amide 10.7 is reacted with one molar equivalent of tert-butyl chlorodimethylsilane and imidazole in dichloromethane, to give 5-(tert-butyl-dimethyl-silanyloxy)-1-methyl-6-oxo-2-phenyl-1,6-dihydro-pyrimidine-4-carboxylic acid (naphthalen-2-ylmethyl)-amide 10.8. This compound 10.8 is then reacted at ambient temperature in dioxane solution with one molar equivalent of sodium hydride, followed by the addition of a dialkyl trifluoromethanesulfonyloxymethyl phosphonate 10.9 (*Tet. Lett.*, 1986, 27, 1477), to afford the alkylated product 10.10. Deprotection, by reaction with tetrabutylammonium fluoride in tetrahydrofuran, then yields the product 10.11.

Using the above procedures, but employing, in place of the amide 10.7, different amides 10.1, and/or different phosphonates 10.3, the corresponding products 10.5 are obtained.

**Scheme 10.**  
**Method**



**Example**



Schemes 11 - 15 illustrate methods for the preparation of the 2-phosphonate esters **Ia** and **Ila**.

Scheme 11 depicts the preparation of 2-substituted pyrimidyl phosphonates **Ila** in which the phosphonate is attached by means of a heteroatom O, S or N, and a variable carbon chain. In this procedure, an amide 11.1, prepared as previously described, is reacted in an aprotic solvent such as dichloromethane, hexachloroethane or ethyl acetate with a free radical brominating agent such as N-bromosuccinimide or N-bromoacetamide, to yield the 5-bromo product 11.2. This compound is then reacted with a dialkyl hydroxy, mercapto or amino-substituted phosphonate 11.3, in which R<sup>5</sup> is as defined as in Scheme 4, to give the ether, thioether or amine product 11.4. The displacement reaction is conducted in a polar aprotic organic solvent such as dimethylformamide or DMPU, at from 100 °C to about 150 °C, in the

presence of a base such as triethylamine or cesium carbonate, for example as described in WO 0230930A2, Examples 57-69.


Cyclohexylmethyl-amide **11.6** is reacted with one molar equivalent of N-bromosuccinimide in dichloromethane to yield the 5-bromo product **11.7**. This material is  
5 then reacted with a dialkyl mercaptoethyl phosphonate **11.8** (*Zh. Obschei. Khim.*, 1973, 43, 2364) and triethylamine at ca 100 °C in a pressure vessel, to produce the thioether **11.9**.

Ketal protected **11.11** is brominated with N-bromosuccinimide in ethyl acetate at reflux temperature to yield the bromo compound **11.12** which is reacted with a dialkyl 3-aminophenyl phosphonate **11.13** (*J. Med. Chem.*, 1984, 27, 654) in dimethylformamide at ca.  
10 130 °C, using the procedure described in WO 0230930 A2 Example 63, to give the phosphonate **11.14**. The product is then reacted with N, N-dimethyloxamide **11.15**, (Japanese Patent 540467 18) and dicyclohexylcarbodiimide in dimethylformamide, to yield the amide product **11.16**.


Using the above procedures, but employing, in place of the amides **11.6** or **11.11**,  
15 different amides **11.1**, and/or different phosphonates **11.3**, the corresponding products **11.4** are obtained.

**Scheme 11.**


**Method**



**Example 1**



**Example 2**



Scheme 12 depicts the preparation of phosphonates **IIa** in which the phosphonate is attached by means of a carbamate linkage. In this procedure, a protected bromophenol **12.1** is reacted, as described in Scheme 11, with an amine **12.2** to give the displacement product **12.3**.


- 5 This compound is then reacted with phosgene, triphosgene, carbonyl diimidazole or a functional equivalent thereof, and a dialkyl hydroxyalkyl phosphonate **12.4**, in which  $\text{R}^5$  is as defined in Scheme 4, to yield, after deprotection of the phenol, the carbamate **12.5**. Various methods for the preparation of carbamates are described in Scheme 33.

- For example, the hydroxyester **12.6** is converted, as described previously, into the amide **12.7**. This material is then reacted, in dimethylformamide solution at  $100^\circ$ , with ethylamine and cesium carbonate in dimethylformamide, to afford 5-(tert-butyl-dimethyl-silanyloxy)-2-ethylamino-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid [2-(4-fluoro-phenyl)-cyclopropyl]-amide **12.9**. The amine is treated with equimolar amounts of a dialkyl hydroxypropyl phosphonate **12.10** (*Zh. Obschei. Khim.*, 1974, 44, 1834) and carbonyldiimidazole in dichloromethane, to prepare, after desilylation, the carbamate phosphonate **12.11**.


Using the above procedures, but employing, in place of the amide **12.7**, different amides **12.3**, and/or different phosphonates **12.4**, the corresponding products **12.5** are obtained.

**Scheme 12.**

**Method**



**Example**



Scheme 13 depicts the preparation of phosphonates **IIa** in which the phosphonate is attached by means of an arylvinyl or aryethyl linkage. In this procedure, a bromophenol **13.1** is protected to give the product **13.2**. This compound is then coupled with tributylvinyltin to yield the 5-vinyl product **13.3**. The coupling reaction is effected in dimethylformamide


solution at ca. 80 °C in the presence of a palladium(0) catalyst, such as tris(dibenzylideneacetone)palladium(0), a triarylphosphine such as tri(2-furyl)phosphine and copper(I) iodide, for example as described in WO 0230930A2, Example 176. The vinyl-substituted product is subjected to a palladium-catalyzed Heck coupling reaction, as described  
5 in Scheme 4, with a dibromoaromatic or heteroaromatic compound 13.4, to give the bromoaryl product 13.5. The latter compound is then coupled, as described in Scheme 3, with a dialkyl phosphite 13.6, in the presence of a palladium catalyst, to give the aryl phosphonate 13.7. Deprotection then affords the phenol 13.8. Optionally, the double bond is reduced, for example as described in Scheme 4, to give the saturated analog 13.9.

10 For example, 5-(tert-butyl-dimethyl-silanyloxy)-1-isopropyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid 3,5-dichloro-benzylamide 13.10, (WO9944992) is converted, using the methods described above, into 2-bromo-5-(tert-butyl-dimethyl-silanyloxy)-1-isopropyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid 3,5-dichloro-benzylamide 13.11. The product is coupled, as described above, with tri(n-butyl)vinyltin to produce 2-ethylene-5-  
15 (tert-butyl-dimethyl-silanyloxy)-1-isopropyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid 3,5-dichloro-benzylamide 13.12. This material is then coupled, in dimethylformamide solution at 80° with one molar equivalent of 2,5-dibromothiophene 13.13, in the presence of tetrakis(triphenylphosphine)palladium(0) and triethylamine, to afford 2-[2-(2-bromothiophene)ethylene, 3-isopropyl, 5-tert-butyl dimethylsilyloxy, 6-[3,5-dichloro-  
20 benzylamide] pyrimidinone 13.14. The product 13.14 is coupled, in the presence of a palladium(0) catalyst and triethylamine, with a dialkyl phosphite 13.15, to afford the phosphonate 13.16. Deprotection, for example by reaction with tetrabutylammonium fluoride in tetrahydrofuran, then yields the phenol 13.17, and hydrogenation of the latter compound in methanol, using 5% palladium on carbon as catalyst, produces the saturated analog 13.18.

25 Using the above procedures, but employing, in place of the amide 13.11, different amides 13.1, and/or different dibromides 13.4, the corresponding products 13.8 and 13.9 are obtained.


**Scheme 13.**

**Method**





**Example**



Scheme 14 depicts the preparation of phosphonates **1a** in which the phosphonate is attached by means of an acetylenic bond. In this procedure, a phenol **14.1** is reacted, as described in WO 0230930 A2 p. 166 and Example 112, with N-iodosuccinimide in dichloromethane-dimethylformamide, to give the 5-iodo product; protection of the phenolic hydroxyl group then affords the compound **14.2**. This material is coupled, as described in WO 0230930 A2 Example 79, in dimethylformamide solution, in the presence of dichlorobis(triphenylphosphine) palladium (II), copper iodide and triethylamine, with a dialkyl ethynyl phosphonate **14.3**, in which R<sup>5a</sup> is as defined in Scheme 4, to give, after deprotection of the phenol, the acetylenic phosphonate **14.4**.


Dibenzoyl amide **14.6** is converted into the 2-iodo compound **14.7**, as described above, and coupled with a dialkyl propynyl phosphonate **14.8**, (*Synthesis*, (1999), 2027) to yield the acetylenic phosphonate **14.9**. After deprotection of the benzoyl groups, the 5,6-

dihydroxy-2-methyl-pyrimidine-4-carboxylic acid (cyclopent-3-enylmethyl)-amide phosphonate compound **14.10** is obtained.


Using the above procedures, but employing, in place of the iodoamide **14.7**, different iodoamides **14.2**, and/or different acetylenic phosphonates **14.3**, the corresponding products **14.4** are obtained.

#### Scheme 14.

##### Method



##### Example



Scheme 15 depicts the preparation of phosphonates **IIa** in which the phosphonate is directly attached to pyrimidinone at the 2-position. In this procedure, a protected 2-


bromopyrimidyl **15.1** is coupled, in the presence of a palladium catalyst, as described in Scheme 3, with a dialkyl phosphite **15.2**, to give after deprotection the aryl phosphonate **15.3**.

For example, 4-oxo-5-(tetrahydro-pyran-2-yloxy)-3-triisopropylsilanyl-3,4-dihydro-pyrimidine-6-carboxylic acid [1-(3-chloro-4-fluoro-phenyl)-1-methyl-ethyl]-amide **15.4**, is  
5 converted, using the procedures described above, is brominated to give 2-bromo-4-oxo-5-(tetrahydro-pyran-2-yloxy)-3-triisopropylsilanyl-3,4-dihydro-pyrimidine-6-carboxylic acid [1-(3-chloro-4-fluoro-phenyl)-1-methyl-ethyl]-amide **15.5**. The product is then coupled, in the presence of tetrakis(triphenylphosphine)palladium(0) and triethylamine, as described in Scheme 3, with a dialkyl phosphite **15.6** (for example, R<sup>1</sup> = ethyl), to afford, after desilylation  
10 of the phenol, the pyrimidinone 2-phosphonate **15.7** which can be deprotected under acidic conditions to **15.8**.


Using the above procedures, but employing, in place of the bromoamide **15.5**, different bromoamides **15.1**, the corresponding products **15.3** are obtained.

**Scheme 15.**

**Method**



**Example**



Schemes 16-18 illustrate methods for the preparation of the 2-amino linked phosphonate esters **Ia** and **IIa**.

- 5        Scheme 16 depicts the N-3 sulfonation of 2-phosphonate compounds. In this procedure, **16.1**, in which the 5-hydroxyl group is protected, prepared as described in Scheme 11, is reacted with a sulfonyl chloride **16.2** or a sulfonic acid **16.3**, in which  $\text{R}^{4a}$  can be  $\text{C}_1\text{--C}_{18}$  alkyl,  $\text{C}_1\text{--C}_{18}$  substituted alkyl,  $\text{C}_2\text{--C}_{18}$  alkenyl,  $\text{C}_2\text{--C}_{18}$  substituted alkenyl,  $\text{C}_2\text{--C}_{18}$  alkynyl,  $\text{C}_2\text{--C}_{18}$  substituted alkynyl,  $\text{C}_6\text{--C}_{20}$  aryl,  $\text{C}_6\text{--C}_{20}$  substituted aryl,  $\text{C}_2\text{--C}_{20}$  heterocycle, or
- 10       $\text{C}_2\text{--C}_{20}$  substituted heterocycle, to afford sulfonamide **16.4**. The reaction between an amine and a sulfonyl chloride, to produce the sulfonamide, is conducted at ambient temperature in an inert solvent such as dichloromethane, in the presence of a tertiary base such as triethylamine. The reaction between a sulfonic acid and an amine to afford a sulfonamide is


conducted in a polar solvent such as dimethylformamide, in the presence of a carbodiimide such as dicyclohexyl carbodiimide, for example as described in *Synthesis*, (1976), 339.

For example, the 5-protected phosphonate diisobutyl ester **16.5**, prepared by the methods described above, is reacted in dichloromethane solution with one molar equivalent of ethylsulfonyl chloride **16.6** and triethylamine, to produce **16.7**. Desilylation of **16.7** gives {2-[(4-dimethylcarbamoyl-1-ethanesulfonyl-5-hydroxy-6-oxo-1,6-dihydro-pyrimidin-2-yl)-methyl-amino]-ethyl}-phosphonic acid di-sec-butyl ester **16.8**.


Using the above procedures, but employing, in place of the amine phosphonate **16.5**, different phosphonates **16.1**, and/or different sulfonyl chlorides **16.2** or sulfonic acids **16.3**, the corresponding products **16.4** are obtained.

#### Scheme 16.

##### Method



##### Example




Scheme 17 depicts an alternative method for the preparation of phosphonate esters **IIa** in which the phosphonate group is attached by means of a variable carbon chain from a 2-sulfonamido group. In this procedure, a dialkyl amino-substituted phosphonate **17.1**, in which the group  $R^{5a}$  is as defined in Scheme 4, is reacted with a sulfonyl chloride **17.2** or sulfonic acid **17.3**, as described in Scheme 16, to yield the sulfonamide **17.4**. The product is then reacted with a bromoamide **17.5**, to prepare the displacement product **17.6**. The displacement reaction is performed in a basic solvent such as pyridine or quinoline, at from about 80° to reflux temperature, optionally in the presence of a promoter such as copper oxide, as described in WO 0230930 A2 Example 154.

For example, a dialkyl 4-aminophenyl phosphonate **17.7** (Epsilon) is reacted in dichloromethane solution with one molar equivalent of methanesulfonyl chloride **17.8** and triethylamine, to give the sulfonamide **17.9**. The product is then reacted in pyridine solution at reflux temperature with 2-bromo-6-(4-fluoro-benzylcarbamoyl)-3-methyl-6-benzoyloxy-3,4-dihydro-pyrimidin-5-yl ester **17.10**, prepared by the methods described above, and copper oxide, to yield the sulfonamide **17.11**.


Using the above procedures, but employing, in place of the amine phosphonate **17.7**, different phosphonates **17.1**, and/or different sulfonyl chlorides **17.2** or sulfonic acids **17.3**, the corresponding products **17.6** are obtained.

**Scheme 17.**

**Method**



**Example**



Scheme 18 depicts an alternative method for the preparation of phosphonate esters **1a** in which the phosphonate group is attached by means of a variable carbon chain. In this procedure, a phenol-protected 5-bromo substituted amide **18.1** is reacted, as described in

Scheme 17, with a sulfonamide 18.2, to give the displacement product 18.3. The product is then reacted with a dialkyl bromoalkyl phosphonate 18.4 to afford, after deprotection of the phenol, the alkylated compound 18.5. The alkylation reaction is performed in a polar aprotic solvent such as dimethylformamide or DMPU, at from ambient temperature to about 100 °C, in the presence of a base such as sodium hydride or lithium hexamethyl disilylazide.


For example, benzoic acid 2-bromo-4-hydroxy-6-[1-(3-methoxy-phenyl)-1-methyl-ethylcarbamoyl]-pyrimidin-5-yl ester 18.6, prepared by the methods described above, is reacted in pyridine solution at reflux temperature with one molar equivalent of propanesulfonamide 18.7 and copper oxide, to afford the sulfonamide 18.8. The product is then reacted in dimethylformamide solution with one molar equivalent of a dialkyl bromoethyl phosphonate 18.9 (Aldrich) and lithium hexamethyl disilylazide, to give after debenzoylation, the sulfonamide phosphonate 18.10. The benzoyl protecting group is removed, for example, by reaction with 1% methanolic sodium hydroxide at ambient temperature, as described in *Tetrahedron*, 26, 803, 1970.

Using the above procedures, but employing, in place of the bromo compound 18.6, different bromo compounds 18.1, and/or different sulfonamides 18.2, and/or different phosphonates 18.4, the corresponding products 18.5 are obtained.




#### Scheme 18. Phosphonates 4.

##### Method



##### Example



Schemes 19 - 21 illustrate methods for the preparation of 2-amino linked phosphonate esters Ia and IIa.

- 5 Scheme 19 illustrates the preparation of phosphonates IIa in which the phosphonate group is attached by means of a variable carbon chain. In this procedure, a bromo-substituted sulfonic acid 19.1 is subjected to an Arbuzov reaction with a trialkyl phosphite 19.2 to give the phosphonate 19.3. The Arbuzov reaction is performed by heating the bromo compound with an excess of the trialkyl phosphite at from 100 °C to 150 °C, as described in Handbook of


Organophosphorus Chem., 1992, 115-72. The resulting phosphonate is then reacted with an amine **19.4**, either directly, in the presence of a carbodiimide, or by initial conversion to the sulfonyl chloride, as described in Scheme 16, to afford, after deprotection of the phenolic hydroxyl group, the sulfonamide **19.5**.

5 For example, 3-bromopropanesulfonic acid **19.6** (Sigma) is heated at 130 °C with a trialkyl phosphite **19.7** to give the phosphonate **19.8**. The product is then reacted in DMPU solution with **19.9**, prepared by the methods described above, in the presence of dicyclohexylcarbodiimide, to give, after desilylation, by reaction with tetrabutylammonium fluoride in tetrahydrofuran, the sulfonamide **19.10**.


10 Using the above procedures, but employing, in place of the bromo sulfonic acid **19.6**, different bromosulfonic acids **19.1**, and/or different amines **19.4**, the corresponding products **19.5** are obtained.

#### Scheme 19.

##### Method



**Example**



Scheme 20 illustrates the preparation of phosphonates **IIa** in which the phosphonate group is attached by means of a saturated or unsaturated carbon chain and an aromatic or heteroaromatic group. In this procedure, a vinyl-substituted sulfonic acid **20.1** is coupled, in a palladium-catalyzed Heck reaction, as described in Scheme 4, with a dibromoaromatic or heteroaromatic compound **20.2**, to yield the sulfonic acid **20.3**. The product is then coupled, in the presence of a palladium catalyst, as described in Scheme 3, with a dialkyl phosphite  $\text{HP(O)(OR}^1\text{)}_2$ , to give the phosphonate **20.4**. The latter compound is then reacted, as described above, with an amine **20.5**, either directly, in the presence of a carbodiimide, or by initial conversion to the sulfonyl chloride, as described in Scheme 16, to afford, after deprotection of the phenolic hydroxyl group, the sulfonamide **20.6**. Optionally, the double bond is reduced, either catalytically or chemically, as described in Scheme 4, to afford the saturated analog **20.7**.


For example, vinylsulfonic acid **20.8** (Sigma) is coupled, in dioxane solution, in the presence of tetrakis(triphenylphosphine)palladium (0) and potassium carbonate, with 2,5-dibromothiophene **20.9**, to form the coupled product **20.10**. The product is then reacted in


toluene solution at 100 °C with a dialkyl phosphite **20.11**, triethylamine and a catalytic amount of tetrakis(triphenylphosphine)palladium (0), to produce the phosphonate **20.12**. This material is then reacted, in dimethylformamide solution at ambient temperature, as described above, with 4-fluoro-benzylamide **20.13**, prepared by the methods described above, in the presence of dicyclohexylcarbodiimide, to give, after desilylation, using tetrabutylammonium fluoride, the sulfonamide **20.14**. Hydrogenation of the double bond, for example using 5% palladium on carbon as catalyst, then yields the saturated analog **20.15**.

Using the above procedures, but employing, in place of the sulfonic acid **20.8**, different sulfonic acids **20.1**, and/or different dibromoaromatic compounds **20.2**, and/or different amines **20.5**, the corresponding products **20.6** and **20.7** are obtained.

#### Scheme 20.

##### Method






Scheme 21 illustrates the preparation of phosphonates **1a** in which the phosphonate group is attached by means of a variable carbon chain. In this procedure, an aliphatic bromo-substituted sulfonic acid **21.1** is subjected to an Arbuzov reaction with a trialkyl phosphite, as described in Scheme 19, to give the phosphonate **21.2**. Alternatively, an aryl bromosulfonic acid **21.1** is coupled, as described in Scheme 3, with a dialkyl phosphite, to give the phosphonate **21.2**. The product is then reacted with an amine **21.3** to afford the sulfonamide **21.4**. The latter compound is then reacted, as described in Scheme 17, with a bromoamide **21.5**, to give the displacement product **21.6**.

For example, 4-bromobenzenesulfonic acid **21.7** is reacted, as described in Scheme 20, with a dialkyl phosphite to form the phosphonate **21.8**. The product is then reacted with phosphoryl chloride to afford the corresponding sulfonyl chloride, and the latter compound is reacted, in dichloromethane solution, in the presence of triethylamine, with 2-methoxyethylamine **21.9**, to yield the sulfonamide **21.10**. This material is then reacted, in pyridine solution at reflux temperature, with 2-bromo-4,5-dimethoxy-pyrimidine-6-carboxylic acid 4-fluoro-benzylamide **21.11**, prepared by the methods described above, and copper oxide, to give the 2-sulfonamide phosphonate **21.12**.


Using the above procedures, but employing, in place of the sulfonic acid **21.7**, different sulfonic acids **21.1**, and/or different amines **21.3**, and/or different bromo compounds **21.5**, the corresponding products **21.6** are obtained.

**Scheme 21.**

**Method**



**Example**



5

**Preparation of phosphonate esters Ia and IIa.**

Scheme 22 depicts the preparation of phosphonate esters Ia in which the phosphonate group is attached by means of an cyclic sulfonamide group at the 2-amino position. In this

procedure, a cyclic sulfonamide **22.1**, where m and n are independently 1, 2, 3, 4, 5, or 6, and incorporating a secondary amine, is coupled, as described in Scheme 5, with a dialkyl carboxy-substituted phosphonate **22.2** to produce the amide **22.3**. The product is then reacted with a bromoamide **22.4** to afford the displacement product **22.5**.

5           Alternatively, the cyclic sulfonamide **22.1** is protected to give the analog **22.6**.

Sulfonamides are protected, for example, by conversion into the N-acyloxymethyl derivatives, such as the pivalyloxymethyl derivative or the benzyloxymethyl derivative, by reaction with the corresponding acyloxymethyl chloride in the presence of dimethylaminopyridine, as described in *Bioorg. Med. Chem. Lett.*, 1995, 5, 937, or by conversion into the carbamate derivative, for example the tert. butyl carbamate, by reaction with an alkyl, aryl or aralkyl chloroformate, in the presence of a base such as triethylamine, as described in *Tet. Lett.*, 1994, 35, 379. The protected sulfonamide is reacted with a dialkyl bromoalkyl phosphonate **22.7** to form the alkylated product **22.8**. The alkylation reaction is effected as described in Scheme 8. The product is then deprotected to yield the sulfonamide **22.9**. Deprotection of

10           pivalyloxymethyl amides is effected by treatment with trifluoroacetic acid; deprotection of benzyloxymethyl amides is effected by catalytic hydrogenation, as described in Protective Groups in Organic Synthesis, by T.W. Greene and P.G.M. Wuts, Wiley, Second Edition 1990, p. 398. Sulfonamide carbamates, for example the tert. butyl carbamate, are deprotected by treatment with trifluoroacetic acid. The sulfonamide **22.9** is then reacted with the bromoamide

15           **22.10** to give the displacement product **22.11**.

For example, [1,2,5]thiadiazepane 1,1-dioxide **22.11A** (WO 0230930A2 p.321) is reacted in dioxane solution with equimolar amounts of a dialkyl 3-carboxypropyl phosphonate **23.12**, (Epsilon) and dicyclohexylcarbodiimide, to produce the amide **22.13**. This material is reacted in pyridine solution at reflux temperature with 2-bromo-3-methyl-4-oxo-5-

20           triisopropylsilanyloxy-3,4-dihydro-pyrimidine-6-carboxylic acid 4-fluoro-benzylamide **22.14**, prepared by the methods described above, and copper oxide, to afford the displacement product **22.15**.

As a further example, the sulfonamide **22.11A** is reacted in dichloromethane with one molar equivalent of t-Boc anhydride, triethylamine and dimethylaminopyridine, to give 1,1-


30           dioxo-[1,2,5]thiadiazepane-2-carboxylic acid tert-butyl ester **22.16**. The product is then reacted at ambient temperature in dimethylformamide solution with a dialkyl 4-bromomethyl

benzyl phosphonate **22.17**, (*Tetrahedron*, 1998, 54, 9341) and potassium carbonate, to yield the alkylation product **22.18**. The BOC group is removed by treatment with trifluoroacetic acid to give the sulfonamide **22.19**, and this material is reacted, as described above, with 2-bromo-3,4-dihydroxy-pyrimidine-6-carboxylic acid 3-fluoro-benzylamide **22.20**, prepared by the methods described above, to afford the displacement product **22.21**.

Using the above procedures, but employing, in place of the sulfonamide **22.11A**, different sulfonamides **22.1**, and/or different carboxylic acids **22.2** or alkyl bromides **22.7**, and/or different bromides **22.4**, the corresponding products **22.5** and **22.11** are obtained.

#### Scheme 22.


##### Method







**Scheme 22.**

**Example 1**



**Example 2**







Scheme 23 depicts the preparation of phosphonates **IIa** in which the phosphonate group is attached by means of an aryl or heterocycle group. In this procedure, a bromoaryl-substituted cyclic sulfonamide, prepared as described in *J. Org. Chem.*, (1991), 56, 3549, is coupled, as described in Scheme 3, with a dialkyl phosphite to afford the phosphonate **23.2**. The product is then reacted, as described above, with a bromoamide **23.3** to yield the displacement product **23.4**.

For example, 4-(4-bromo-phenyl)-[1,2]thiazinane 1,1-dioxide **23.5** (*J. Org. Chem.*, 1991, 56:3549) is reacted in dimethylformamide solution with a dialkyl phosphite **23.6** and tetrakis(triphenylphosphine)palladium(0), to give the phosphonate **23.7**. The product is then reacted with 2-bromo-3-(2-methoxy-ethyl)-4-oxo-5-triisopropylsilyloxy-3,4-dihydropyrimidine-6-carboxylic acid (5-fluoro-indan-1-yl)-amide **23.8**, prepared by the methods described above, to give the phosphonate **23.9**.



Using the above procedures, but employing, in place of the sulfonamide **23.5**, different sulfonamides **23.1**, and/or different bromo compounds **23.3**, the corresponding products **23.4** are obtained.

# Scheme 23. Phosphonates 6.

## Method



## Example



Scheme 24 depicts the preparation of phosphonates **Ia** in which the phosphonate group is attached by means of an amide linkage. In this procedure, a carboxy-substituted cyclic sulfonamide **24.1** is coupled with an amino-substituted dialkyl phosphonate **24.2**, as described in Scheme 5, to give the amide **24.3**. The product is then reacted with the bromoamide **24.4** to afford the displacement product **24.5**.


For example, 1,1-dioxo-[1,2]thiazinane-3-carboxylic acid **24.6** (*Izvest. Akad. Nauk. SSSR Ser. Khim.*, 1964, 9, 1615) is reacted in dimethylformamide solution with equimolar amounts of an amino-substituted butyl phosphonate **24.7** (Acros) and dicyclohexylcarbodiimide, to afford the amide **24.8**. The latter compound is then condensed with 2-bromo-5,6,7,8,8a,10a-hexahydro-9,10-dioxo-1,3-diaza-anthracene-6-carboxylic acid

[1-(3-chloro-4-fluoro-phenyl)-ethyl]-amide **24.9**, prepared by the methods described above, to give the product **24.10**.


Using the above procedures, but employing, in place of the sulfonamide **24.6**, different sulfonamides **24.1**, and/or different bromo compounds **24.4**, the corresponding products **24.5** are obtained.

#### Scheme 24.

##### Method



##### Example



Schemes 25-27 illustrate methods for the preparation of the phosphonate esters **Ia** and **IIa** in which the phosphonate is attached by means of a carbon link or a variable carbon chain incorporating a heteroatom. In these procedures, for example, a tolyl-substituted pyrimidine

25.1 is reacted with a free radical brominating agent such as N-bromosuccinimide to prepare the bromomethyl derivative 25.3. The benzylic bromination reaction is performed at reflux temperature in an inert organic solvent such as hexachloroethane or ethyl acetate, optionally in the presence of an initiator such as dibenzoyl peroxide. The bromomethyl compound 25.3  
5 is then reacted with a trialkyl phosphite in an Arbuzov reaction, as described in Scheme 19, to give, after deprotection of the phenolic hydroxyl group, the phosphonate 25.4.


Alternatively, the benzylic bromide 25.3 is reacted with a dialkyl hydroxy, mercapto or amino-substituted phosphonate 25.5, to afford, after deprotection of the phenolic hydroxyl group, the displacement product 25.6. The displacement reaction is effected at from ambient  
10 temperature to about 100 °C, in a polar organic solvent such as dimethylformamide or DMPU, in the presence of a suitable base such as sodium hydride or lithium hexamethyldisilazide, for instances in which Y is O, or cesium carbonate or triethylamine for instances in which Y is S or N.

For example 6-p-tolyl-2,3,3a,9a-tetrahydro-1H-4,9-dioxo-5,7-diaza-  
15 cyclopenta[b]naphthalene-8-carboxylic acid 4-fluoro-benzylamide 25.8 is reacted with one molar equivalent of N-bromosuccinimide in ethyl acetate at reflux, to afford the bromomethyl analog 25.9. This product is reacted with a dialkyl hydroxyethyl phosphonate 25.11 (Epsilon) and sodium hydride in dimethylformamide at 80°, to yield, after desilylation, the phosphonate 25.12. Alternatively, the bromomethyl compound 25.9 is reacted at 120 °C with a trialkyl  
20 phosphite, to obtain, after desilylation, the phosphonate 25.10.


Using the above procedures, but employing, in place of the anhydride 25.7, different anhydrides 25.1, and/or different phosphonates 25.5, the corresponding products 25.4 and 25.6 are obtained.

**Scheme 25.**

**Method**



Example



Scheme 26 illustrates the preparation of phosphonate esters **IIa** in which the phosphonate is attached by means of an aminomethyl linkage through the 2-position. In this procedure, a bromomethyl-substituted bicyclic amide **26.1a**, prepared as described in Scheme 25, is oxidized to the corresponding aldehyde **26.1**. The oxidation of halomethyl compounds to aldehydes is described, for example, in Comprehensive Organic Transformations, by R. C. Larock, VCH, 1989, p. 599ff. The transformation is effected by treatment with dimethylsulfoxide and base, optionally in the presence of a silver salt, or by reaction with trimethylamine N-oxide or hexamethylene tetramine. The aldehyde **26.1** is then reacted with a dialkyl amino-substituted phosphonate **26.2** in a reductive amination reaction ( $\text{H}^-$  = reducing agent), as described in Scheme 9, to yield, after deprotection of the phenolic hydroxyl group, the aminomethyl product **26.3**.

For example, 5-benzoyloxymethoxy-2-(4-bromomethyl-phenyl)-4-oxo-3,4-dihydro-pyrimidine-6-carboxylic acid 3,5-dichloro-benzylamide **26.4**, prepared from the anhydride


25.7, using the methods described in Scheme 25, is reacted with dimethylsulfoxide and 2,4,6-collidine at 90°, as described in *J. Org. Chem.*, 51, 1264, 1986, to afford the aldehyde 26.5. The product is then reacted with one molar equivalent of a dialkyl aminoethyl phosphonate 26.6 (Epsilon) and sodium triacetoxyborohydride to produce, after desilylation, the  
5 phosphonate 26.7.

Using the above procedures, but employing, in place of the bromomethyl compound 26.4, different bromomethyl compounds 25.3, and/or different phosphonates 26.2, the corresponding products 26.3 are obtained.




# Scheme 26.

## Method



## Example




A reductive amination procedure can also be employed to attach a phosphonate ester through an amino linker. 1-Methyl-6-oxo-2-(2-oxo-ethyl)-5-trisopropylsilanyloxy-1,6-dihydro-pyrimidine-4-carboxylic acid 4-fluoro-benzylamide **26.8**, prepared by the method of WO 03/03577 at page 96 can be reductively aminated by amino phosphonate reagents, **26.9**, **26.10**, and **26.11** to give **26.12**, **26.13**, and **26.14**, respectively, after desilylation with tetrabutylammonium fluoride (TBAF) (Scheme 26a). As with the previous examples herein,

$R^1$  may be further converted to other phosphorus substituents, e.g. X and Y. Embodiments of phosphonate substituent X include OPh, OAr,  $OCH_2CF_3$ , and NHR, where R is the residue of an amino acid. Embodiments of phosphonate substituent Y include a lactate ester or a phosphoramidate.

5

**Scheme 26a.**

**Example**




6-Oxo-1-(2-oxo-ethyl)-5-trisopropylsilanyloxy-1,6-dihydro-pyrimidine-4-carboxylic acid 4-fluoro-benzylamide **26.15**, prepared from 1-allyl-5-(2,2-dimethyl-propionyloxy)-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid methyl ester **26.16** (piv = pivalate,  $(CH_3)_3CC(O)-$ ) by the method of WO 03/03577 at page 110 can be reductively aminated by


10

amino phosphonate reagents, **26.9**, **26.10**, and **26.11** to give **26.17**, **26.18**, and **26.19**, respectively after desilylation with TBAF (Scheme 26b).

**Scheme 26b.**

**Example**





Scheme 27 illustrates the preparation of phosphonate esters **Ia** in which the phosphonate is attached by coupling a carboxylic acid with an amino phosphonate reagent to form an amide linkage. In this procedure, an aldehyde **27.1**, or **26.1** from Scheme 26, is oxidized to the corresponding carboxylic acid **27.2**. The conversion of aldehydes to the corresponding carboxylic acids is described in Comprehensive Organic Transformations, by R. C. Larock, VCH, 1989, p. 838. The reaction is effected by the use of various oxidizing agents such as, for example, potassium permanganate, ruthenium tetroxide, silver oxide or sodium chlorite. The resultant carboxylic acid **27.2** is then coupled, as described in Scheme 5, with a dialkyl amino-substituted phosphonate **27.3**, to yield the amide **27.4**.

For example, 2-(4-formyl-phenyl)-4-methoxy-5-triisopropylsilanyloxy-pyrimidine-6-carboxylic acid (cyclohex-3-enylmethyl)-amide **27.5** is reacted with silver oxide in aqueous sodium hydroxide, as described in Org. Syn. Coll. Vol. 4, 919, 1963, to afford the carboxylic acid **27.6**. The latter compound is then reacted in dioxane solution at ambient temperature


with equimolar amounts of a dialkyl aminomethyl phosphonate **27.7** (Interchim) and dicyclohexylcarbodiimide, to give, after desilylation, the amide phosphonate **27.8**.

Using the above procedures, but employing, in place of the aldehyde **27.5**, different aldehydes **26.1**, and/or different phosphonates **27.3**, the corresponding amides **27.4** are  
5 obtained. For example, 5,6-dihydroxy-pyrimidine-2,4-dicarboxylic acid 4-methyl ester **27.9**, prepared by the method of WO 03/035077, p.85, may be converted to the 4-fluorobenzyl amide **27.10** with 4-fluorobenzylamine (Scheme **27a**), and the carboxylic acid group coupled with a plethora of amines, including **26.9**, **26.10**, and **26.11** to give **27.11**, **27.12**, and **27.13**, respectively (Scheme **27b**).


10

**Scheme 27.**


**Method**




**Example**



**Scheme 27a.**



Scheme 27b.




- Scheme 28 illustrates the preparation of phosphonate esters **1b** in which the
- 5 phosphonate is attached by means of a heteroatom O or S and a variable carbon link at the 4-position. In this procedure, the 5-hydroxyl protected methyl ester **28.1** is subjected to a Mitsunobu reaction, as described in Scheme 7, with a dialkyl hydroxy or mercapto-substituted phosphonate **28.8**, to produce the ether or thioether phosphonate **28.9**. This compound is then reacted, as described in Scheme 3, with the amine  $\text{ArLNR}^3\text{H}$ , to give amide **28.10**.
- 10 Alternatively, **28.1** is reacted with a dialkyl bromoalkyl-substituted phosphonate **28.5**, as described in Scheme 6, to yield the ether **28.6**. The latter compound is then transformed, as described above, into the amide **28.7**.

In other embodiments, Scheme 28a shows 5-hydroxy-3-methyl-4-oxo-2-p-tolyl-1,6-dihydro-pyrimidine-6-carboxylic acid benzylamide **28.11** reacting with a dialkyl 2-mercaptoethyl phosphonate **28.18** (*Zh. Obshchei. Khim.*, (1973), 43, 2364), diethylazodicarboxylate and triphenylphosphine to give thioether **28.12**. 3-Ethyl-5-hydroxy-4-oxo-2-p-tolyl-3,4-dihydro-pyrimidine-6-carboxylic acid [1-(4-fluoro-phenyl)-cyclopropyl]-amide **28.13** is reacted with a dialkyl bromomethyl phosphonate **28.15** (Lancaster) and potassium carbonate, to produce the phosphonate **28.16**. 5-Hydroxy-4-oxo-3-propyl-2-p-tolyl-3,4-dihydro-pyrimidine-6-carboxylic acid (5-sulfamoyl-naphthalen-2-ylmethyl)-amide **28.17** is alkylated with 2-chloroethyl dialkylphosphonate reagent **28.19** to give phosphonate pyrimidinone **28.20**.

#### Scheme 28.


##### Method





**Scheme 28a.**

**Examples**



- Scheme 29 illustrates the preparation of phosphonate esters Ia in which the phosphonate is attached either directly, or by means of a saturated or unsaturated carbon chain at the 2-position. In this procedure, a bromo-substituted anhydride **29.1** is converted, as described above, into the phenol-protected amide **29.2**. The product is then subjected to a Heck coupling reaction, in the presence of a palladium (0) catalyst, as described in Scheme 4, with a dialkyl alkenyl phosphonate **29.3**, to afford the phosphonate **29.4**. Optionally, the olefinic bond is reduced, as described in Scheme 4, to yield the saturated analog **29.5**.

Alternatively, the bromo-substituted amide **29.1** is coupled, as described in Scheme 3, with a dialkyl phosphite, in the presence of a palladium (0) catalyst, to generate, after deprotection of the phenolic hydroxyl group, the amide phosphonate **29.6**.


For example, 2-bromo-4,5-dihydroxy-pyrimidine-6-carboxylic acid 4-trifluoromethyl-benzylamide **29.8**. This compound is then reacted, in dimethylformamide solution at 80 °C, with one molar equivalent of a dialkyl vinyl phosphonate **29.9**, (Aldrich), triethylamine and a catalytic amount of tetrakis(triphenylphosphine)palladium(0) to yield, after desilylation, the unsaturated phosphonate **29.10**. The product is then reacted with diimide, prepared by basic hydrolysis of diethyl azodicarboxylate, as described in *Angew. Chem. Int. Ed.*, 4, 271, 1965, to yield the saturated product **29.11**.

Alternatively, **29.8** is reacted in toluene solution at ca. 100 °C, with one molar equivalent of a dialkyl phosphite **29.2**, triethylamine and 3 mol % tetrakis(triphenylphosphine)palladium(0), to give, after desilylation, the phosphonate product **29.12**.

Using the above procedures, but employing, in place of the anhydride **29.7**, different anhydrides **29.1**, and/or different phosphonates **29.3**, the corresponding products **29.4**, **29.5** and **29.6** are obtained.


**Scheme 29.**

**Method**



**Scheme 29.**

**Example**



Scheme 30 illustrates the preparation of phosphonate esters **IIa** in which the phosphonate is attached by means of a saturated or unsaturated carbon link at the 2-position.

- 5 In this procedure, the amide **30.2** is condensed, under basic conditions, with a dialkyl formyl-substituted phosphonate **30.3**, to afford the unsaturated phosphonate **30.4**. The reaction is conducted at from ambient temperature to about 100 °C, in a polar aprotic solvent such as dimethylformamide or dioxane, in the presence of a base such as sodium hydride, potassium tert. butoxide or lithium hexamethyldisilazide. Optionally, the product **30.4** is reduced, as
- 10 described in Scheme 4, to afford the saturated analog **30.5**.



- For example, 3-(4-methoxy-benzyl)-2-methyl-4-oxo-5-triisopropylsilyloxy-3,4-dihydro-pyrimidine-6-carboxylic acid (3,5-dichloro-benzyl)-ethyl-amide **30.7** is reacted, in dimethylformamide solution at 60 °C, with one molar equivalent of a dialkyl formylmethyl phosphonate **30.8** (Aurora) and sodium hydride, to give, after desilylation, the unsaturated
- 15 phosphonate **30.9**. The product is then reacted with diimide, prepared by basic hydrolysis of

diethyl azodicarboxylate, as described in *Angew. Chem. Int. Ed.*, 4, 271, 1965, to yield the saturated phosphonate **30.10**.

Using the above procedures, but employing, in place of the anhydride **30.6**, different anhydrides **30.1**, and/or different phosphonates **30.3**, the corresponding products **30.4**, and  
 5 **30.5** are obtained.

#### Scheme 30.

##### Method



10

Scheme 31 illustrates the preparation of phosphonate esters **1a** in which the phosphonate is attached by means of an oxime linkage at the 2-position. In this procedure, a

2-methyl, 6-amide **31.2** is brominated to give the 2-bromomethyl compound **31.3**. Oxidation, as described in Scheme 26, of **31.3** affords the corresponding aldehyde **31.4**. The aldehyde **31.4** is then converted, by reaction with hydroxylamine, into the oxime **31.5**. The latter compound is then reacted, in a polar solvent such as tetrahydrofuran or dimethylformamide, in the presence of a base such as sodium hydroxide or potassium carbonate, with a dialkyl bromomethyl-substituted phosphonate **31.6**, to prepare, after deprotection of the phenolic hydroxyl group, the oxime derivative **31.7**.


For example, 2-formyl-4,5-dimethoxy-pyrimidine-6-carboxylic acid 4-fluoro-benzylamide **31.9** is reacted in tetrahydrofuran solution with three molar equivalents of hydroxylamine hydrochloride and sodium acetate, to produce 2-(hydroxyimino-methyl)-4,5-dimethoxy-pyrimidine-6-carboxylic acid 4-fluoro-benzylamide **31.10**, which is then reacted in dioxane solution at ambient temperature, with one molar equivalent of a dialkyl bromopropyl phosphonate **31.11** (Synthelec) and potassium carbonate, to yield, after desilylation of the phenolic hydroxyl group, the oxime ether **31.12**.

Also for example, a 2-phosphonate Formula Ia compound can be prepared with a morpholino linkage. The 5-hydroxyl of 3-[4-(4-Fluoro-benzylcarbamoyl)-5-hydroxy-3-methyl-4-oxo-3,4-dihydro-pyrimidin-2-yl]-morpholine-4-carboxylic acid tert-butyl ester **31.13** can be esterified as the 2-iodobenzoate to give **31.14**. The Boc group can be removed under acidic conditions from **31.14** and the amino group of 2-iodo-benzoic acid 4-(4-fluoro-benzylcarbamoyl)-1-methyl-2-morpholin-3-yl-6-oxo-1,6-dihydro-pyrimidin-5-yl ester **31.15** may be condensed with aldehyde **31.16** to give **31.17** by reductive amination with sodium cyanoborohydride. The 2-iodobenzoate group may be removed under mild oxidative conditions, following the methods of R. Moss et al, *Tetrahedron Letters*, 28, 5005 (1989), to give morpholino phosphonate **31.18**.


Using the above procedures, but employing, in place of the anhydride **31.8**, different anhydrides **31.1**, and/or different phosphonates **31.6**, the corresponding products **31.7** are obtained.


**Scheme 31.**

**Method**



**Example**





**Interconversions of the phosphonates R-link-P(O)(OR<sup>1</sup>)<sub>2</sub>, R-link-P(O)(OR<sup>1</sup>)(OH) and R-link-P(O)(OH)<sub>2</sub>.**

Schemes 1-31 described the preparation of phosphonate esters of the general structure R-link-P(O)(OR<sup>1</sup>)<sub>2</sub>, in which the groups R<sup>1</sup> may be the same or different. The R<sup>1</sup> groups attached to a phosphonate ester **Ia-d** and **IIa-d**, or to precursors thereto, may be changed using established chemical transformations. The interconversion reactions of phosphonates are illustrated in Scheme 32. The group R in Scheme 32 represents the substructure to which the substituent link-P(O)(OR<sup>1</sup>)<sub>2</sub> is attached, either in the compounds **Ia-d** and **IIa-d**, or in precursors thereto. The R<sup>1</sup> group may be changed, using the procedures described below,



either in the precursor compounds, or in the esters **Ia-d** and **IIa-d**. The methods employed for a given phosphonate transformation depend on the nature of the substituent  $R^1$ , and of the substrate to which the phosphonate group is attached. The preparation and hydrolysis of phosphonate esters is described in Organic Phosphorus Compounds, G. M. Kosolapoff, L. Maeir, eds, Wiley, 1976, p. 9ff.

The conversion of a phosphonate diester **32.1** into the corresponding phosphonate monoester **32.2** (Scheme 32, Reaction 1) is accomplished by a number of methods. For example, the ester **32.1** in which  $R^1$  is an aralkyl group such as benzyl, is converted into the monoester compound **32.2** by reaction with a tertiary organic base such as diazabicyclooctane (DABCO) or quinuclidine, as described in *J. Org. Chem.*, 1995, 60, 2946. The reaction is performed in an inert hydrocarbon solvent such as toluene or xylene, at about 110 °C. The conversion of the diester **32.1** in which  $R^1$  is an aryl group such as phenyl, or an alkenyl group such as allyl, into the monoester **32.2** is effected by treatment of the ester **32.1** with a base such as aqueous sodium hydroxide in acetonitrile or lithium hydroxide in aqueous tetrahydrofuran. Phosphonate diesters **32.1** in which one of the groups  $R^1$  is aralkyl, such as benzyl, and the other is alkyl, is converted into the monoesters **32.2** in which  $R^1$  is alkyl by hydrogenation, for example using a palladium on carbon catalyst. Phosphonate diesters in which both of the groups  $R^1$  are alkenyl, such as allyl, is converted into the monoester **32.2** in which  $R^1$  is alkenyl, by treatment with chlorotris(triphenylphosphine)rhodium (Wilkinson's catalyst) in aqueous ethanol at reflux, optionally in the presence of diazabicyclooctane, for example by using the procedure described in *J. Org. Chem.*, 38, 3224, 1973 for the cleavage of allyl carboxylates.

The conversion of a phosphonate diester **32.1** or a phosphonate monoester **32.2** into the corresponding phosphonic acid **32.3** (Scheme 32, Reactions 2 and 3) can effected by reaction of the diester or the monoester with trimethylsilyl bromide, as described in *J. Chem. Soc., Chem. Comm.*, 739, 1979. The reaction is conducted in an inert solvent such as, for example, dichloromethane, optionally in the presence of a silylating agent such as bis(trimethylsilyl)trifluoroacetamide, at ambient temperature. A phosphonate monoester **32.2** in which  $R^1$  is aralkyl such as benzyl, is converted into the corresponding phosphonic acid **32.3** by hydrogenation over a palladium catalyst, or by treatment with hydrogen chloride in an ethereal solvent such as dioxane. A phosphonate monoester **32.2** in which  $R^1$  is alkenyl such

as, for example, allyl, is converted into the phosphonic acid **32.3** by reaction with Wilkinson's catalyst in an aqueous organic solvent, for example in 15% aqueous acetonitrile, or in aqueous ethanol, for example using the procedure described in *Helv. Chim. Acta.*, 68, 618, 1985.

Palladium catalyzed hydrogenolysis of phosphonate esters **32.1** in which  $R^1$  is benzyl is described in *J. Org. Chem.*, 24, 434, 1959. Platinum-catalyzed hydrogenolysis of phosphonate esters **32.1** in which  $R^1$  is phenyl is described in *J. Am. Chem. Soc.*, 78, 2336, 1956.


The conversion of a phosphonate monoester **32.2** into a phosphonate diester **32.1** (Scheme 32, Reaction 4) in which the newly introduced  $R^1$  group is alkyl, aralkyl, haloalkyl such as chloroethyl, or aralkyl is effected by a number of reactions in which the substrate **32.2** is reacted with a hydroxy compound  $R^1OH$ , in the presence of a coupling agent. Suitable coupling agents are those employed for the preparation of carboxylate esters, and include a carbodiimide such as dicyclohexylcarbodiimide, in which case the reaction is preferably conducted in a basic organic solvent such as pyridine, or (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PYBOP, Sigma), in which case the reaction is performed in a polar solvent such as dimethylformamide, in the presence of a tertiary organic base such as diisopropylethylamine, or Aldrithiol-2 (Aldrich) in which case the reaction is conducted in a basic solvent such as pyridine, in the presence of a triaryl phosphine such as triphenylphosphine. Alternatively, the conversion of the phosphonate monoester **32.2** to the diester **32.1** is effected by the use of the Mitsunobu reaction, as described above (Scheme 7). The substrate is reacted with the hydroxy compound  $R^1OH$ , in the presence of diethyl azodicarboxylate and a triarylphosphine such as triphenyl phosphine. Alternatively, the phosphonate monoester **32.2** is transformed into the phosphonate diester **32.1**, in which the introduced  $R^1$  group is alkenyl or aralkyl, by reaction of the monoester with the halide  $R^1Br$ , in which  $R^1$  is as alkenyl or aralkyl. The alkylation reaction is conducted in a polar organic solvent such as dimethylformamide or acetonitrile, in the presence of a base such as cesium carbonate. Alternatively, the phosphonate monoester is transformed into the phosphonate diester in a two step procedure. In the first step, the phosphonate monoester **32.2** is transformed into the chloro analog  $RP(O)(OR^1)Cl$  by reaction with thionyl chloride or oxalyl chloride and the like, as described in Organic Phosphorus Compounds, G. M. Kosolapoff, L. Maeir, eds, Wiley, 1976, p. 17, and the thus-obtained product  $RP(O)(OR^1)Cl$  is

then reacted with the hydroxy compound  $R^1OH$ , in the presence of a base such as triethylamine, to afford the phosphonate diester **32.1**.

5 A phosphonic acid  $R\text{-link-P(O)(OH)}_2$  is transformed into a phosphonate monoester  $RP(O)(OR^1)(OH)$  (Scheme 32, Reaction 5) by means of the methods described above of for the preparation of the phosphonate diester  $R\text{-link-P(O)(OR}^1)_2$  **32.1**, except that only one molar proportion of the component  $R^1OH$  or  $R^1Br$  is employed.

10 A phosphonic acid  $R\text{-link-P(O)(OH)}_2$  **32.3** is transformed into a phosphonate diester  $R\text{-link-P(O)(OR}^1)_2$  **32.1** (Scheme 32, Reaction 6) by a coupling reaction with the hydroxy compound  $R^1OH$ , in the presence of a coupling agent such as Aldrithiol-2 (Aldrich) and triphenylphosphine. The reaction is conducted in a basic solvent such as pyridine. Alternatively, phosphonic acids **32.3** is transformed into phosphonic esters **32.1** in which  $R^1$  is aryl, by means of a coupling reaction employing, for example, dicyclohexylcarbodiimide in pyridine at ca 70 °C. Alternatively, phosphonic acids **32.3** is transformed into phosphonic esters **32.1** in which  $R^1$  is alkenyl, by means of an alkylation reaction. The phosphonic acid is  
15 reacted with the alkenyl bromide  $R^1Br$  in a polar organic solvent such as acetonitrile solution at reflux temperature, the presence of a base such as cesium carbonate, to afford the phosphonic ester **32.1**.

**Scheme 32**



### Preparation of carbamates.

The phosphonate esters 1 - 9 may contain a carbamate linkage. The preparation of carbamates is described in Comprehensive Organic Functional Group Transformations, A. R. Katritzky, ed., Pergamon, 1995, Vol. 6, p. 416ff, and in Organic Functional Group Preparations, by S. R. Sandler and W. Karo, Academic Press, 1986, p. 260ff.

Scheme 33 illustrates various methods by which the carbamate linkage is synthesized. As shown in Scheme 33, in the general reaction generating carbamates, a carbinol 33.1, is converted into the activated derivative 33.2 in which Lv is a leaving group such as halo, imidazolyl, benztriazolyl and the like, as described herein. The activated derivative 33.2 is then reacted with an amine 33.3, to afford the carbamate product 33.4. Examples 1 - 7 in Scheme 33 depict methods by which the general reaction is effected. Examples 8 - 10 illustrate alternative methods for the preparation of carbamates.

Scheme 33, Example 1 illustrates the preparation of carbamates employing a chloroformyl derivative of the carbinol 33.5. In this procedure, the carbinol 33.5 is reacted

with phosgene, in an inert solvent such as toluene, at about 0°, as described in Org. Syn. Coll. Vol. 3, 167, 1965, or with an equivalent reagent such as trichloromethoxy chloroformate, as described in Org. Syn. Coll. Vol. 6, 715, 1988, to afford the chloroformate **33.6**. The latter compound is then reacted with the amine component **33.3**, in the presence of an organic or inorganic base, to afford the carbamate **33.7**. For example, the chloroformyl compound **33.6** is reacted with the amine **33.3** in a water-miscible solvent such as tetrahydrofuran, in the presence of aqueous sodium hydroxide, as described in Org. Syn. Coll. Vol. 3, 167, 1965, to yield the carbamate **33.7**. Alternatively, the reaction is performed in dichloromethane in the presence of an organic base such as diisopropylethylamine or dimethylaminopyridine.

Scheme 33, Example 2 depicts the reaction of the chloroformate compound **33.6** with imidazole to produce the imidazolide **33.8**. The imidazolide product is then reacted with the amine **33.3** to yield the carbamate **33.7**. The preparation of the imidazolide is performed in an aprotic solvent such as dichloromethane at 0°, and the preparation of the carbamate is conducted in a similar solvent at ambient temperature, optionally in the presence of a base such as dimethylaminopyridine, as described in *J. Med. Chem.*, 1989, 32, 357.

Scheme 33 Example 3, depicts the reaction of the chloroformate **33.6** with an activated hydroxyl compound R"OH, to yield the mixed carbonate ester **33.10**. The reaction is conducted in an inert organic solvent such as ether or dichloromethane, in the presence of a base such as dicyclohexylamine or triethylamine. The hydroxyl component R"OH is selected from the group of compounds **33.19** - **33.24** shown in Scheme 33, and similar compounds. For example, if the component R"OH is hydroxybenztriazole **33.19**, N-hydroxysuccinimide **33.20**, or pentachlorophenol, **33.21**, the mixed carbonate **33.10** is obtained by the reaction of the chloroformate with the hydroxyl compound in an ethereal solvent in the presence of dicyclohexylamine, as described in *Can. J. Chem.*, 1982, 60, 976. A similar reaction in which the component R"OH is pentafluorophenol **33.22** or 2-hydroxypyridine **33.23** is performed in an ethereal solvent in the presence of triethylamine, as described in *Syn.*, 1986, 303, and *Chem. Ber.* 118, 468, 1985.

Scheme 33 Example 4 illustrates the preparation of carbamates in which an alkyloxycarbonylimidazole **33.8** is employed. In this procedure, a carbinol **33.5** is reacted with an equimolar amount of carbonyl diimidazole **33.11** to prepare the intermediate **33.8**. The reaction is conducted in an aprotic organic solvent such as dichloromethane or

tetrahydrofuran. The acyloxyimidazole 33.8 is then reacted with an equimolar amount of the amine  $R'NH_2$  to afford the carbamate 33.7. The reaction is performed in an aprotic organic solvent such as dichloromethane, as described in *Tet. Lett.*, 42, 2001, 5227, to afford the carbamate 33.7.

5        Scheme 33, Example 5 illustrates the preparation of carbamates by means of an intermediate alkoxycarbonylbenztriazole 33.13. In this procedure, a carbinol ROH is reacted at ambient temperature with an equimolar amount of benztriazole carbonyl chloride 33.12, to afford the alkoxycarbonyl product 33.13. The reaction is performed in an organic solvent such as benzene or toluene, in the presence of a tertiary organic amine such as triethylamine, as  
10        described in *Synthesis.*, 1977, 704. The product is then reacted with the amine  $R'NH_2$  to afford the carbamate 33.7. The reaction is conducted in toluene or ethanol, at from ambient temperature to about 80 °C as described in *Synthesis.*, 1977, 704.

      Scheme 33, Example 6 illustrates the preparation of carbamates in which a carbonate  $(R''O)_2CO$ , 33.14, is reacted with a carbinol 33.5 to afford the intermediate alkyloxycarbonyl  
15        intermediate 33.15. The latter reagent is then reacted with the amine  $R'NH_2$  to afford the carbamate 33.7. The procedure in which the reagent 33.15 is derived from hydroxybenztriazole 33.19 is described in *Synthesis*, 1993, 908; the procedure in which the reagent 33.15 is derived from N-hydroxysuccinimide 33.20 is described in *Tet. Lett.*, 1992, 2781; the procedure in which the reagent 33.15 is derived from 2-hydroxypyridine 33.23 is  
20        described in *Tet. Lett.*, 1991, 4251; the procedure in which the reagent 33.15 is derived from 4-nitrophenol 33.24 is described in *Synthesis*, 1993, 103. The reaction between equimolar amounts of the carbinol ROH and the carbonate 33.14 is conducted in an inert organic solvent at ambient temperature.

      Scheme 33, Example 7 illustrates the preparation of carbamates from alkoxycarbonyl  
25        azides 33.16. In this procedure, an alkyl chloroformate 33.6 is reacted with an azide, for example sodium azide, to afford the alkoxycarbonyl azide 33.16. The latter compound is then reacted with an equimolar amount of the amine  $R'NH_2$  to afford the carbamate 33.7. The reaction is conducted at ambient temperature in a polar aprotic solvent such as dimethylsulfoxide, for example as described in *Synthesis.*, 1982, 404.

30        Scheme 33, Example 8 illustrates the preparation of carbamates by means of the reaction between a carbinol ROH and the chloroformyl derivative of an amine 33.17. In this


procedure, which is described in Synthetic Organic Chemistry, R. B. Wagner, H. D. Zook, Wiley, 1953, p. 647, the reactants are combined at ambient temperature in an aprotic solvent such as acetonitrile, in the presence of a base such as triethylamine, to afford the carbamate 33.7.

5            Scheme 33, Example 9 illustrates the preparation of carbamates by means of the reaction between a carbinol ROH and an isocyanate 33.18. In this procedure, which is described in Synthetic Organic Chemistry, R. B. Wagner, H. D. Zook, Wiley, 1953, p. 645, the reactants are combined at ambient temperature in an aprotic solvent such as ether or dichloromethane and the like, to afford the carbamate 33.7.





10           Scheme 33, Example 10 illustrates the preparation of carbamates by means of the reaction between a carbinol ROH and an amine R'NH<sub>2</sub>. In this procedure, which is described in *Chem. Lett.* 1972, 373, the reactants are combined at ambient temperature in an aprotic organic solvent such as tetrahydrofuran, in the presence of a tertiary base such as triethylamine, and selenium. Carbon monoxide is passed through the solution and the reaction  
15           proceeds to afford the carbamate 33.7.

**Scheme 33. Preparation of carbamates.**








**General reaction**



**Examples**







PREPARATION OF CARBOALKOXY-SUBSTITUTED PHOSPHONATE DIAMIDATES, MONOAMIDATES, DIESTERS AND MONOESTERS.

A number of methods are available for the conversion of phosphonic acids into amidates and esters. In one group of methods, the phosphonic acid is either converted into an isolated activated intermediate such as a phosphoryl chloride, or the phosphonic acid is activated in situ for reaction with an amine or a hydroxy compound.

5       The conversion of phosphonic acids into phosphoryl chlorides is accomplished by reaction with thionyl chloride, for example as described in *J. Gen. Chem. USSR*, 1983, 53, 480, *Zh. Obshchei Khim.*, 1958, 28, 1063, or *J. Org. Chem.*, 1994, 59, 6144, or by reaction with oxalyl chloride, as described in *J. Am. Chem. Soc.*, 1994, 116, 3251, or *J. Org. Chem.*, 1994, 59, 6144, or by reaction with phosphorus pentachloride, as described in *J. Org. Chem.*, 10   2001, 66, 329, or in *J. Med. Chem.*, 1995, 38, 1372. The resultant phosphoryl chlorides are then reacted with amines or hydroxy compounds in the presence of a base to afford the amidate or ester products.

Phosphonic acids are converted into activated imidazolyl derivatives by reaction with carbonyl diimidazole, as described in *J. Chem. Soc., Chem. Comm.*, 1991, 312, or *Nucleosides & Nucleotides* 2000, 19, 1885. Activated sulfonyloxy derivatives are obtained by the reaction 15   of phosphonic acids with trichloromethylsulfonyl chloride, as described in *J. Med. Chem.* 1995, 38, 4958, or with triisopropylbenzenesulfonyl chloride, as described in *Tet. Lett.*, 1996, 7857, or *Bioorg. Med. Chem. Lett.*, 1998, 8, 663. The activated sulfonyloxy derivatives are then reacted with amines or hydroxy compounds to afford amidates or esters.

20       Alternatively, the phosphonic acid and the amine or hydroxy reactant are combined in the presence of a diimide coupling agent. The preparation of phosphonic amidates and esters by means of coupling reactions in the presence of dicyclohexyl carbodiimide is described, for example, in *J. Chem. Soc., Chem. Comm.*, 1991, 312, or *J. Med. Chem.*, 1980, 23, 1299 or *Coll. Czech. Chem. Comm.*, 1987, 52, 2792. The use of ethyl dimethylaminopropyl 25   carbodiimide for activation and coupling of phosphonic acids is described in *Tet. Lett.*, 2001, 42, 8841, or *Nucleosides & Nucleotides*, 2000, 19, 1885.

A number of additional coupling reagents have been described for the preparation of amidates and esters from phosphonic acids. The agents include Aldrithiol-2, and PYBOP and BOP, as described in *J. Org. Chem.*, 1995, 60, 5214, and *J. Med. Chem.*, 1997, 40, 3842, 30   mesitylene-2-sulfonyl-3-nitro-1,2,4-triazole (MSNT), as described in *J. Med. Chem.*, 1996, 39, 4958, diphenylphosphoryl azide, as described in *J. Org. Chem.*, 1984, 49, 1158, 1-(2,4,6-

triisopropylbenzenesulfonyl-3-nitro-1,2,4-triazole (TPSNT) as described in *Bioorg. Med. Chem. Lett.*, 1998, 8, 1013, bromotris(dimethylamino)phosphonium hexafluorophosphate (BroP), as described in *Tet. Lett.*, 1996, 37, 3997, 2-chloro-5,5-dimethyl-2-oxo-1,3,2-dioxaphosphinane, as described in *Nucleosides Nucleotides* 1995, 14, 871, and diphenyl chlorophosphate, as described in *J. Med. Chem.*, 1988, 31, 1305.

Phosphonic acids are converted into amidates and esters by means of the Mitsunobu reaction, in which the phosphonic acid and the amine or hydroxy reactant are combined in the presence of a triaryl phosphine and a dialkyl azodicarboxylate. The procedure is described in *Org. Lett.*, 2001, 3, 643, or *J. Med. Chem.*, 1997, 40, 3842.

Phosphonic esters are also obtained by the reaction between phosphonic acids and halo compounds, in the presence of a suitable base. The method is described, for example, in *Anal. Chem.*, 1987, 59, 1056, or *J. Chem. Soc. Perkin Trans., I*, 1993, 19, 2303, or *J. Med. Chem.*, 1995, 38, 1372, or *Tet. Lett.*, 2002, 43, 1161.

Schemes 34-37 illustrate the conversion of phosphonate esters and phosphonic acids into carboalkoxy-substituted phosphondiamidates (Scheme 34), phosphonamidates (Scheme 35), phosphonate monoesters (Scheme 36) and phosphonate diesters, (Scheme 37). Scheme 38 illustrates synthesis of gem-dialkyl amino phosphonate reagents.

Scheme 34 illustrates various methods for the conversion of phosphonate diesters 34.1 into phosphondiamidates 34.5. The diester 34.1, prepared as described previously, is hydrolyzed, either to the monoester 34.2 or to the phosphonic acid 34.6. The methods employed for these transformations are described above. The monoester 34.2 is converted into the monoamidate 34.3 by reaction with an aminoester 34.9, in which the group  $R^2$  is H or alkyl, the group  $R^{4b}$  is an alkylene moiety such as, for example,  $CHCH_3$ ,  $CHPr^I$ ,  $CH(CH_2Ph)$ ,  $CH_2CH(CH_3)$  and the like, or a group present in natural or modified aminoacids, and the group  $R^{5b}$  is alkyl. The reactants are combined in the presence of a coupling agent such as a carbodiimide, for example dicyclohexyl carbodiimide, as described in *J. Am. Chem. Soc.*, 1957, 79, 3575, optionally in the presence of an activating agent such as hydroxybenztriazole, to yield the amidate product 34.3. The amidate-forming reaction is also effected in the presence of coupling agents such as BOP, as described in *J. Org. Chem.*, 1995, 60, 5214, Aldrithiol, PYBOP and similar coupling agents used for the preparation of amides and esters. Alternatively, the reactants 34.2 and 34.9 are transformed into the monoamidate 34.3 by

means of a Mitsunobu reaction. The preparation of amidates by means of the Mitsunobu reaction is described in *J. Med. Chem.*, 1995, 38, 2742. Equimolar amounts of the reactants are combined in an inert solvent such as tetrahydrofuran in the presence of a triaryl phosphine and a dialkyl azodicarboxylate. The thus-obtained monoamidate ester **34.3** is then transformed  
5 into amidate phosphonic acid **34.4**. The conditions used for the hydrolysis reaction depend on the nature of the R<sup>1</sup> group, as described previously. The phosphonic acid amidate **34.4** is then reacted with an aminoester **34.9**, as described above, to yield the bisamidate product **34.5**, in which the amino substituents are the same or different.

An example of this procedure is shown in Scheme 34, Example 1. In this procedure, a  
10 dibenzyl phosphonate **34.14** is reacted with diazabicyclooctane (DABCO) in toluene at reflux, as described in *J. Org. Chem.*, 1995, 60, 2946, to afford the monobenzyl phosphonate **34.15**. The product is then reacted with equimolar amounts of ethyl alaninate **34.16** and dicyclohexyl carbodiimide in pyridine, to yield the amidate product **34.17**. The benzyl group is then removed, for example by hydrogenolysis over a palladium catalyst, to give the monoacid  
15 product **34.18**. This compound is then reacted in a Mitsunobu reaction with ethyl leucinate **34.19**, triphenyl phosphine and diethylazodicarboxylate, as described in *J. Med. Chem.*, 1995, 38, 2742, to produce the bisamidate product **34.20**.

Using the above procedures, but employing in place of ethyl leucinate **34.19** or ethyl alaninate **34.16**, different aminoesters **34.9**, the corresponding products **34.5** are obtained.

20 Alternatively, the phosphonic acid **34.6** is converted into the bisamidate **34.5** by use of the coupling reactions described above. The reaction is performed in one step, in which case the nitrogen-related substituents present in the product **34.5** are the same, or in two steps, in which case the nitrogen-related substituents can be different.

An example of the method is shown in Scheme 34, Example 2. In this procedure, a  
25 phosphonic acid **34.6** is reacted in pyridine solution with excess ethyl phenylalaninate **34.21** and dicyclohexylcarbodiimide, for example as described in *J. Chem. Soc., Chem. Comm.*, 1991, 1063, to give the bisamidate product **34.22**.

Using the above procedures, but employing, in place of ethyl phenylalaninate, different aminoesters **34.9**, the corresponding products **34.5** are obtained.

30 As a further alternative, the phosphonic acid **34.6** is converted into the mono or bis-activated derivative **34.7**, in which Lv is a leaving group such as chloro, imidazolyl,

triisopropylbenzenesulfonyloxy etc. The conversion of phosphonic acids into chlorides **34.7** (Lv = Cl) is effected by reaction with thionyl chloride or oxalyl chloride and the like, as described in Organic Phosphorus Compounds, G. M. Kosolapoff, L. Maeir, eds, Wiley, 1976, p. 17. The conversion of phosphonic acids into monoimidazolides **34.7** (Lv = imidazolyl) is described in *J. Med. Chem.*, 2002, 45, 1284 and in *J. Chem. Soc. Chem. Comm.*, 1991, 312. Alternatively, the phosphonic acid is activated by reaction with triisopropylbenzenesulfonyl chloride, as described in *Nucleosides and Nucleotides*, 2000, 10, 1885. The activated product is then reacted with the aminoester **34.9**, in the presence of a base, to give the bisamidate **34.5**. The reaction is performed in one step, in which case the nitrogen substituents present in the product **34.5** are the same, or in two steps, via the intermediate **34.11**, in which case the nitrogen substituents can be different.

Examples of these methods are shown in Scheme 34, Examples 3 and 5. In the procedure illustrated in Scheme 34, Example 3, a phosphonic acid **34.6** is reacted with ten molar equivalents of thionyl chloride, as described in *Zh. Obshchei Khim.*, 1958, 28, 1063, to give the dichloro compound **34.23**. The product is then reacted at reflux temperature in a polar aprotic solvent such as acetonitrile, and in the presence of a base such as triethylamine, with butyl serinate **34.24** to afford the bisamidate product **34.25**.

Using the above procedures, but employing, in place of butyl serinate **34.24**, different aminoesters **34.9**, the corresponding products **34.5** are obtained.

In the procedure illustrated in Scheme 34, Example 5, the phosphonic acid **34.6** is reacted, as described in *J. Chem. Soc. Chem. Comm.*, 1991, 312, with carbonyl diimidazole to give the imidazolidine **34.32**. The product is then reacted in acetonitrile solution at ambient temperature, with one molar equivalent of ethyl alaninate **34.33** to yield the monodisplacement product **34.34**. The latter compound is then reacted with carbonyl diimidazole to produce the activated intermediate **34.35**, and the product is then reacted, under the same conditions, with ethyl N-methylalaninate **34.33a** to give the bisamidate product **34.36**.

Using the above procedures, but employing, in place of ethyl alaninate **34.33** or ethyl N-methylalaninate **34.33a**, different aminoesters **34.9**, the corresponding products **34.5** are obtained.

The intermediate monoamidate **34.3** is also prepared from the monoester **34.2** by first converting the monoester into the activated derivative **34.8** in which Lv is a leaving group such as halo, imidazolyl etc, using the procedures described above. The product **34.8** is then reacted with an aminoester **34.9** in the presence of a base such as pyridine, to give an intermediate monoamidate product **34.3**. The latter compound is then converted, by removal of the R<sup>1</sup> group and coupling of the product with the aminoester **34.9**, as described above, into the bisamidate **34.5**.

An example of this procedure, in which the phosphonic acid is activated by conversion to the chloro derivative **34.26**, is shown in Scheme 34, Example 4. In this procedure, the phosphonic monobenzyl ester **34.15** is reacted, in dichloromethane, with thionyl chloride, as described in *Tet. Letters.*, 1994, 35, 4097, to afford the phosphoryl chloride **34.26**. The product is then reacted in acetonitrile solution at ambient temperature with one molar equivalent of ethyl 3-amino-2-methylpropionate **34.27** to yield the monoamidate product **34.28**. The latter compound is hydrogenated in ethylacetate over a 5% palladium on carbon catalyst to produce the monoacid product **34.29**. The product is subjected to a Mitsunobu coupling procedure, with equimolar amounts of butyl alaninate **34.30**, triphenyl phosphine, diethylazodicarboxylate and triethylamine in tetrahydrofuran, to give the bisamidate product **34.31**.

Using the above procedures, but employing, in place of ethyl 3-amino-2-methylpropionate **34.27** or butyl alaninate **34.30**, different aminoesters **34.9**, the corresponding products **34.5** are obtained.

The activated phosphonic acid derivative **34.7** is also converted into the bisamidate **34.5** via the diamino compound **34.10**. The conversion of activated phosphonic acid derivatives such as phosphoryl chlorides into the corresponding amino analogs **34.10**, by reaction with ammonia, is described in Organic Phosphorus Compounds, G. M. Kosolapoff, L. Maeir, eds, Wiley, 1976. The diamino compound **34.10** is then reacted at elevated temperature with a haloester **34.12** (Hal = halogen, i.e. F, Cl, Br, I), in a polar organic solvent such as dimethylformamide, in the presence of a base such as 4, 4-dimethylaminopyridine (DMAP) or potassium carbonate, to yield the bisamidate **34.5**.

An example of this procedure is shown in Scheme 34, Example 6. In this method, a dichlorophosphonate **34.23** is reacted with ammonia to afford the diamide **34.37**. The reaction

is performed in aqueous, aqueous alcoholic or alcoholic solution, at reflux temperature. The resulting diamino compound is then reacted with two molar equivalents of ethyl 2-bromo-3-methylbutyrate **34.38**, in a polar organic solvent such as N-methylpyrrolidinone at ca. 150 °C, in the presence of a base such as potassium carbonate, and optionally in the presence of a catalytic amount of potassium iodide, to afford the bisamidate product **34.39**.

Using the above procedures, but employing, in place of ethyl 2-bromo-3-methylbutyrate **34.38**, different haloesters **34.12** the corresponding products **34.5** are obtained.

The procedures shown in Scheme 34 are also applicable to the preparation of bisamidates in which the aminoester moiety incorporates different functional groups. Scheme 34, Example 7 illustrates the preparation of bisamidates derived from tyrosine. In this procedure, the monoimidazolide **34.32** is reacted with propyl tyrosinate **34.40**, as described in Example 5, to yield the monoamidate **34.41**. The product is reacted with carbonyl diimidazole to give the imidazolide **34.42**, and this material is reacted with a further molar equivalent of propyl tyrosinate to produce the bisamidate product **34.43**.

Using the above procedures, but employing, in place of propyl tyrosinate **34.40**, different aminoesters **34.9**, the corresponding products **34.5** are obtained. The aminoesters employed in the two stages of the above procedure can be the same or different, so that bisamidates with the same or different amino substituents are prepared.

Scheme 35 illustrates methods for the preparation of phosphonate monoamidates.

In one procedure, a phosphonate monoester **34.1** is converted, as described in Scheme 34, into the activated derivative **34.8**. This compound is then reacted, as described above, with an aminoester **34.9**, in the presence of a base, to afford the monoamidate product **35.1**.

The procedure is illustrated in Scheme 35, Example 1. In this method, a monophenyl phosphonate **35.7** is reacted with, for example, thionyl chloride, as described in *J. Gen. Chem. USSR.*, 1983, 32, 367, to give the chloro product **35.8**. The product is then reacted, as described in Scheme 34, with ethyl alaninate **35.9**, to yield the amidate **35.10**.

Using the above procedures, but employing, in place of ethyl alaninate **35.9**, different aminoesters **34.9**, the corresponding products **35.1** are obtained.

Alternatively, the phosphonate monoester **34.1** is coupled, as described in Scheme 34, with an aminoester **34.9** to produce the amidate **35.1**. If necessary, the R<sup>1</sup> substituent is then altered, by initial cleavage to afford the phosphonic acid **35.2**. The procedures for this


5

$$\begin{array}{c}
 \text{Hal}(\text{R}^{4b})\text{CO}_2\text{R}^{5b} \\
 \xleftarrow{\text{34.12}} \text{R-link}-\text{P}(\text{O})(\text{NH}_2)_2 \xleftarrow{\text{34.7}} \text{R-link}-\text{P}(\text{O})(\text{Lv})(\text{Lv or OH}) \\
 \text{34.5} \quad \text{Ex6} \quad \text{34.10} \quad \text{34.7} \\
 \text{R-link}-\text{P}(\text{O})(\text{NH})(\text{NH}(\text{R}^{4b})\text{CO}_2\text{R}^{5b}) \\
 \text{34.5}
 \end{array}$$


$$\begin{array}{c}
 \text{R-link}-\text{P}(\text{O})(\text{OR}^1)_2 \xrightarrow{\text{34.2}} \text{R-link}-\text{P}(\text{O})(\text{OR}^1)(\text{OH}) \xrightarrow{\text{34.6}} \text{R-link}-\text{P}(\text{O})(\text{OH})_2 \\
 \text{34.1} \quad \text{34.2} \quad \text{34.6} \\
 \text{R-link}-\text{P}(\text{O})(\text{OR}^1)(\text{Lv}) \xrightarrow{\text{R}^2\text{NH}(\text{R}^{4b})\text{CO}_2\text{R}^{5b}} \text{R-link}-\text{P}(\text{O})(\text{OR}^1)(\text{N}(\text{R}^2)(\text{R}^{4b})\text{CO}_2\text{R}^{5b}) \xrightarrow{\text{34.9}} \text{R-link}-\text{P}(\text{O})(\text{OH})(\text{N}(\text{R}^2)(\text{R}^{4b})\text{CO}_2\text{R}^{5b}) \\
 \text{34.8} \quad \text{34.9} \quad \text{34.3} \quad \text{34.4} \\
 \text{R-link}-\text{P}(\text{O})(\text{Lv})(\text{Lv or OH}) \xrightarrow{\text{34.9}} \text{R-link}-\text{P}(\text{O})(\text{N}(\text{R}^2)(\text{R}^{4b})\text{CO}_2\text{R}^{5b})_2 \xrightarrow{\text{34.9}} \text{R-link}-\text{P}(\text{O})(\text{N}(\text{R}^2)(\text{R}^{4b})\text{CO}_2\text{R}^{5b})(\text{Lv or OH}) \\
 \text{34.7} \quad \text{34.9} \quad \text{34.5} \quad \text{34.11}
 \end{array}$$




**Scheme 34 Example 1**





**Scheme 34 Example 2**




**Scheme 34 Example 3**




**Scheme 34 Example 4**




**Scheme 34 Example 5**



**Scheme 34 Example 6**



**Scheme 34 Example 7**



Examples of this method are shown in Scheme 35, Examples and 2 and 3. In the sequence shown in Example 2, a monobenzyl phosphonate **35.11** is transformed by reaction with ethyl alaninate, using one of the methods described above, into the monoamidate **35.12**.

5 The benzyl group is then removed by catalytic hydrogenation in ethylacetate solution over a 5% palladium on carbon catalyst, to afford the phosphonic acid amidate **35.13**. The product is then reacted in dichloromethane solution at ambient temperature with equimolar amounts of 1-(dimethylaminopropyl)-3-ethylcarbodiimide and trifluoroethanol **35.14**, for example as described in *Tet. Lett.*, 2001, 42, 8841, to yield the amidate ester **35.15**.

10 In the sequence shown in Scheme 35, Example 3, the monoamidate **35.13** is coupled, in tetrahydrofuran solution at ambient temperature, with equimolar amounts of dicyclohexyl carbodiimide and 4-hydroxy-N-methylpiperidine **35.16**, to produce the amidate ester product **35.17**.

Using the above procedures, but employing, in place of the ethyl alaninate product **35.12** different monoacids **35.2**, and in place of trifluoroethanol **35.14** or 4-hydroxy-N-methylpiperidine **35.16**, different hydroxy compounds  $R^3OH$ , the corresponding products **35.3** are obtained.

Alternatively, the activated phosphonate ester **34.8** is reacted with ammonia to yield the amidate **35.4**. The product is then reacted, as described in Scheme 34, with a haloester **35.5**, in the presence of a base, to produce the amidate product **35.6**. If appropriate, the nature of the  $R^1$  group is changed, using the procedures described above, to give the product **35.3**. The method is illustrated in Scheme 35, Example 4. In this sequence, the monophenyl phosphoryl chloride **35.18** is reacted, as described in Scheme 34, with ammonia, to yield the amino product **35.19**. This material is then reacted in N-methylpyrrolidinone solution at 170° with butyl 2-bromo-3-phenylpropionate **35.20** and potassium carbonate, to afford the amidate product **35.21**.

Using these procedures, but employing, in place of butyl 2-bromo-3-phenylpropionate **35.20**, different haloesters **35.5**, the corresponding products **35.6** are obtained.


The monoamidate products **35.3** are also prepared from the doubly activated phosphonate derivatives **34.7**. In this procedure, examples of which are described in *Synlett.*, 1998, 1, 73, the intermediate **34.7** is reacted with a limited amount of the aminoester **34.9** to

give the mono-displacement product 34.11. The latter compound is then reacted with the hydroxy compound  $R^3OH$  in a polar organic solvent such as dimethylformamide, in the presence of a base such as diisopropylethylamine, to yield the monoamidate ester 35.3.


The method is illustrated in Scheme 35, Example 5. In this method, the phosphoryl dichloride 35.22 is reacted in dichloromethane solution with one molar equivalent of ethyl N-methyl tyrosinate 35.23 and dimethylaminopyridine, to generate the monoamidate 35.24. The product is then reacted with phenol 35.25 in dimethylformamide containing potassium carbonate, to yield the ester amidate product 35.26.

Using these procedures, but employing, in place of ethyl N-methyl tyrosinate 35.23 or phenol 35.25, the aminoesters 34.9 and/or the hydroxy compounds  $R^3OH$ , the corresponding products 35.3 are obtained.



**Scheme 35**




**Scheme 35 Example 1**




**Scheme 35 Example 2**




**Scheme 35 Example 3**



**Scheme 35 Example 4**



**Scheme 35 Example 5**



Scheme 36 illustrates methods for the preparation of carboalkoxy-substituted phosphonate diesters in which one of the ester groups incorporates a carboalkoxy substituent.

- 5 In one procedure, a phosphonate monoester **34.1**, prepared as described above, is coupled, using one of the methods described above, with a hydroxyester **36.1**, in which the groups  $\text{R}^{4b}$  and  $\text{R}^{5b}$  are as described in Scheme 34. For example, equimolar amounts of the reactants are coupled in the presence of a carbodiimide such as dicyclohexyl carbodiimide, as described in *Aust. J. Chem.*, 1963, 609, optionally in the presence of dimethylaminopyridine,
- 10 as described in *Tet.*, 1999, 55, 12997. The reaction is conducted in an inert solvent at ambient temperature.

The procedure is illustrated in Scheme 36, Example 1. In this method, a monophenyl phosphonate **36.9** is coupled, in dichloromethane solution in the presence of dicyclohexyl carbodiimide, with ethyl 3-hydroxy-2-methylpropionate **36.10** to yield the phosphonate mixed diester **36.11**.

5        Using this procedure, but employing, in place of ethyl 3-hydroxy-2-methylpropionate **36.10**, different hydroxyesters **33.1**, the corresponding products **33.2** are obtained.

      The conversion of a phosphonate monoester **34.1** into a mixed diester **36.2** is also accomplished by means of a Mitsunobu coupling reaction with the hydroxyester **36.1**, as described in *Org. Lett.*, 2001, 643. In this method, the reactants **34.1** and **36.1** are combined in  
10    a polar solvent such as tetrahydrofuran, in the presence of a triarylphosphine and a dialkyl azodicarboxylate, to give the mixed diester **36.2**. The R<sup>1</sup> substituent is varied by cleavage, using the methods described previously, to afford the monoacid product **36.3**. The product is then coupled, for example using methods described above, with the hydroxy compound R<sup>3</sup>OH, to give the diester product **36.4**.

15        The procedure is illustrated in Scheme 36, Example 2. In this method, a monoallyl phosphonate **36.12** is coupled in tetrahydrofuran solution, in the presence of triphenylphosphine and diethylazodicarboxylate, with ethyl lactate **36.13** to give the mixed diester **36.14**. The product is reacted with tris(triphenylphosphine) rhodium chloride (Wilkinson catalyst) in acetonitrile, as described previously, to remove the allyl group and  
20    produce the monoacid product **36.15**. The latter compound is then coupled, in pyridine solution at ambient temperature, in the presence of dicyclohexyl carbodiimide, with one molar equivalent of 3-hydroxypyridine **36.16** to yield the mixed diester **36.17**.

      Using the above procedures, but employing, in place of the ethyl lactate **36.13** or 3-hydroxypyridine, a different hydroxyester **36.1** and/or a different hydroxy compound R<sup>3</sup>OH,  
25    the corresponding products **36.4** are obtained.

      The mixed diesters **36.2** are also obtained from the monoesters **34.1** via the intermediacy of the activated monoesters **36.5**. In this procedure, the monoester **34.1** is converted into the activated compound **36.5** by reaction with, for example, phosphorus pentachloride, as described in *J. Org. Chem.*, 2001, 66, 329, or with thionyl chloride or oxalyl  
30    chloride (Lv = Cl), or with triisopropylbenzenesulfonyl chloride in pyridine, as described in *Nucleosides and Nucleotides*, 2000, 19, 1885, or with carbonyl diimidazole, as described in *J.*



*Med. Chem.*, 2002, 45, 1284. The resultant activated monoester is then reacted with the hydroxyester **36.1**, as described above, to yield the mixed diester **36.2**.

The procedure is illustrated in Scheme 36, Example 3. In this sequence, a monophenyl phosphonate **36.9** is reacted, in acetonitrile solution at 70 °C, with ten equivalents of thionyl chloride, so as to produce the phosphoryl chloride **36.19**. The product is then reacted with ethyl 4-carbamoyl-2-hydroxybutyrate **36.20** in dichloromethane containing triethylamine, to give the mixed diester **36.21**.

Using the above procedures, but employing, in place of ethyl 4-carbamoyl-2-hydroxybutyrate **36.20**, different hydroxyesters **36.1**, the corresponding products **36.2** are obtained.

The mixed phosphonate diesters are also obtained by an alternative route for incorporation of the R<sup>3</sup>O group into intermediates **36.3** in which the hydroxyester moiety is already incorporated. In this procedure, the monoacid intermediate **36.3** is converted into the activated derivative **36.6** in which Lv is a leaving group such as chloro, imidazole, and the like, as previously described. The activated intermediate is then reacted with the hydroxy compound R<sup>3</sup>OH, in the presence of a base, to yield the mixed diester product **36.4**.

The method is illustrated in Scheme 36, Example 4. In this sequence, the phosphonate monoacid **36.22** is reacted with trichloromethanesulfonyl chloride in tetrahydrofuran containing collidine, as described in *J. Med. Chem.*, 1995, 38, 4648, to produce the trichloromethanesulfonyloxy product **36.23**. This compound is reacted with 3-(morpholinomethyl)phenol **36.24** in dichloromethane containing triethylamine, to yield the mixed diester product **36.25**.


Using the above procedures, but employing, in place of with 3-(morpholinomethyl)phenol **36.24**, different carbinols R<sup>3</sup>OH, the corresponding products **36.4** are obtained.

The phosphonate esters **36.4** are also obtained by means of alkylation reactions performed on the monoesters **34.1**. The reaction between the monoacid **34.1** and the haloester **36.7** is performed in a polar solvent in the presence of a base such as diisopropylethylamine, as described in *Anal. Chem.*, 1987, 59, 1056, or triethylamine, as described in *J. Med. Chem.*, 1995, 38, 1372, or in a non-polar solvent such as benzene, in the presence of 18-crown-6, as described in *Syn. Comm.*, 1995, 25, 3565.


The method is illustrated in Scheme 36, Example 5. In this procedure, the monoacid **36.26** is reacted with ethyl 2-bromo-3-phenylpropionate **36.27** and diisopropylethylamine in dimethylformamide at 80 °C to afford the mixed diester product **36.28**.

Using the above procedure, but employing, in place of ethyl 2-bromo-3-phenylpropionate **36.27**, different haloesters **36.7**, the corresponding products **36.4** are obtained.


**Scheme 36**





**Scheme 36 Example 1**




**Scheme 36 Example 2**




**Scheme 36 Example 3**



#### Scheme 36 Example 4



#### Scheme 36 Example 5



Scheme 37 illustrates methods for the preparation of phosphonate diesters in which both the ester substituents incorporate carboalkoxy groups.

- 5        The compounds are prepared directly or indirectly from the phosphonic acids **34.6**. In one alternative, the phosphonic acid is coupled with the hydroxyester **37.2**, using the conditions described previously in Schemes 34-36, such as coupling reactions using dicyclohexyl carbodiimide or similar reagents, or under the conditions of the Mitsunobu reaction, to afford the diester product **37.3** in which the ester substituents are identical.
- 10       This method is illustrated in Scheme 37, Example 1. In this procedure, the phosphonic acid **34.6** is reacted with three molar equivalents of butyl lactate **37.5** in the presence of Aldrithiol-2 and triphenyl phosphine in pyridine at ca. 70 °C, to afford the diester **37.6**.

Using the above procedure, but employing, in place of butyl lactate 37.5, different hydroxyesters 37.2, the corresponding products 37.3 are obtained.

Alternatively, the diesters 37.3 are obtained by alkylation of the phosphonic acid 34.6 with a haloester 37.1. The alkylation reaction is performed as described in Scheme 36 for the  
5 preparation of the esters 36.4.

This method is illustrated in Scheme 37, Example 2. In this procedure, the phosphonic acid 34.6 is reacted with excess ethyl 3-bromo-2-methylpropionate 37.7 and diisopropylethylamine in dimethylformamide at ca. 80 °C, as described in *Anal. Chem.*, 1987, 59, 1056, to produce the diester 37.8.

10 Using the above procedure, but employing, in place of ethyl 3-bromo-2-methylpropionate 37.7, different haloesters 37.1, the corresponding products 37.3 are obtained.

The diesters 37.3 are also obtained by displacement reactions of activated derivatives 34.7 of the phosphonic acid with the hydroxyesters 37.2. The displacement reaction is  
15 performed in a polar solvent in the presence of a suitable base, as described in Scheme 36. The displacement reaction is performed in the presence of an excess of the hydroxyester, to afford the diester product 37.3 in which the ester substituents are identical, or sequentially with limited amounts of different hydroxyesters, to prepare diesters 37.3 in which the ester substituents are different.


20 The methods are illustrated in Scheme 37, Examples 3 and 4. As shown in Example 3, the phosphoryl dichloride 35.22 is reacted with three molar equivalents of ethyl 3-hydroxy-2-(hydroxymethyl)propionate 37.9 in tetrahydrofuran containing potassium carbonate, to obtain the diester product 37.10.

Using the above procedure, but employing, in place of ethyl 3-hydroxy-2-  
25 (hydroxymethyl)propionate 37.9, different hydroxyesters 37.2, the corresponding products 37.3 are obtained.


Scheme 37, Example 4 depicts the displacement reaction between equimolar amounts of the phosphoryl dichloride 35.22 and ethyl 2-methyl-3-hydroxypropionate 37.11, to yield the monoester product 37.12. The reaction is conducted in acetonitrile at 70° in the presence  
30 of diisopropylethylamine. The product 37.12 is then reacted, under the same conditions, with one molar equivalent of ethyl lactate 37.13, to give the diester product 37.14.

Using the above procedures, but employing, in place of ethyl 2-methyl-3-hydroxypropionate 37.11 and ethyl lactate 37.13, sequential reactions with different hydroxyesters 37.2, the corresponding products 37.3 are obtained.


**Scheme 37**




**Scheme 37 Example 1**





**Scheme 37 Example 2**



### Scheme 37 Example 3




### Scheme 37 Example 4




2,2-Dimethyl-2-aminoethylphosphonic acid intermediates can be prepared by the route in Scheme 5. Condensation of 2-methyl-2-propanesulfonamide with acetone give sulfinyl imine **38.11** (*J. Org. Chem.* **1999**, *64*, 12). Addition of dimethyl methylphosphonate lithium to **38.11** afford **38.12**. Acidic methanolysis of **38.12** provide amine **38.13**. Protection of amine with Cbz group and removal of methyl groups yield phosphonic acid **38.14**, which can be converted to desired **38.15** (Scheme 5a) using methods reported earlier on. An alternative synthesis of compound **38.14** is also shown in Scheme 5b. Commercially available 2-amino-2-methyl-1-propanol is converted to aziridines **38.16** according to literature methods (*J. Org. Chem.* **1992**, *57*, 5813; *Syn. Lett.* **1997**, *8*, 893). Aziridine opening with phosphite give **38.17** (*Tetrahedron Lett.* **1980**, *21*, 1623). Reprotection of **38.17** affords **38.14**.

### Scheme 38a





**Scheme 38b**



## 5 BIOLOGICAL ACTIVITY OF HIV-INTEGRASE INHIBITOR COMPOUNDS

Representative compounds of the invention are tested for biological activity by methods including anti-HIV assay, measuring inhibition of HIV-integrase strand transfer catalysis, and cytotoxicity. See: Wolfe, et al *J. Virol.* (1996) 70:1424-1432; Hazuda, et al *Nucleic Acids Res.* (1994) 22:1121-22; Hazuda, et al *J. Virol.* (1997) 71:7005-7011; Hazuda, et al *Drug Design and Discovery* (1997) 15:17-24; and Hazuda, et al *Science* (2000) 287:646-650. The antiviral activity of a compound of the invention can be determined using pharmacological models which are well known in the art. While many of the compounds of the present invention demonstrate inhibition of integration of HIV reverse-transcribed DNA, there may be other mechanisms of action whereby HIV replication or proliferation is affected.

- 15 The compounds of the invention may be active via inhibition of HIV-integrase or other enzymes associated with HIV infection, AIDS, or ARC. Furthermore, the compounds of the invention may have significant activity against other viral diseases. Thus, the specific assays embodied in Examples x-y are not meant to limit the present invention to a specific mechanism of action.

## PHARMACEUTICAL FORMULATIONS AND ROUTES OF ADMINISTRATION

The compounds of the invention may be formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice. Tablets will contain excipients, glidants, fillers, binders and the like. Aqueous formulations are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. Formulations optionally contain excipients such as those set forth in the Handbook of Pharmaceutical Excipients (1986) and include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like.

Compounds of the invention and their physiologically acceptable salts (hereafter collectively referred to as the active ingredients) may be administered by any route appropriate to the condition to be treated, suitable routes including oral, rectal, nasal, topical (including ocular, buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural). The preferred route of administration may vary with for example the condition of the recipient.

While it is possible for the active ingredients to be administered alone it is preferably to present them as pharmaceutical formulations. The formulations, both for veterinary and for human use, of the present invention comprise at least one active ingredient, as above defined, together with one or more pharmaceutically acceptable carriers therefor and optionally other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

The formulations include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.

For infections of the eye or other external tissues e.g. mouth and skin, the formulations are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc), preferably 0.2 to 15% w/w and most preferably 0.5 to 10% w/w. When formulated in an ointment, the active ingredients may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base.

If desired, the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG400) and mixtures thereof. The topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs.

The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier

(otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.

Emulgents and emulsion stabilizers suitable for use in the formulation of the present invention include Tween™ 60, Span™ 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.

The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.

Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% particularly about 1.5% w/w.

Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.

- 5 Formulations suitable for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns (including particle sizes in a range between 20 and 500 microns in increments of 5 microns such as 30 microns, 35 microns, etc), which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration as for example a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient.
- 10 Formulations suitable for aerosol administration may be prepared according to conventional methods and may be delivered with other therapeutic agents such as pentamidine for treatment of pneumocystis pneumonia.

- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- 15

- Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- 20
- 25 Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient.

- It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
- 30

The present invention further provides veterinary compositions comprising at least one active ingredient as above defined together with a veterinary carrier therefor. Veterinary carriers are materials useful for the purpose of administering the composition and may be solid, liquid or gaseous materials which are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered orally, parenterally or by any other desired route.

Compounds of the invention can be used to provide controlled release pharmaceutical formulations containing as active ingredient one or more compounds of the invention ("controlled release formulations") in which the release of the active ingredient can be controlled and regulated to allow less frequency dosing or to improve the pharmacokinetic or toxicity profile of a given invention compound. Controlled release formulations adapted for oral administration in which discrete units comprising one or more compounds of the invention can be prepared according to conventional methods. Controlled release formulations may be employed for the treatment or prophylaxis of various microbial infections particularly human bacterial, human parasitic protozoan or human viral infections caused by microbial species including Plasmodium, Pneumocystis, herpes viruses (CMV, HSV 1, HSV 2, VZV, and the like), retroviruses, adenoviruses and the like. The controlled release formulations can be used to treat HIV infections and related conditions such as tuberculosis, malaria, pneumocystis pneumonia, CMV retinitis, AIDS, AIDS-related complex (ARC) and progressive generalized lymphadenopathy (PGL), and AIDS-related neurological conditions such as multiple sclerosis, and tropical spastic paraparesis. Other human retroviral infections that may be treated with the controlled release formulations according to the invention include Human T-cell Lymphotropic virus (HTLV)-I and IV and HIV-2 infections. The invention accordingly provides pharmaceutical formulations for use in the treatment or prophylaxis of the above-mentioned human or veterinary conditions and microbial infections.

#### COMBINATION THERAPY

The compounds of the invention may be employed in combination with other therapeutic agents for the treatment or prophylaxis of the infections or conditions indicated above. Examples of such further therapeutic agents include agents that are effective for the treatment or prophylaxis of viral, parasitic or bacterial infections or associated conditions or for treatment of tumors or related conditions include 3'-azido-3'-deoxythymidine (zidovudine,

AZT), 2'-deoxy-3'-thiacytidine (3TC), 2',3'-dideoxy-2',3'-didehydroadenosine (D4A), 2',3'-  
 dideoxy-2',3'-didehydrothymidine (D4T), carbovir (carbocyclic 2',3'-dideoxy-2',3'-  
 didehydroguanosine), 3'-azido-2',3'-dideoxyuridine, 5-fluorothymidine, (E)-5-(2-bromovinyl)-  
 2'-deoxyuridine (BVDU), 2-chlorodeoxyadenosine, 2-deoxycytosine, 5-fluorouracil, 5-  
 5 fluorouridine, 5-fluoro-2'-deoxyuridine, 5-trifluoromethyl-2'-deoxyuridine, 6-azauridine, 5-  
 fluoro-orotic acid, methotrexate, triacetyluridine, 1-(2'-deoxy-2'-fluoro-1- $\beta$ -arabinosyl)-5-  
 iodocytidine (FIAC), tetrahydro-imidazo(4,5,1-jk)-(1,4)-benzodiazepin-2(1H)-thione (TIBO),  
 2'-nor-cyclicGMP, 6-methoxypurine arabinoside (ara-M), 6-methoxypurine arabinoside 2'-O-  
 valerate, cytosine arabinoside (ara-C), 2',3'-dideoxynucleosides such as 2',3'-dideoxycytidine  
 10 (ddC), 2',3'-dideoxyadenosine (ddA) and 2',3'-dideoxyinosine (ddI), acyclic nucleosides such  
 as acyclovir, penciclovir, famciclovir, ganciclovir, HPMPC, PMEA, PMEG, PMPA,  
 PMPDAP, FMPA, HPMPA, HPMPDAP, (2R, 5R)-9 $\rightarrow$ -tetrahydro-5-(phosphonomethoxy)-2-  
 furanyladenine, (2R, 5R)-1 $\rightarrow$ -tetrahydro-5-(phosphonomethoxy)-2-furanylthymine, other  
 antivirals including ribavirin (adenine arabinoside), 2-thio-6-azauridine, tubercidin,  
 15 aurintricarboxylic acid, 3-deazaneoplanocin, neoplanocin, rimantidine, adamantane, and  
 foscarnet (trisodium phosphonoformate), antibacterial agents including bactericidal  
 fluoroquinolones (ciprofloxacin, pefloxacin and the like), aminoglycoside bactericidal  
 antibiotics (streptomycin, gentamicin, amikacin and the like)  $\beta$ -lactamase inhibitors  
 (cephalosporins, penicillins and the like), other antibacterials including tetracycline, isoniazid,  
 20 rifampin, cefoperazone, clarithromycin and azithromycin, antiparasite or antifungal agents  
 including pentamidine (1,5-bis(4'-aminophenoxy)pentane), 9-deaza-inosine,  
 sulfamethoxazole, sulfadiazine, quinapyramine, quinine, fluconazole, ketoconazole,  
 itraconazole, Amphotericin B, 5-fluorocytosine, clotrimazole, hexadecylphosphocholine and  
 nystatin, renal excretion inhibitors such as probenecid, nucleoside transport inhibitors such as  
 25 dipyridamole, dilazep and nitrobenzylthioinosine, immunomodulators such as FK506,  
 cyclosporin A, thymosin  $\alpha$ -1, cytokines including TNF and TGF- $\beta$ , interferons including  
 IFN- $\alpha$ , IFN- $\beta$ , and IFN- $\gamma$ , interleukins including various interleukins,  
 macrophage/granulocyte colony stimulating factors including GM-CSF, G-CSF, M-CSF,  
 cytokine antagonists including anti-TNF antibodies, anti-interleukin antibodies, soluble  
 30 interleukin receptors, protein kinase C inhibitors and the like.

The invention includes a pharmaceutical composition comprising a therapeutically effective amount of a Formula I or II compound in combination with a therapeutically effective amount of an AIDS treatment agent selected from:

- (1) an AIDS antiviral agent,
- 5       (2) an anti-infective agent, and
- (3) an immunomodulator.

It is also possible to combine any of the compounds of the invention in a unitary dosage form for simultaneous administration with a second, or third, active pharmaceutical ingredient. The two or three-part combination may also be administered sequentially in two  
10   or three administrations. Second and third active ingredients may have anti-HIV activity and include protease inhibitors (Prt), nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), and integrase inhibitors. Exemplary second and third active anti-HIV ingredients to be administered in combination with the compounds of the invention, i.e. Formulas I and II compounds, are:

- 15       5,6 dihydro-5-azacytidine
- 5-aza 2'deoxycytidine
- 5-azacytidine
- 5-yl-carbocyclic 2'-deoxyguanosine (BMS200,475)
- 9 (arabinofuranosyl)guanine; 9-(2' deoxyribofuranosyl)guanine
- 20       9-(2'-deoxy 2'fluororibofuranosyl)-2,6-diaminopurine
- 9-(2'-deoxy 2'fluororibofuranosyl)guanine
- 9-(2'-deoxyribofuranosyl)-2,6 diaminopurine
- 9-(arabinofuranosyl)-2,6 diaminopurine
- Abacavir, Ziagen®
- 25       Acyclovir, ACV; 9-(2-hydroxyethoxymethyl)guanine
- Adefovir dipivoxil, Hepsera®
- amdoxivir, DAPD
- Amprenavir, Agenerase®
- araA; 9-b-D-arabinofuranosyladenine (Vidarabine)
- 30       AZT; 3'-azido-2',3'-dideoxythymidine, Zidovudine, (Retrovir®)
- BHCG; (+-)-(1a,2b,3a)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine



BMS200,475; 5-yl-carbocyclic 2'-deoxyguanosine  
 Buciclovir; (R) 9-(3,4-dihydroxybutyl)guanine  
 BvaraU; 1-b-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (Sorivudine)  
 Calanolide A  
 5 Capravirine  
 CDG; carbocyclic 2'-deoxyguanosine  
 Cidofovir, HPMPC; (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine  
 Clevudine, L-FMAU; 2'-Fluoro-5-methyl- $\beta$ -L-arabino-furanosyluracil  
 Cytallene; [1-(4'-hydroxy-1',2'-butadienyl)cytosine]  
 10 d4C; 3'-deoxy-2',3'-didehydrocytidine  
 DAPD; (-)- $\beta$ -D-2,6-diaminopurine dioxolane  
 ddA; 2',3'-dideoxyadenosine  
 ddAPR; 2,6-diaminopurine-2',3'-dideoxyriboside  
 ddC; 2',3'-dideoxycytidine (Zalcitabine)  
 15 ddI; 2',3'-dideoxyinosine, didanosine, (Videx®)  
 Delavirdine, Rescriptor®  
 Didanosine, ddI, Videx®; 2',3'-dideoxyinosine  
 DXG; dioxolane guanosine  
 E-5-(2-bromovinyl)-2'-deoxyuridine  
 20 Efavirenz, Sustiva®  
 Enfuvirtide, Fuzeon®  
 F-ara-A; fluoroarabinosyladenosine (Fludarabine)  
 FDOC; (-)- $\beta$ -D-5-fluoro-1-[2-(hydroxymethyl)-1,3-dioxolane]cytosine  
 FEAU; 2'-deoxy-2'-fluoro-1- $\beta$ -D-arabinofuranosyl-5-ethyluracil  
 25 FIAC; 1-(2-deoxy-2-fluoro- $\beta$ -D-arabinofuranosyl)-5-iodocytosine  
 FIAU; 1-(2-deoxy-2-fluoro- $\beta$ -D-arabinofuranosyl)-5-iodouridine  
 FLG; 2',3'-dideoxy-3'-fluoroguanosine  
 FLT; 3'-deoxy-3'-fluorothymidine  
 Fludarabine; F-ara-A; fluoroarabinosyladenosine  
 30 FMAU; 2'-Fluoro-5-methyl-b-L-arabino-furanosyluracil

FMdC  
 Foscarnet; phosphonoformic acid, PFA  
 FPMPA; 9-(3-fluoro-2-phosphonylmethoxypropyl)adenine  
 Gancyclovir, GCV; 9-(1,3-dihydroxy-2-propoxymethyl)guanine  
 5 GS-7340; 9-[R-2-[[[(S)-[(S)-1-(isopropoxycarbonyl)ethyl]amino]-  
     phenoxyposphinyl]methoxy]propyl]adenine  
 HPMPA; (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine  
 HPMPG; (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (Cidofovir)  
 Hydroxyurea, Droxia®  
 10 Indinavir, Crixivan®  
 Lamivudine, 3TC, Epivir™; (2R, 5S, cis)-4-amino-1-(2-hydroxymethyl-1,3-  
     oxathiolan-5-yl)-(1H)-pyrimidin-2-one  
 L-d4C; L-3'-deoxy-2',3'-didehydrocytidine  
 L-ddC; L-2',3'-dideoxycytidine  
 15 L-Fd4C; L-3'-deoxy-2',3'-didehydro-5-fluorocytidine  
 L-FddC; L-2',3'-dideoxy-5-fluorocytidine  
 Lopinavir  
 Nelfinavir, Viracept®  
 Nevirapine, Viramune®  
 20 Oxetanocin A; 9-(2-deoxy-2-hydroxymethyl-beta-D-erythro-oxetanosyl)adenine  
 Oxetanocin G; 9-(2-deoxy-2-hydroxymethyl-β-D-erythro-oxetanosyl)guanine  
 Penciclovir  
 PMEDAP; 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine  
 PMPA, tenofovir; (R)-9-(2-phosphonylmethoxypropyl)adenine  
 25 PPA; phosphonoacetic acid  
 Ribavirin; 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide  
 Ritonavir, Norvir®  
 Saquinavir, Invirase®, Fortovase®  
 Sorivudine, BvaraU; 1-β-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil  
 30 Stavudine, d4T, Zerit®; 2',3'-didehydro-3'-deoxythymidine

Trifluorothymidine, TFT; Trifluorothymidine  
Vidarabine, araA; 9- $\beta$ -D-arabinofuranosyladenine  
Zalcitabine, Hivid®, ddC; 2',3'-dideoxycytidine  
Zidovudine, AZT, Retrovir®; 3'-azido-2',3'-dideoxythymidine  
5 Zonavir; 5-propynyl-1-arabinosyluracil

### ASSAY PROTOCOL EXAMPLES

#### HIV Integrase Assay (IC<sub>50</sub> determination)

10 IC<sub>50</sub> (also referred to as CC<sub>50</sub>, CD<sub>50</sub>, TC<sub>50</sub>, TD<sub>50</sub> or cytotoxicity) is the inhibitory concentration that reduces cellular growth or viability of uninfected cells by 50%.

HIV Integrase assay is carried out in Reacti-Bind High Binding Capacity Streptavidin coated plates (Pierce # 15502) in 100  $\mu$ l reactions. The wells of the plate are rinsed once with PBS. Each well is then coated at room temperature for 1 h with 100  $\mu$ l of 0.14  $\mu$ M double-stranded, 5'-biotin labelled donor DNA.

15 After coating, the plate is washed twice with PBS. 3' Processing of the donor DNA is started by adding 80  $\mu$ l of Integrase/buffer mixture (25 mM HEPES, pH 7.3, 12.5 mM DTT, 93.75 mM NaCl, 12.5 mM MgCl<sub>2</sub>, 1.25% Glycerol, 0.3125  $\mu$ M integrase) to each well. 3'-Processing is allowed to proceed for 30 min at 37 °C, after which, 10  $\mu$ l of test compound and 10  $\mu$ l of 2.5  $\mu$ M 3'-DIG (digitoxygenin)-labeled, double-stranded Target DNA are added to

20 each well to allow strand transfer to proceed for 30 min at 37 °C. The plate is then washed three times with 2X SSC for 5 min and rinsed once with PBS. For detection of integrated product, 100  $\mu$ l of a 1/2000 dilution of HRP-conjugated anti-DIG antibody (Pierce #31468) are added to each well and incubated for 1 hour. The plate is then washed three times for 5 min each, with 0.05% Tween-20 in PBS. For signal development and amplification, 100  $\mu$ l of

25 SuperSignal ELISA Femto Substrate (Pierce #37075) are added to each well.

Chemiluminescence (in relative light units) is read immediately at 425 nm in the SPECTRAMax GEMINI Microplate Spectrophotometer using the end point mode at 5 sec per well. For IC<sub>50</sub> determinations, eight concentrations of test compounds in a 1/2.2 dilution series are used. Certain compounds of the invention, including those in Tables 1-5, had a

30 strand transfer IC<sub>50</sub> less than about 10  $\mu$ M.

#### Anti-HIV Assay (EC<sub>50</sub> determination)

EC<sub>50</sub> (also commonly referred to as ED<sub>50</sub> or IC<sub>50</sub>) is the effective concentration that inhibits 50% of viral production, 50% of viral infectivity, or 50% of the virus-induced cytopathic effect.



- 5        Anti-HIV assay is carried out in 96-well Clear Bottom Black Assay Plate (Costar # 3603) in 100  $\mu$ l of culture medium, using the CellTiter-Glo™ Reagent (Promega # G7570) for signal detection. MT-2 cells ( $1.54 \times 10^4$  cells) are infected with wild-type virus at an m.o.i. (multiplicity of infection, i.e. the ratio between the number of infectious viral particles and cells in an assay) of about 0.025, and grown in the presence of various drug
- 10       concentrations (serial 5-fold dilutions) in 100  $\mu$ l of RPMI medium containing 10% FBS, 2% glutamine, 1% HEPES and 1% penicillin/streptomycin for 5 days. At the end of the incubation period, 100  $\mu$ l of CellTiter-Glo™ Reagent is added to each well in the Assay Plate and the chemiluminescence (in relative light units) is measured after 10 mins of incubation with the Wallac Victor<sup>2</sup> 1420 MultiLabel Counter. Certain compounds of the invention,
- 15       including those in Tables 1-5, had an anti-HIV MT2 EC<sub>50</sub> less than about 10  $\mu$ M.

#### Cytotoxicity Assay (CC<sub>50</sub> determination)

- For the determination of compound cytotoxicity, the plate and reagents are the same as those of anti-HIV assay. Uninfected MT-2 cells ( $1.54 \times 10^4$  cells) are grown in the presence of various drug concentrations (serial 2-fold dilutions) in 100  $\mu$ l of RPMI medium containing
- 20       10% FBS, 2% glutamine, 1% HEPES and 1% penicillin/streptomycin for 5 days. At the end of the incubation period, 100  $\mu$ l of CellTiter-Glo™ Reagent is added to each well in the assay plate and the chemiluminescence (in relative light units) is measured after 10 mins of incubation with the Wallac Victor<sup>2</sup> 1420 MultiLabel Counter.

The following are enumerated embodiments of the invention:

1. A compound selected from Formulas I and II:



or a pharmaceutically acceptable salt thereof, and including all enol, tautomeric, and resonance isomers, enantiomers, diastereomers, and racemic mixtures thereof;

wherein:

- 10  $R^1$  is selected from H, F, Cl, Br, I, OH, OR, amino ( $-NH_2$ ), ammonium ( $-NH_3^+$ ), alkylamino ( $-NHR$ ), dialkylamino ( $-NR_2$ ), trialkylammonium ( $-NR_3^+$ ), carboxyl ( $-CO_2H$ ), sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, 4-dialkylaminopyridinium, alkylsulfone ( $-SO_2R$ ), arylsulfone ( $-SO_2Ar$ ), arylsulfoxide ( $-SOAr$ ), arylthio ( $-SAr$ ), sulfonamide ( $-SO_2NR_2$ ), alkylsulfoxide ( $-SOR$ ), formyl ( $-CHO$ ), ester ( $-CO_2R$ ), amido ( $-C(=O)NR_2$ ), 5-7
- 15 membered ring lactam, 5-7 membered ring lactone, nitrile ( $-CN$ ), azido ( $-N_3$ ), nitro ( $-NO_2$ ),  $C_1-C_{18}$  alkyl,  $C_1-C_{18}$  substituted alkyl,  $C_2-C_{18}$  alkenyl,  $C_2-C_{18}$  substituted alkenyl,  $C_2-C_{18}$  alkynyl,  $C_2-C_{18}$  substituted alkynyl,  $C_6-C_{20}$  aryl,  $C_6-C_{20}$  substituted aryl,  $C_2-C_{20}$  heterocycle,

and C<sub>2</sub>-C<sub>20</sub> substituted heterocycle, phosphonate, phosphate, polyethyleneoxy, a protecting group, L-A<sup>3</sup>, and a prodrug moiety;

R<sup>2a</sup> and R<sup>5</sup> are each independently selected from H, carboxyl (-CO<sub>2</sub>H), sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, 4-dialkylaminopyridinium, alkylsulfone (-SO<sub>2</sub>R), arylsulfone (-SO<sub>2</sub>Ar), arylsulfoxide (-SOAr), arylthio (-SAr), sulfonamide (-SO<sub>2</sub>NR<sub>2</sub>), alkylsulfoxide (-SOR), formyl (-CHO), ester (-CO<sub>2</sub>R), amido (-C(=O)NR<sub>2</sub>), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile (-CN), azido (-N<sub>3</sub>), nitro (-NO<sub>2</sub>), C<sub>1</sub>-C<sub>18</sub> alkyl, C<sub>1</sub>-C<sub>18</sub> substituted alkyl, C<sub>2</sub>-C<sub>18</sub> alkenyl, C<sub>2</sub>-C<sub>18</sub> substituted alkenyl, C<sub>2</sub>-C<sub>18</sub> alkynyl, C<sub>2</sub>-C<sub>18</sub> substituted alkynyl, C<sub>6</sub>-C<sub>20</sub> aryl, C<sub>6</sub>-C<sub>20</sub> substituted aryl, C<sub>2</sub>-C<sub>20</sub> heterocycle, and C<sub>2</sub>-C<sub>20</sub> substituted heterocycle, phosphonate, phosphate, polyethyleneoxy, a protecting group, L-A<sup>3</sup>, and a prodrug moiety;

R<sup>2b</sup>, R<sup>3</sup>, and R<sup>4</sup> are each independently selected from H, OH, OR, amino (-NH<sub>2</sub>), ammonium (-NH<sub>3</sub><sup>+</sup>), alkylamino (-NHR), dialkylamino (-NR<sub>2</sub>), trialkylammonium (-NR<sub>3</sub><sup>+</sup>), carboxyl (-CO<sub>2</sub>H), sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, 4-dialkylaminopyridinium, alkylsulfone (-SO<sub>2</sub>R), arylsulfone (-SO<sub>2</sub>Ar), arylsulfoxide (-SOAr), arylthio (-SAr), sulfonamide (-SO<sub>2</sub>NR<sub>2</sub>), alkylsulfoxide (-SOR), formyl (-CHO), ester (-CO<sub>2</sub>R), amido (-C(=O)NR<sub>2</sub>), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile (-CN), azido (-N<sub>3</sub>), nitro (-NO<sub>2</sub>), C<sub>1</sub>-C<sub>18</sub> alkyl, C<sub>1</sub>-C<sub>18</sub> substituted alkyl, C<sub>2</sub>-C<sub>18</sub> alkenyl, C<sub>2</sub>-C<sub>18</sub> substituted alkenyl, C<sub>2</sub>-C<sub>18</sub> alkynyl, C<sub>2</sub>-C<sub>18</sub> substituted alkynyl, C<sub>6</sub>-C<sub>20</sub> aryl, C<sub>6</sub>-C<sub>20</sub> substituted aryl, C<sub>2</sub>-C<sub>20</sub> heterocycle, and C<sub>2</sub>-C<sub>20</sub> substituted heterocycle, phosphonate, phosphate, polyethyleneoxy, a protecting group, L-A<sup>3</sup>, and a prodrug moiety;

R is independently selected from H, C<sub>1</sub>-C<sub>18</sub> alkyl, C<sub>1</sub>-C<sub>18</sub> substituted alkyl, C<sub>2</sub>-C<sub>18</sub> alkenyl, C<sub>2</sub>-C<sub>18</sub> substituted alkenyl, C<sub>2</sub>-C<sub>18</sub> alkynyl, C<sub>2</sub>-C<sub>18</sub> substituted alkynyl, C<sub>6</sub>-C<sub>20</sub> aryl, C<sub>6</sub>-C<sub>20</sub> substituted aryl, C<sub>2</sub>-C<sub>20</sub> heterocycle, C<sub>2</sub>-C<sub>20</sub> substituted heterocycle, phosphonate, phosphate, polyethyleneoxy, a protecting group, and a prodrug moiety;

L is selected from a bond, O, S, NR, N-OR, C<sub>1</sub>-C<sub>12</sub> alkylene, C<sub>1</sub>-C<sub>12</sub> substituted alkylene, C<sub>2</sub>-C<sub>12</sub> alkenylene, C<sub>2</sub>-C<sub>12</sub> substituted alkenylene, C<sub>2</sub>-C<sub>12</sub> alkynylene, C<sub>2</sub>-C<sub>12</sub> substituted alkynylene, C<sub>6</sub>-C<sub>20</sub> arylene, C<sub>6</sub>-C<sub>20</sub> substituted arylene, C(=O)NH, C(=O), S(=O)<sub>2</sub>, C(=O)NH(CH<sub>2</sub>)<sub>n</sub>, and (CH<sub>2</sub>CH<sub>2</sub>O)<sub>n</sub>, where n may be 1, 2, 3, 4, 5, or 6;